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PROPOSITIONS OF THIS THESIS
Bone and phosphate in relation to health, survival and
genetic factors
1. The relation between low bone mineral density and increased mortality 
in men is in part explained by higher mortality from chronic obstructive 
pulmonary disease.
            [Looker, 2014 & this thesis]
2. Bone mineral density of the femoral neck, composed predominantly of 
cortical bone, is not causally related to arterial calcification.
                 
                                   [Schulz et al, 2004; Chow et al, 2008 & this thesis]
3. Increased serum phosphate levels within the normal range are causally 
related to coronary artery calcification in the general population, and, as 
such, must be considered a cardiovascular risk factor. 
[Dhingra, 2007 & this thesis]
4. The associations we found between low bone mineral density and increased 
yet normal phosphate levels with decreased survival, lung emphysema, and 
coronary artery calcification (P), strongly resemble the premature ageing 
syndrome described in Fgf23-/- and kl/kl mouse phenocopies.
                         [Kuro-o et al, 1997; Shimada et al, 2004 & this thesis]
5. Regardless of kidney function, increased phosphate levels are related 
to fracture risk in men, especially at trabecular-enriched bones (such 
as vertebral bodies and wrist); this finding is partly attributable to a 
predominant synthesis of FGF23 at trabecular osteocytes.
 [Pereira et al, 2009; Delgado-Calle et al, 2011 & this thesis]
6. In pregnancy and lactation associated osteoporosis, a persistent low bone 
mineral density should trigger investigation for secondary causes for 
osteoporosis, including potential underlying genetic factors.
                                                                                          [this thesis]
7. Bone metabolism plays an important role in the anti-ageing FGF23/Klotho 
axis, as indicated by osteocytes being the main source of FGF23, Klotho 
being expressed also in osteocytes, and our findings of low bone mineral 
density being related to decreased survival.
   [Riminucci et al, 2003; Komaba et al, 2017; Kuro-o, 2018 & this thesis]
8. Additional evidence to support that bone metabolism plays an important 
role in ageing and survival is indicated by the findings of nitrogenated 
bisphosphonates being related to decreased mortality -mediated through a 
reduction in bone loss and independent of fracture prevention.
                                           [Reid et al, 2020 & Bliuc et al, 2019]
9. The sex difference in the association of serum phosphate with several 
clinical cardiovascular outcomes is not explained by sex dimorphism in its 
genetic factors.
  [Felsenfeld et al, 1999; Calvo et al, 1988; Kemi et al, 2006 & this thesis] 
10. Entropy-based methods (ε) are required to disentangle the strong linkage 
disequilibrium of the Major Histocompatibility Complex (6p21.3) to 
identify causal variants in genetic association studies (such as in the GWAS 
of serum phosphate).
                         [Nothnagel et al, 2002; Hirata et al, 2019 & this thesis]
11. Very early-on global collaboration and sharing of clinical, epidemiological, 
and genetic data in local infectious disease outbreaks, can limit societal 
and economic consequences for all countries in potential pan-epidemic 
outbreaks.
PROPOSICIONES DE ESTA TESIS
Hueso y fosfato en relación con salud, supervivencia y 
factores genéticos
1. La relación entre baja densidad mineral ósea y aumento en la mortalidad 
en los hombres se explica parcialmente por una mayor mortalidad por 
enfermedad pulmonar obstructiva crónica.
                
[Looker, 2014 & esta tesis]
2. La densidad mineral ósea del cuello femoral, compuesta predominantemente 
de hueso cortical, no está causalmente relacionada con calcificación 
arterial.
                                  [Schulz y otros, 2004; Chow et al, 2008 & esta tesis]
3. El nivel elevado de fosfato sérico - aún dentro del rango normal - está 
causalmente relacionado con calcificación de las arterias coronarias en la 
población general, y como tal, debe ser considerado un factor de riesgo 
cardiovascular. 
  [Dhingra, 2007 & esta tesis]
4. Las asociaciones que encontramos entre baja densidad mineral ósea y 
aumento en los niveles normales de fosfato - aún dentro del rango normal 
- con disminución de la supervivencia, enfisema pulmonar y calcificación 
de las arterias coronarias (P), se asemejan fuertemente al síndrome de 
envejecimiento prematuro descrito en fenocopias de ratones Fgf23-/- y kl/
kl.
          [Kuro-o et al, 1997; Shimada et al, 2004 & esta tesis]
5. Independientemente de la función renal, el aumento en los niveles de 
fosfato está asociado con riesgo de fractura en los hombres, especialmente 
en los huesos enriquecidos en componente trabecular (como los cuerpos 
vertebrales y el radio distal); este hallazgo es parcialmente atribuible a una 
síntesis predominante de FGF23 en los osteocitos trabeculares.
                 [Pereira et al, 2009; Delgado-Calle et al, 2011 & esta tesis]
6. En la osteoporosis asociada a embarazo y lactancia, la persistencia de una 
densidad mineral ósea disminuida debe desencadenar la investigación 
de factores secundarios de osteoporosis, incluyendo potenciales factores 
genéticos subyacentes. 
                                                                                        [esta tesis]
7. El metabolismo óseo desempeña un papel importante en el eje anti-
envejecimiento FGF23/Klotho, indicado por los siguientes hallazgos: los 
osteocitos son la fuente principal de FGF23, la expresión de Klotho también 
ocurre en osteocitos, y nuestros hallazgos de baja densidad mineral ósea 
asociados con disminución en la supervivencia.
         [Riminucci et al, 2003; Komaba et al, 2017; Kuro-o, 2018 & esta tesis]
8. La evidencia adicional para apoyar que el metabolismo óseo tiene un 
papel importante en el envejecimiento y la supervivencia está basada 
en el hallazgo que los bifosfonatos nitrogenados están relacionados con 
disminución de la mortalidad - mediada por una reducción en la pérdida 
ósea e independientemente de la prevención de fracturas. 
                                            [Reid et al, 2020 y Bliuc et al, 2019]
9. La diferencia por sexo en la asociación de fosfato sérico con diversos 
resultados cardiovasculares clínicos no se explica por dimorfismo sexual 
en los factores genéticos del fosfato.
     [Felsenfeld et al, 1999; Calvo et al, 1988; Kemi et al, 2006 & esta tesis]
10. Se requieren métodos basados  en entropía (ε) para dilucidar el fuerte 
desequilibrio de ligamiento del Complejo Mayor de Histocompatibilidad 
(6p21.3) y así poder identificar las variantes causales en los estudios de 
asociación genética (como en el GWAS de fosfato sérico).
                       [Nothnagel y et al, 2002; Hirata et al, 2019 & esta tesis]
11. La implementación de colaboración temprana a nivel global y el intercambio 
de datos clínicos, epidemiológicos y genéticos durante los brotes locales 
de enfermedades infecciosas, pueden limitar las consecuencias sociales y 
económicas para todos los países en potenciales brotes de pandemias.
Some abbreviations implemented in this thesis:
BMD: bone mineral density 
LS: lumbar spine
P: serum phosphate levels 
CAC: coronary artery calcification
FN: femoral neck 
COPD: chronic obstructive pulmonary disease
HR: hazard ratio 
CVD: cardiovascular disease
RS: Rotterdam Study 
CKD: chronic kidney disease
AC: arterial calcification 
FGF23: fibroblast growth factor 23
MR: Mendelian Randomization
1 Introduction
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Knowledge of bone disorders and bone-related traits have progressively evolved 
from a fracture perspective into a broader spectrum of effects and consequences 
beyond fracture incidence. This burst of knowledge has been enabled by the wide 
availability of tools that assess crucial aspects of bone, such as bone mineral 
density (1) and microarchitecture (2). Introduced in the 1970s, the quantification 
of bone mass through radiographic absorptiometry became possible and provided 
an estimate of cortical hand bone mass (3). However, the assessment of bone 
mineral density (BMD) through dual X-energy absorptiometry (DXA)  (1988) 
has become the most widely applied tool for quantifying bone mass (4). 
Although not exactly yielding a density – due to its two-dimensional perspective 
- (5) DXA assessments have led to a standardization of bone mass into categories 
of clinical importance, such as normal BMD, osteopenia and osteoporosis (6). The 
definition of osteoporosis by the World Health Organization (WHO) in 1991 (7, 8) 
already acknowledged not only the decrease in bone quantity, but also emphasized 
a more recent concept of bone quality as part of its strength and structure that 
when compromised, similar to bone mass, its ability to sustain trauma and avoid 
a fracture can decrease (9).
Parallel to this evolution in bone density-related concepts, several important 
discoveries have allowed the incorporation of bone tissue within physiologic axes 
of relevance for energy homeostasis, immunity and mineral balance, due to the 
discovery that bone cells can synthesize factors as osteocalcin (10), lipocalin 2 (11) 
and FGF23 (12-14). In particular, the description of the bone-derived hormone 
FGF23 has enabled the establishment of the “bone-kidney axis” (15-17), where 
bone tissue exerts a major regulatory role in physiology. This axis highlights the 
important role of bone tissue far beyond a mere structure that supports loading and 
allows locomotion. 
The key role of FGF23 as a hormone exerting master control in phosphate 
homeostasis (12, 18, 19) - has probably responded to the imminent need of 
avoiding conditions of excess after the incorporation of phosphate into the bone 
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skeletons of vertebrate. Occurring in late Silurian or early Devonian Period, circa 
540 Mya, the evolution from aragonite (CaCO3)-derived to hydroxyapatite-
derived (3Ca3[PO4]2Ca[OH]2; Ca10[PO4]6Ca[OH]2) skeletons took place (15). It 
has been postulated that this landmark transition was responsible for a decrease in 
bone solubility and therefore an increase in the stability required for the intense 
activity of vertebrates in comparison to their ancestors, as their high metabolic 
activity induces decreases in pH that would have dissolved bone were it totally 
calcitic instead of phosphatic (20). 
Identified in 2000 in human families with severe hereditary hypophosphatemia 
(13), FGF23 became known as a potent phosphaturic hormone (13, 15) that 
depends on α-Klotho (21) as a cofactor to exert its classical effects in target tissues 
through its specific receptor, FGFR1c (19). It has been consistently shown that 
osteocytes, osteoblasts and bone lining cells (19, 22, 23) are the main source of 
FGF23 synthesis in health and also in disease - such as  chronic kidney disease 
(CKD) across all its stages (24). 
Therefore, bone is not merely a phosphate reservoir but importantly exerts a 
tight control on its homeostasis (Figure 1). This growing body of evidence has 
definitely placed phosphate as a bone trait –and not only phosphate: the statement 
is valid also for calcium, especially considering the recent description of FGF23 
as a calciotropic hormone, exerting fine tuning of serum calcium levels (25). 
Therefore, the available evidence has also highlighted the key importance that 
bone tissue exerts in both health and disease.
Introduction
4
Parathyroid
glands
Intestine
Dietary
phosphate intake
1500 mg/day
Fecal
phosphate
600 mg/day
Stimulates
PTH
secretion
Stimulates
FGF23
secretion Urinaryphosphate
excretion
900 mg/day
Extracellular
phosphate
Bone
PTH
FGF23
klotho?
Kidney
Npt2a/2c
Phosphate
absorption
900 mg/day
Formation
Resorption
Reabsorption
Filtration
Figure 1.  Serum phosphate levels homeostasis (modified from (26)).
Continuous arrows show established axes; the intermittent arrows show a su-
ggested axis; the red arrow shows negative homeostatic control. (Reprodu-
ced with permission from Copyright Clearance Center, Elsevier. Source (26))
Part I. Bone traits and phosphate in relation to health & survival
a. Previous studies on BMD beyond fracture incidence: impact on mortality
Aside from fracture incidence, one of the most important research questions 
studied in the context of low BMD conditions has been whether it has an impact 
on survival independently of shared risk factors for both mortality and BMD 
decrease. An initial perspective assigned to low bone density was that it only 
reflects the process of ageing and frailty (27-30), without an active role in it. 
This concept has been challenged since several studies carried out in different 
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populations have indeed described an independent association between low BMD 
and mortality (28, 31, 32). Nevertheless, previous research has not been able to 
identify a specific cause of mortality attributable to low BMD. 
A putative relation of low BMD with cardiovascular disease (CVD) mortality 
has been based on the observation of a counterintuitive coexistence of vascular 
calcification and low BMD in several common clinical settings - condensed under 
the hypothesis of the “calcification paradox” (33) – where the presence of altered 
bone mineralization increases the pathological calcification in arterial walls (34). 
Due to the increase in CVD risk that vascular calcification entails (35), it has 
naturally been of great interest whether low BMD is related to CV events. Indeed, 
low BMD affecting CVD mortality was initially described in a large cohort of 
healthy-at-baseline women (29) but it has not been consistently reproduced 
throughout population-based cohorts (28, 31, 36). Though pooled evidence from 
the largest available meta-analysis provided evidence of a relation between low 
BMD and CV death (37), these findings were nullified due to publication bias (38). 
Similarly, an initial description of low BMD in association with stroke mortality 
(29) has not been reproduced in the analyses of pooled evidence (37, 39).
However, when a comprehensive classification of mortality causes has been 
applied, a systematic and strong relationship of low BMD with the residual non-
CVD & non-cancer causes of mortality has been homogeneously reported across 
populations of different ethnic groups. It has therefore raised the question whether 
there is a specific (non-CVD & non-cancer) disease in which the condition of a 
low BMD impairs survival (28, 31, 40).
	 	BMD and mortality: are there sex differences?
In addition to the acknowledgment of a relationship between low BMD and 
mortality, evidence of a potential sex difference has progressively emerged. Data 
from NHANES (40), MrOS (31), SOF Research Group (29) and the Rotterdam 
Study (41) have clearly shown that survival in men is affected by a condition of low 
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BMD; but not so in women (40, 41). To date, no satisfactory explanation has been 
found to explain this difference. Nevertheless, despite these results from several 
cohorts, a consistent sex difference in the relationship between low BMD and 
mortality has not become manifest at the meta-analysis level (37).
	 	Low BMD and mortality in The Rotterdam Study: previous knowledge
In 2002, van der Klift and co-authors (41) published a prospective analysis on 
femoral neck BMD and all-cause mortality (in a follow-up period of 5.4 years) 
and demonstrated that men’s survival was independently shortened by a condition 
of low BMD. Furthermore, the data provided evidence that the association was 
not linear, as high BMD values were also related to increased mortality in men; 
accordingly, the age-adjusted population average of BMD (Z=0) was found to be 
the safest value in terms of mortality, i.e., the BMD value not related to impaired 
survival. However, the authors did not find evidence that BMD influences survival 
in women. 
These previous findings led us to formulate the following set of questions:
Q1a. Is femoral neck BMD still related to all-cause mortality in a longer follow-
up study? Q1b. Can we identify a specific disease whose survival is impaired by 
a condition of low BMD and explain this relationship, or is it all explained by 
fractures?
BMD and the calcification paradox: rationale & how to analyze it in the Rotterdam 
Study
Independently of an association (or lack thereof) of BMD with mortality, the 
question of whether there is evidence of a joint occurrence of low BMD with 
vascular calcification (VC) beyond shared risk factors encloses importance for two 
main reasons:  a) the prevalence of osteoporosis in the population is estimated 
for European countries to be 22% in women and 7% in men (42);  and b) in the 
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general population, the presence of VC – more specifically, arterial calcification 
– is a major risk factor for cardiovascular events, such as myocardial infarction, 
stroke and heart failure (35, 43, 44). These two reasons highlight that the adverse 
effects of VC are definitely not confined to CKD (45).
In general, reports from the literature have not been consistent in the description 
of an association between BMD and arterial calcification (33). Nevertheless, 
longitudinal studies have found a relation between bone loss and arterial 
calcification progression in a more homogenous way (46, 47), especially in women. 
One of the most relevant circulatory beds for VC is at the coronary artery level, a 
process that mostly involves the intima  (35, 48). Based on the available data 
on coronary calcification in the first cohort of the Rotterdam Study (Figure 
2), we aimed to answer the following set of questions:
Q2a. Is femoral neck BMD related to coronary artery calcification? Q2b. In 
addition, is femoral neck bone loss related to coronary artery calcification? 
Q2c. Is there evidence that the presence of coronary calcification increases 
fracture risk?
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Figure 2. Schematic representation of the Rotterdam Study cohorts, inclu-
ding the baseline visit and the subsequent follow-up examination cycles.
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	Serum phosphate levels (P) as a bone trait: rationale 
Phosphorus is the most abundant anion in the human body and the second most 
common mineral (49). The majority of phosphorus is stored in bone and teeth 
(85%) and only 1% is present in extracellular fluids, either as organic or inorganic 
forms. Phosphate measured in serum (from now onwards P) corresponds to the 
amount of phosphorus in inorganic form (50). 
Knowledge of an association of phosphorus with bone dates back more than 
80 year ago, when Fuller Albright and his group described its crucial role in 
bone mineralization, as a condition of severely decreased phosphate levels – 
corresponding to the first description of X-linked hypophosphatemia - was 
found to induce a clinical picture of rickets with marked bone deformities, pain 
and multiple fractures in children. The status of defective mineralization was 
confirmed at the histologic level through a remarkable accumulation of wide 
osteoid seams without fibrosis (51). Not only is phosphorus an obligate substrate 
for hydroxyapatite formation: sustained hypophosphatemia has been shown to 
induce in mammals severe delays in the stages of osteocyte maturation and in the 
formation of secondary ossification centers (16, 17).
b. P and bone outcomes: BMD and fractures
Most reports and position statements focusing on the association between P 
and  BMD and fractures have focused in the specific contexts where P levels lie 
in the extremes of its distribution: i.e., severe hyperphosphatemia and severe 
hypophosphatemia (52, 53). This probably reflects a tacit assumption of the lack of 
a relationship between normal P with bone outcomes. 
The context of hypophosphatemia as risk factor for adverse skeletal outcomes is 
intuitive. As previously mentioned, P is an essential component of hydroxyapatite 
and exerts master control on osteocyte differentiation (16).
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Though seemingly less intuitive, hyperphosphatemia has also been related to 
mineralization defects (14, 54), particularly in the setting of CKD (55), - where 
an altered bone mineral metabolism occurs partly in response to progressive P 
retention (15, 56). Indeed, hyperphosphatemia has been related to adverse bone 
consequences in both extremes of the spectrum of bone turnover:
 a) Initially, a classic mechanism of severe secondary hyperparathyroidism 
(i.e., parathyroid hormone (PTH)-induced increased bone turnover) was described 
(57), characterized by increasing PTH in the course of CKD (58) and initially 
ascribed to decreased ionized calcium (57). Nevertheless, hyperphosphatemia is 
able per se to induce secondary hyperparathyroidism independently of serum 
levels of ionized calcium and 1,25-dihydroxyvitamin D (18, 59).
 b) Currently, the opposite clinical setting of adynamic bone disease – a 
condition of extreme low bone turnover (60), - is also acknowledged to induce 
bursts in P and calcium as they cannot be normally incorporated into bone, leading 
to wide excursions in their serum levels (e.g., after food or medication intake) with 
subsequent adverse effects (61, 62).
Consistently, the impact of CKD-related hyperphosphatemia on bone metabolism 
has translated clinically into a substantially increased fracture risk (63).
In contrast, whether serum P levels are related to bone outcomes at the population 
level has been scarcely explored (64) and although some recent research has been 
performed between e.g., FGF23 levels and BMD (65), to the best of our knowledge 
a relation between BMD and P has not been studied. Motivated by the predominant 
role that bone-derived FGF23 has in P homeostasis - suggested by some studies 
as more important than PTH (58, 66) - and by the growing number of findings 
of normal P with adverse outcomes, we postulated the following set of questions:
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Q3a. Is serum P related to BMD in the general population? Are there differences 
according to skeletal site? Q3b. Is P related to fracture risk –even within normal 
ranges? If so, can a particular pattern in fracture-site be identified? Q3c. Are 
there sex differences for any of these outcomes?
P beyond bone: mortality as outcome
In (apparent) contrast to the impaired mineralization induced by 
hypophosphatemia, Block & Lowrie showed that marked hyperphosphatemia 
(>6.5 mg/dL) in patients with advanced CKD was associated with excess mortality 
(45, 67) due to a pathogenic mechanism of vascular calcification (VC). Recent 
research has revealed that VC is induced by calciprotein particles, in turn tightly 
related to P (68, 69). The risk of mortality in CKD patients without dialysis is also 
increased by P (70, 71).
More recently, moderate increases in P were found to be related to a higher mortality 
risk in patients with prevalent CVD (72). Finally, data from the Framingham 
Offspring Study revealed that an increasing yet normal P was associated with risk 
of CVD in both fatal and non-fatal events (73). The findings led the authors to raise 
an important question: Can a higher yet normal phosphate be actually considered 
a cardiovascular risk factor? (Dhingra et al, Framingham Offspring Study, 2007; 
(73)).
Subsequent studies have reproduced the Framingham Study findings (74, 75), 
and have found men as the only affected sex (75, 76). Furthermore, a report from 
NHANES III has replicated the finding that the impaired survival seems not to be 
driven by hyperphosphatemia, as the results have been found with predominantly 
normal P  (76). 
These cumulative findings have been considered to be important for public health 
by the European Food Safety Authority and by the European Commission (77, 78) 
as they concern P even within its normal range. In addition, the still unrestricted 
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phosphate intake in the population – especially from food additives – can not only 
increase time-average P levels but can also induce acute adverse effects, particularly 
in the cardiovascular and renal systems (68, 79).
Given these findings, we aimed to test for evidence of these associations within the 
Rotterdam Study, applying a few constraints directed towards improved inference, 
such as strictly normal P levels and exclusion of CKD patients. Our main set of 
questions are the following:
Q4a. Is there evidence that higher - but within normal range - P increases all-
cause mortality in data from Rotterdam? If so, what specific diseases are impaired 
by P, or is it driven by cardiovascular mortality? If not, is there evidence of P 
influencing other causes of mortality, as suggested from findings in animal studies? 
Q4b. Are there sex differences in our results? 
	 	Is increasing but normal P a CV risk factor? Analysis to improve cau-
sal inference
Undoubtedly, from all possible questions concerning P & BMD in their association 
with health and disease, one of the most relevant was already raised by colleagues 
from Framingham more than 10 years ago (73). The (potential) establishment of 
increasing but normal P as a true CV risk factor would represent an important 
paradigm in the field of bone physiology, in epidemiology and, ideally, in public 
health policies. Therapeutically it would also mean a complex challenge to address.
We aimed therefore to answer this question and – eventually - provide a 
pathogenic mechanism underlying normal P levels and CV mortality. For such 
purposes, we selected coronary calcification as outcome due to its atherosclerotic 
nature, its ability to improve risk discrimination and the increased hazard for 
myocardial infarction, heart failure and death (35, 44) that it yields. Although 
severe hyperphosphatemia can induce arterial calcification of the media layer 
(80), whether this statement is also true for normal P in the intima layer has not 
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been explored from a causal perspective (81, 82).
To go further into causal inference, we aimed to apply Mendelian Randomization 
(MR), an Econometrics-derived technique based on the instrumentation of 
variables to avoid, or decrease, the chances of reverse causation and confounding 
(83, 84). P can be instrumented through its genetic variants (single nucleotide 
polymorphisms: SNPs) which genome-wide association studies (GWAS) have 
found to be associated with its levels (85, 86).
Using MR, we attempt to answer the following set of questions:
Q5a. Are P serum levels causally related to coronary calcification? If so, are the 
results driven by hyperphosphatemia, CKD or prevalent CVD? Q5b. Can we find 
evidence at the MR level of a sex-difference, strongly suggested by epidemiological 
papers on the association between P & coronary calcification, CVD morbidity 
and CVD mortality?
Part II. Sex differences in calcium and phosphate levels
	 	P and adverse outcomes: sex differences
Further studies in the general population have not only widened the spectrum 
of outcomes associated with P beyond CVD risk, but have also systematically 
reported that men are, by far, more affected by (high / high-normal / normal) 
P-related consequences than women. The outcomes where such a sex dimorphism 
have been demonstrated include: all-cause mortality at the meta-analysis level 
(76, 87), subclinical atherosclerosis (75) and CKD progression (88) and possibly 
coronary artery disease (76). 
Although from a statistical perspective the sex difference is evident, from a 
biological perspective it poses a significant challenge as women display higher P 
than men in the postmenopausal state (89) – a difference only partially mediated 
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through gonadal steroids and not through FGF23 (50, 90, 91). Higher P has been 
systematically reported in postmenopausal women than men of the same age, 
despite the findings of attenuated - or even absent - associations of P with adverse 
outcomes in women (75, 76, 92). Although there must be a complex homeostatic 
mechanism explaining this apparent paradox, to date none has been elucidated.
Based on data from the Rotterdam Study and from patients at Erasmus MC 
Hospital we attempt to answer the following set of questions:
Q6a. Do the differences in calcium and P span several age categories? Are they 
explained by gonadal steroids? Q6b. Can we find evidence in our data of another 
potential mechanism underlying the sex differences in calcium and P levels?
Part III. Genetic studies in relation to bone and phosphate
	 	  Exploring unusual genetic causes for osteoporosis and fractures: a 
Mendelian approach
Advances in genotyping technology and in joint efforts from large Consortia 
have allowed a progressive identification of genetic variants – single nucleotide 
polymorphisms: SNPs - that determine the heritable fraction of BMD (93-95). Most 
of these variants are common in frequency and individually explain a tiny amount 
of the heritability, but jointly explain an increasing proportion of the variance 
due to ever larger genome-wide association studies. Currently, under an additive 
model the variance in BMD explained by the cumulative set of SNPs identified 
in well-powered studies reaches approximately 12% (95). Some heterogeneity 
has been described according to skeletal site and to sex; this is as expected due to 
physiological differences (94). 
The current evidence supports BMD to be determined by a large number of 
variants with a small individual effect – i.e., the polygenic or infinitesimal model, 
originally proposed by Sir Ronald Fisher for quantitative traits such as height 
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(96). Nevertheless, knowledge from clinical settings has also shown the existence 
of Mendelian disorders (97) due to several genes harboring variants that when 
mutated induce large effects on BMD and fracture risk, highlighting that BMD 
genetic architecture is far from simple and fully defined.       
We include in this thesis two reports of clinical cases of severe osteoporosis 
and fractures following Mendelian inheritance and whose clinical evolution has 
diverged from expected of a common low BMD context:
 a) A cluster of five families with severe early-onset osteoporosis and 
fractures following an unusual X-linked inheritance pattern and in whom a genetic 
diagnosis of osteogenesis imperfecta could not be found.
 b) A young woman with congenital unilateral blindness who suffered from 
severe back pain after first pregnancy and delivery. The clinical workup showed 
severe osteoporosis and multiple vertebral fractures. She had close relatives with 
a positive history of osteoporosis and fractures.
Through these clinical reports, we aim to answer the following set of questions:
Q7a. What are the mutations underlying the phenotype of these patients? Are they 
lying in BMD annotated genes?  If not, what additional evidence can be obtained 
to support causality? Q7b. What lessons useful for the common clinical practice 
can be learned from these cases?    
	 	  Exploring the genetic determinants of human serum phosphate: a 
non-infinitesimal genome-wide approach through large-scale Biobanks 
Knowledge of the genetic determinants of a trait is important for understanding 
underlying biology and it can help to identify therapeutic targets (98). In addition, 
this knowledge may help in diagnostics and patient stratification in the framework 
of personalized medicine. Specifically for P as a trait, the possibility of potential 
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new therapeutics should be emphasized not only because of the high prevalence 
of CKD as a growing public health problem - reaching a prevalence of 13% 
worldwide (99) - but also because of the increasing evidence of adverse effects 
described in a strictly normal P context. This is especially the case concerning 
CVD outcomes in men (75, 76) and potentially affecting a large, but as of yet, 
undefined fraction of the general population. 
In contrast to approaches implemented for the identification of genetic 
determinants for Mendelian disorders, the genetic architecture of most complex 
traits is currently resolved by genome-wide, hypothesis-free approaches (100). 
This method is based on the interrogation between common SNPs – usually 
one at a time-  and the phenotype, and is currently known as GWAS: genome-
wide association study (101). Methods such as the assessment of populations 
stratification (102) and genomic control (103) have improved the replication of 
findings in comparison to the pre-GWAS era.
Currently, only two GWAS have been published on serum P levels in the general 
population: one on European ancestry (86), and one on Japanese ancestry (85). 
The former study included a meta-analysis involving ~16000 participants within 
the CHARGE Consortium and identified five loci influencing P levels (86). 
The latter involved a GWAS within BioBank Japan (104) and included ~42000 
participants; it showed replication of previous findings on CHARGE Consortium 
and in addition, identified another seven loci (85).
These GWAS suggest a locus close to ALPL, which encodes for the enzyme 
alkaline phosphatase (AP), as the most strongly locus associated with P levels. 
ALP hydrolyzes inorganic pyrophosphate into P - raising intracellular P levels 
but the effect on serum P levels is not yet clear (86). Nevertheless, the fraction of 
P variance explained by the identified SNPs until now is still low (<5%) and the 
studies have not determined if there is a sex-specific architecture underlying P 
levels, as might be expected from biology and epidemiological data.
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With the aim of identifying more genetic determinants of P levels, we have made 
use of the UK Biobank, a large genetic and phenotypic resource comprising half 
a million participants and available for research only in the last few years (105). 
The high degree of relatedness and stratification (106) of this cohort makes it an 
optimal candidate to apply mixed models rather than standard linear regression 
models, in order to avoid the exclusion of a large number of samples (~30%). 
Through conditioning on polygenic SNPs, mixed models can also increase the 
effective sample size (107). 
Recent developments in mixed-models software (107) allow for the incorporation 
of the non-infinitesimal model, whose underlying and more realistic assumption is 
that traits are determined by a finite number (a few thousand) of causal loci (108). 
If indeed P genetic architecture follows this pattern, a substantial gain in power for 
loci discovery can be obtained.
Through a large-scale biobanks approach, we aim to answer the following set of 
questions: 
Q8a. What are the common genetic determinants of P levels in humans? Q8b. 
Are we able to identify low frequency or rare genetic variants with large effects? 
Q8c. Is there evidence of a non-infinitesimal architecture for P? Q8d. Can we find 
evidence of a sex-dimorphism in the genetic structure for serum P levels?
Outline of this thesis
This thesis aims to provide evidence to answer the postulated questions -and 
related queries- in as much detail as possible within the following structure:
In Chapter 2, a potential association between BMD measured at the femoral neck 
and all-cause and in detailed, cause-specific mortality is tested. In particular, we 
aim to carefully evaluate whether or not the burden attributable to fracture-related 
mortality underlies or not this relation.
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In Chapter 3, we assess whether femoral neck BMD and femoral neck bone loss 
are related to coronary calcification scores. In addition, we test whether coronary 
calcification is prospectively related to fracture risk.
In Chapter 4, the tacit assumption of no association between P levels within 
the normal range and fracture risk is challenged. We proceed further to explore 
a potential association between P and BMD under normal conditions – with a 
possible meaning  for P in physiologic regulation, site-specific fracture risk, and 
the effect that CKD has on the association of P with fracture risk.  
In Chapter 5, we aim to replicate previous findings of an association of (normal) 
P with all-cause mortality but, in addition, we want to explore further whether 
all the relationship is driven by CVD mortality or if another disease (s) can be 
identified for which survival is also impaired by P, as suggested by animal studies.
In Chapter 6, we accomplish two main objectives: first, we assess whether there 
is a phenotypic relationship between serum P levels and coronary calcification 
scores. Secondly, we move deeper into causal inference by applying the Mendelian 
Randomization technique to the obtained results in order to conclude whether or 
not high-normal serum P levels are a CVD risk factor.
In Chapter 7, the influence of sex hormones and serum vitamin D levels in 
differences in calcium and phosphate levels between men and women is evaluated.
In Chapter 8, we assess whether the sex differences in calcium and phosphate 
levels are consistent across a wide range of ages.
In Chapter 9, a clinical and genetic study is presented, assessing five families with 
X-linked osteoporosis and early-onset fractures, in whom osteogenesis imperfecta 
has been excluded. This study is the result of the joint efforts of several research 
groups in the Netherlands and Germany.
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In Chapter 10, the case of a young pregnant woman with severe osteoporosis and 
vertebral fracture risk is described  to illustrate the clinical and genetic work-up 
performed in the context of a diagnosis of transient osteoporosis of pregnancy.
In Chapter 11, a large scale GWAS within the Biobanks is shown, to explore further 
the genetic variants that influence P levels in humans. We aim to test whether there 
is sex dimorphism in P genetic architecture; furthermore, we evaluate the role of 
the X-chromosome in serum  P levels.
The general aim of these studies is that the outcome of this research will not only 
add to common knowledge concerning bone and P in relation to health, disease 
and genetic factors. It will also widen the clinical perspective of bone and bone 
diseases and provide a rational for more proactive pursuit of adequate bone health 
in our patients. We also aim to increase awareness of potential P-related adverse 
effects on human health. Finally, we hope to contribute to the important initiative 
from the European Food and Safety Agency to improve the health of the general 
population regarding the dietary intake of phosphate.
Chapte r  1
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Abstract
Context: Low bone mineral density (BMD) has been associated with increased 
all-cause mortality. Cause-specific mortality studies have been controversial.
Objective: The aim of the study was to investigate associations between BMD 
and all-cause mortality and in-depth cause-specific mortality.
Design and setting: We studied two cohorts from the prospective Rotterdam 
Study (RS), initiated in 1990 (RS-I) and 2000 (RS-II) with average follow-up 
of 17.1 (RS-I) and 10.2 (RS-II) years until January 2011. Baseline femoral neck 
BMD was analyzed in SD values. Deaths were classified according to International 
Classification of Diseases into seven groups: cardiovascular diseases, cancer, 
infections, external, dementia, chronic lung diseases, and other causes. Gender-
stratified Cox and competing-risks models were adjusted for age, body mass 
index, and smoking. 
Participants: The study included 5779 subjects from RS-I and 2055 from RS-II.
Main outcome measurements: We measured all-cause and cause-specific 
mortality.
Results: A significant inverse association between BMD and all-cause mortality 
was found in males [expressed as hazard ratio (95% confidence interval)]: RS-I, 
1.07 (1.01-1.13), P=.020; RS-II, 1.31 (1.12-1.55), P=.001); but it was not found 
in females: RS-I, 1.05 (0.99-1.11), P=.098; RS-II, 0.91 (0.74-1.12), P=.362). An 
inverse association with chronic lung disease mortality was found in males [RS-I, 
1.75 (1.34-2.29), P <.001; RS-II, 2.15 (1.05-4.42), P=.037) and in RS-I in females 
[1.72 (1.16-2.57), P=.008) persisting after multiple adjustments and excluding 
prevalent chronic obstructive pulmonary disease. A positive association between 
BMD and cancer mortality was detected in females in RS-I [0.89 (0.80-0.99); 
P=.043]. No association was found with cardiovascular mortality.
Conclusions: BMD is inversely associated with mortality. The strong association 
of BMD with chronic lung disease mortality is a novel finding that needs further 
analysis to clarify underlying mechanisms.  
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Osteoporosis is a condition characterized by low bone mineral density (BMD) 
and microarchitectural deterioration leading to decreased bone strength, which 
predisposes to fragility fractures and is associated with high morbidity and mortality 
(1). Low BMD has been linked to an increased risk of fracture-independent 
mortality and could be considered a predictor of survival (2,3). Regarding cause-
specific mortality, studies on the association between BMD and cardiovascular 
disease (CVD) mortality have not been consistent, with some showing an inverse 
relation with BMD (2,4,5) whereas others found no association (6,7).  Potential 
gender differences have been found both for both CVD mortality and cancer-
related mortality, but results remain inconclusive (5,8,9). An inverse association 
between the group of remaining unspecified causes of mortality and BMD has 
been found in both genders (2,6).
Besides the association between low BMD and mortality, recent studies suggest 
that osteoporosis treatment reduces mortality, which could not be completely 
explained by a decrease in fracture-related mortality (10). Previously (3), we 
examined the relationship of femoral neck BMD with overall mortality in the first 
cohort of The Rotterdam Study (RS-I) and found an inverse association for all-
cause mortality in men but not women after average follow-up of 5.4 years. The 
aim of this study was to analyze the relationship between BMD and all-cause and 
detailed cause-specific mortality in males and females from two cohorts of the 
Rotterdam Study with long-term follow-up.  
Subjects and Methods
Study population
The Rotterdam Study is a prospective cohort study of males and females designed 
to investigate the incidence and determinants of chronic disabling diseases. 
Rationale and design have been described previously (11). Inhabitants of the 
well-defined Ommoord district in the city of Rotterdam in The Netherlands were 
invited to participate; their names and addresses were drawn from the municipal 
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register. The RS-I, initiated in 1990, consisted of 7983 subjects;  the second cohort 
(RS-II), initiated in 2000, included 3011 subjects. All participants were  >55 years 
old at recruitment and reside in Ommoord, a district in Rotterdam. Analyses were 
performed in 5779 and 2055 subjects from RS-I and RS-II, respectively - all with 
available BMD measured at baseline and signed informed consent. The Rotterdam 
Study was approved by the Medical Ethics Committee of Erasmus MC.
Dual-energy x-ray absorptiometry (DXA) scanning 
BMD was assessed using DXA. Trained radiographic technicians performed BMD 
measurements for participants with a GE Lunar DPX-L densitometer (GE Lunar 
Corp), as previously described (12). Femoral neck BMD was chosen because it is 
not affected by degenerative changes seen with age as lumbar spine is, and it has 
been proposed for defining osteoporosis in epidemiologic studies (12,13). 
Covariates
Several baseline covariates known to influence both BMD and mortality were 
included in the regression models, particularly  age, gender, body mass index 
(BMI), and smoking status (14). BMI was calculated in kilograms per meter 
squared, from height and weight measured in a standing position without shoes. 
Smoking status was assessed by interview and coded as never, former, and current 
smokers. Other potential confounders were considered in additional analyses, 
such as physical activity, prevalent morbidity,  medication, high-sensitivity 
C-reactive protein (hsCRP), and fracture incidence. For RS-I,  a lower limb 
disability score was recorded using a modified version of the Stanford Health 
Assessment Questionnaire (15). For RS-II, a questionnaire on physical activity 
was collected. Baseline comorbidities were also assessed, such as prevalent 
myocardial infarction, dementia, type 2 diabetes mellitus, and chronic obstructive 
pulmonary disease (COPD); likewise, baseline medication use information was 
collected, such as bisphosphonate, hormone replacement therapy, and systemic 
corticosteroid use. Myocardial infarction prevalence was verified by a cardiologist, 
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a general practitioner (GP), or electrocardiogram. Prevalent COPD, diabetes 
mellitus, and dementia were defined as previously described (11,16). hsCRP 
was assessed as a marker of inflammation. Continuous covariates are described 
as mean and SD if there is normality of distribution; otherwise, median and 
interquartile range are shown.  Fracture events were obtained from computerized 
records of GPs in the research area (covering 80% of the cohort); additionally, 
research physicians regularly followed participant information in the GPs’ records 
outside the research area. All reported events were verified by two trained research 
physicians, who independently reviewed and coded the information. Finally, all 
coded events were reviewed by a medical expert for final classification according 
to the International Classification of Diseases, 10th revision (ICD-10) (17). 
Participants were followed from the baseline visit until January 1, 2007, or until a 
first fracture or death occurred. In addition, thoracolumbar spine radiographs were 
collected at both the baseline visit and the second follow-up visit (between 1997 
and 1999). All thoracolumbar spine radiographs of the follow-up visit were scored 
morphometrically for the presence of vertebral fractures using the McCloskey/
Kanis method (18). If a vertebral fracture was diagnosed, the baseline radiograph 
was also evaluated, and if present, it was considered a prevalent vertebral 
fracture. If it was not present at baseline, the fracture was considered as incident. 
Information on spinal radiographs was available for 3145 subjects with baseline 
DXA information.
Assessment of cause-specific mortality
Information on vital status is obtained continuously from the municipal autho-
rities in Rotterdam. The cohorts are monitored for major disease outcomes and 
mortality through computerized linkage of the study database to GPs’ medical 
files. For subjects who moved outside Ommoord, these data are obtained from 
GPs, who report all important events through a computerized system (3). Two 
research physicians independently coded the mortality events according to ICD-
10 (19). Medical specialists in the respective field reviewed the coded events and 
confirmed the diagnosis. Information on cause-specific mortality was available 
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until January, 2011. 
Different causes of mortality were recorded according to ICD-10 codes and first 
grouped into cardiovascular diseases (CVD), cancer, and “other causes” (5,6). To 
perform comprehensive analyses, the group of other causes was further catego-
rized into external causes, dementia, infections, chronic lung disease, and other 
causes, following a slightly modified previous approach (8). This categorization 
yielded seven groups: CVDs (cardio- and cerebrovascular diseases; ICD10 codes 
I05-I30.0, I31, I32, I32.8, I34-I37, I42-I79, I81-I99, G95.1, F01), Cancer (codes 
C00-D09.9), chronic lung diseases (COPD comprised 80% of this group; codes 
J21.9, J39.9, J40, J42-J84.9, J90-J96), dementia (mostly Alzheimer’s disease, co-
des F00, F02, F03, F05.1), external causes (mainly fatal fractures; mostly hip frac-
tures, but also accidents and suicides; codes S00-T98 except T82.7), Infectious 
diseases (pneumonia and septic shock were the most common; codes A00-B99, 
G00-G09, I30.1, I32.0, I32.1, I33.0, J15-J18, J85-86, J41, K35-K38, K57.0, 
K75.0, I38-I41, I80, M00.9, M86, N71, T82.7) and other causes (heterogeneous 
group composed mainly of unspecified, unattended and sudden death and a mino-
rity of nontumoral gastrointestinal, renal, hematologic and cerebral diseases, seni-
lity and cachexia; codes D10-D48.9, E00-E90, D50-D89.9, G10-G26, K22-K34, 
K40-K52, K55.0, K56, K64, K73, K80, K83, K92, L12, L88, M05, M06, M31, 
M35, N03, N04, N10,N17, N18, N28, R54, R64, R96, R98, R99).  
Statistical Analyses
For analysis of all-cause and cause-specific mortality, BMD was expressed in SD 
values, calculated as (patient BMD-cohort BMD mean)/cohort BMD SD, specific 
for gender. For RS-I, BMD was further categorized according to the number of 
SD (T-scores)- below the mean BMD for young adults (age, 20-29 y), leading to 
three strata: osteoporosis (T-score < -2.5), osteopenia (-2.5  < T-score < -1.0), and 
normal BMD (T-score > -1.0). Reference values for normal BMD were extracted 
from the Third National Health and Nutrition Examination Survey (NHANES III) 
for a non-Hispanic white population (20).   
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Table 1. Baseline Characteristics of the Participants of the Rotterdam Study with 
Femoral Neck BMD Measurement Available
RS-I RS-II
Males Females Males Females
n 2438 3341 954 1101
Age, y 66.5 (61.3-72.7)a 67.5 (61.5-74.0)
a
61.5 (8.9)
b
61.4 (7.9)
b
BMI, kg/m2 25.6 (23.8-27.6)
a
26.2 (23.9-29.1)
a
26.7 (4.2)
b
26.8 (5.8)
b
FN BMD, g/cm
2
0.91 (0.82-1.00)
a
0.82 (0.73-0.91)
a
0.97 (0.13)
b
0.89 (0.14)
b
Never smokers, n (%) 197 (8) 1706 (51) 502 (53) 861 (78)
Former smokers, n (%) 1517 (62) 961 (29) 206 (22) 3(<0.1)
Current smokers, n (%) 711 (29) 646 (19) 243 (25) 234 (21)
Prevalent DM, n (%) 252 (10.3) 325 (9.7) 128(13.4) 112 (10.2)
Prevalent MI, n (%) 258 (10.6) 419 (12.5) 62 (6.5) 19 (1.7)
Abbreviations: FN, femoral neck; DM, diabetes mellitus; MI, myocardial infarction.
a
 Median (interquartile range). 
b
 Mean (SD).
To assess the relation between BMD and mortality, Cox proportional hazard 
regressions were used, adjusting for age, BMI, and smoking. The proportional 
hazard assumption of the Cox models was assessed using the Schoenfeld resi-
duals-based test - the standard diagnostic test. Both the P value for the BMD 
covariate itself and the P value for the global model were taken into account. For 
cause-specific mortality, additional analyses were performed running the com-
peting-risk regressions based on the method of Fine and Gray (21) and taking 
into account informative censoring due to competing events. Proportionality was 
tested, evaluating interaction terms with time. All significant hazard ratios (HRs) 
reported here do not violate the proportionality assumption and thus are cons-
tant over follow-up time, unless stated otherwise. Analyses were sex-stratified 
because: 1) previous reports on gender differences have been described in the re-
lation between BMD and mortality; and 2) Cox proportional hazards assumption 
violations were found due to gender. Because of fracture-related mortality (22), 
analyses were further adjusted for fracture incidence as a time-varying covariate. 
HRs with 95% confidence interval (CI) are expressed: 1) per decrease in SD of 
BMD; and 2) per category of osteopenia or osteoporosis, setting normal BMD as 
the reference. In a later step, analyses were repeated after exclusion of participants 
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with fatal events within the first 3 years, taking into account that low BMD might 
be a marker of underlying illness.
The association between BMD and cause-specific mortality was evaluated 
through cumulative incidence curves (CICs) instead of Kaplan Meier curves, 
which overestimate the risk probability when there are several types of possible 
events (21). CICs were calculated after running competing-risk regressions. 
Results from individual cohorts were meta-analyzed. SPSS version 17 (SPSS 
Inc) and Stata version 12 (StataCorp) were used for the individual analyses. 
Comprehensive Meta-Analysis version 2.0 (Biostat) was used for the meta-
analysis.
Results
All-cause mortality
In total, 5779 RS-I and 2055 RS-II subjects were followed for a median of 17.1 
years and a mean of 10.2 years, respectively. During the follow-up, 3117 deaths 
occurred in RS-I and 295 in RS-II. Baseline characteristics for both cohorts 
are presented in Table 1. In both cohorts, a significant and inverse association 
between BMD and overall mortality was found in males, expressed as HR (95% 
confidence interval[CI]): RS-I, 1.07 (1.01-1.13), P=.020; RS-II, 1.31 (1.12-1.55), 
P= .001. In females, there was no association with overall mortality in either 
cohort. Adjustment for incident fractures yielded essentially the same results (data 
not shown). 
Cause-specific mortality
A brief description of each cause and the frequencies are shown in Table 2. The 
HRs for BMD and cause-specific mortality adjusted for age, BMI, and smoking 
are shown in Table 3. 
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Table 2. Description and Frequencies of Cause-specific Mortality for Participants 
with BMD Available in RS-I and RS-II, up to 2011
Cause Description       RS-I RS-II
CVD Cardio- and cerebrovascular pathology 1021 (32.8) 89 (30.1)
Cancer All cancer-related deaths    829 (26.6) 110 (37.3)
Other causes
Non-cancerous gastrointestinal, hema-
tological, cerebral and renal pathology; 
cachexia, senility, unattended, unspeci-
fied, and sudden death
640 (20.5) 45 (15.3)
Dementia Dementia as final cause of death 241 (7.7) 18 (6.1)
Infectious diseases All infectious-related deaths 162 (5.2) 12 (4.1)
Lung diseases COPD, interstitial diseases, respiratory failure 121 (3.9) 13 (4.4)
External causes Mainly hip fractures, accidents, suicides 91 (2.9) 7 (2.4)
Missing causes Cases without ICD-10 codification 12 (0.4) 1 (0.3)
Total    3117 (100) 295 (100)
Data are expressed as number (percentage).
A relationship between lower BMD and higher chronic lung disease mortality was 
observed in RS-I and RS-II for males [RS-I, HR, 1.75 (95% CI, 1.34-2.29), P < 
.001; RS-II, 2.15 (1.05-4.42), P=.037) and in RS-I for females [1.72 (1.16-2.57), 
P= .008]; whereas for females in RS-II, a similar but nonsignificant trend was 
observed [1.77 (0.28-11.2), P= .544) with only two deaths due to chronic lung 
disease. Most cases of chronic lung disease mortality were due to COPD (RS-I 
and RS-II combined, 104 of 134 cases, 77.6%), whereas the non-COPD cases 
were mainly due to interstitial pulmonary disease, pneumonitis, and unspecified 
respiratory failure. When we restricted the analyses to COPD mortality, the 
association between BMD and COPD mortality showed similar or even higher 
HRs than for chronic lung disease mortality (data not shown).
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Table 3. All-Cause and Cause-Specific Mortality HRs for RS-I and RS-II per 
Decrease in SD of Femoral Neck BMD
Males Females
No.  of 
Deaths
HR (95%CI) P
No of
Deaths
HR (95%CI) P
All-cause
RS-I 1488 1.07 (1.01-1.13) .020  1629 1.05 (0.99-1.11) .098
RS-II 177 1.31 (1.12-1.55) .001 118 0.91 (0.74-1.12) .362
Cardiovascular
RS-I 507 0.97 (0.88-1.07) .576 514 0.99 (0.90-1.09) .865
RS-II 52 1.24 (0.91-1.67) .168 37 0.91 (0.63-1.32) .615
Cancer
RS-I 438 1.04 (0.94-1.15) .453 391 0.89 (0.80-0.99) .043
RS-II 66 1.29 (0.99-1.68) .060 44 0.91 (0.65-1.27) .598
Other causes
RS-I 266 1.18 (1.02-1.35) .021 374 1.21 (1.07-1.37) .003
RS-II 27 1.25 (0.82-1.91) .293 18 0.66 (0.41-1.07) .092
Dementia
RS-I 67 1.08 (0.82-1.42) .594 174 1.20 (0.99-1.45) .060
RS-II 09 1.83 (0.93-3.60) .081 09 0.91 (0.40-2.08) .822
Infections
RS-I 84 1.14 (0.89-1.46) .295 78 0.93 (0.72-1.20) .572
RS-II 06 0.84 (0.41-1.74) .650 06 2.51 (0.81-7.78) .111
Chronic lung disease
RS-I 81 1.75 (1.34-2.29) <.001 40 1.72 (1.16-2.57) .008
RS-II 11 2.15 (1.05-4.42) .037 02 1.77 (0.28-11.2) .544
External causes
RS-I 37 1.26 (0.86-1.82) .231 54 1.87 (1.30-2.68) .001
RS-II 05 1.58 (0.59-4.23) .361 02 0.96 (0.18-5.12) .958
Adjustments were made for age, smoking, and BMI. 
Boldface data corresponds to hazard ratios with statistically significant P values.
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The HR magnitudes for chronic lung disease mortality were higher for males than 
females in both cohorts, and this difference remained after further adjustments 
for baseline medication use, such as bisphosphonates and hormone replacement 
therapy use (data not shown). Furthermore, adjustments for corticosteroid use, 
prevalent and incident radiographic and clinical vertebral fractures, log C-reactive 
protein (CRP) and lower limb disability score, and exclusion of COPD prevalent 
cases yielded similar results (Table 4). Figure 1A shows RS-I CICs (ie, the 
probability of dying of a chronic lung disease taking into account competing 
risks) for participants of median age, according to baseline BMD in SD values 
and adjusted for gender, BMI, lower limb disability, and smoking. Figure 1, 
B-D, shows the CICs stratified by smoking status in RS-I. Figure 1, E-H, shows 
correspondent CICs for RS-II.
There was a significant relationship between BMD and mortality due to other 
causes in RS-I [for males, HR, 1.18 (95% CI, 1.02-1.35), P=.021; for females 
1.21 (1.07-1.37), P=.003]; whereas it was not significant in RS-II. Subanalysis of 
this group in RS-I attributed mortality mainly to unattended death, sudden death-
cause unknown, and unspecified cause of mortality. For females in RS-I, there was 
a significant relationship between external causes of mortality and BMD [1.87 
(1.30-2.68), P=.001], driven mainly by hip fracture mortality and a significant 
positive association between BMD and cancer mortality [0.89 (0.80-0.99), P= 
.043), whereas no associations were found in men. 
There were no significant associations between BMD and mortality due to CVD, 
dementia, or infectious diseases. 
Results from competing-risk regression models were similar to Cox models (data 
not shown). 
The HRs from combined analysis of the two cohorts mostly reflected the results 
from the much larger RS-I cohort, both in all-cause and in cause-specific mortality 
analysis (data not shown).
45
Chapte r  2
Further adjustments for baseline comorbidity, bisphosphonate use, log CRP, and 
physical exercise did not substantially change the results in either cohort or gender 
(data not shown).
Risk of all-cause and cause-specific mortality in subjects with osteopenia and 
osteoporosis compared to those with normal BMD in RS-I
When analyzing the mortality in subjects with osteopenia and osteoporosis com-
pared to those with normal BMD in RS-I, similar trends were found as with BMD 
in SD, except that females with osteoporosis also had increased risk of death. For 
all-cause mortality in RS-I, the HR for males with osteopenia was 1.26 (95% CI, 
1.10-1.43; P< .001); and the HR for males with osteoporosis was 2.40 (1.39-4.16; 
P= .002), compared with those with normal BMD (Figure 2). Females with os-
teoporosis had 1.66 (1.17-2.35; P= .004) times increased risk of death. For chronic 
lung diseases mortality, males with osteopenia had 2.21 (1.34-3.62), P= .002) 
times increased risk, whereas for those with osteoporosis, the risk was increased 
16.6 times (5.84-47.0), P< .001). Females with osteoporosis had 5.91 (1.20-29.0; 
P= .029) times increased risk for chronic lung diseases mortality. Figure 2, A and 
B, shows the HRs for all-cause mortality and mortality due to chronic lung disea-
se in males and females with normal BMD, osteopenia, and osteoporosis. These 
analyses have been adjusted for age, BMI, and smoking. Further adjustments for 
incidental fractures yielded similar results (data not shown).
Exclusion of participants with early fatal events
Analyses excluding participants who died within the first 3 years of follow-up did 
not change results essentially (data not shown). 
Discussion   
  
In these analyses in two large prospective cohorts of elderly subjects from the 
Rotterdam Study, femoral neck BMD in SD was significantly inversely related 
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to overall mortality in males but not in females. This relationship was not driven 
by fracture-related mortality because adjustment for incident fractures yielded si-
milar results. However, both males and females with osteoporosis had increased 
risk of death compared to those with normal BMD. When assessing cause-spe-
cific mortality in detail, we found a novel and inverse relation in both genders 
between BMD and mortality related to chronic lung diseases (mainly COPD).
Figure 1. A, CIC for chronic lung disease mortality according to baseline BMD expressed in SD 
values (BMDsd), adjusted for gender, BMI, lower limb disability and smoking, for participants 
of median age of RS-I cohort. B-D, CIC according to baseline smoking status: current smokers 
(B), former smokers (C), and never smokers (D). The solid line represents participants with avera-
ge BMD (BMDsd=0), and the dashed line represents participants with 3 SD below average BMD 
(BMDsd= -3). The analysis time is in years. E, CICs for chronic lung disease mortality according 
to baseline BMD expressed in BMDsd (BMDsd= -3). The analysis time is in years. E, CICs for 
chronic lung disease mortality according to baseline BMD expressed in BMDsd, adjusted for gen-
der, BMI, physical activity, and smoking, for participants of median age of RS-II cohort. F-H, CIC 
according to baseline smoking status: current smokers (F), former smokers (G), and never smokers 
(H). The solid line represents participants with average BMD (BMDsd=0) and the dashed line re-
presents participants with 3 SD below average BMD (BMDsd= -3). The analysis time is in years. 
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Figure 1. Continued.  
In RS-I there was a significant inverse relationship between BMD and other cau-
ses of mortality in both genders, which was mainly observed in participants with 
unattended, unspecified, and sudden deaths. An inverse association of BMD with 
external causes of mortality (mainly due to hip fracture) was found in females in 
RS-I. No association was found between BMD and CVD mortality, dementia-re-
lated mortality, and death due to infectious diseases in either cohort. To the best 
of our knowledge, the relation we found between baseline BMD and chronic lung 
disease mortality has not been described before. The direction of association was 
consistent between genders and study cohorts and  was not explained by prevalent 
COPD. Males and females with osteoporosis in RS-I had a 17 and 6 times increa-
sed risk of death due to chronic lung disease, respectively. It has been known that 
patients with COPD are at increased risk for low BMD and fractures (23,24), part-
ly related to factors such as older age, smoking, physical inactivity, corticosteroid 
use, and low BMI (25), the latter being one of the more important determinants of 
low BMD according to a recent systematic review (26). All of these factors have 
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been taken into account in our analyses, and the HRs did not change, suggesting 
that other, yet unknown factors explain this relationship between BMD and COPD 
mortality. Chronic inflammation, associated to COPD, may induce low BMD, 
but additional adjustments for hsCRP did not modify the associations. Likewise, 
smoking, the most recognized environmental trigger for COPD (27), produces 
profound bone loss, mainly through increased osteoclast activity (28). Smoking 
induces IL-17 production, which is related to the development of emphysema 
(29) and is a potent inductor of inflammatory bone loss via stimulation of receptor 
activator of nuclear factor-κB ligand (30). Nevertheless, adjusting for smoking 
did not modify the association, and competing risk regression analyses showed 
similar associations in smokers as in nonsmokers. 
Although vertebral fractures could compromise lung function and thus mortality 
(31,32), we did not find this to be an explanation for our findings because 
adjustment for prevalent and incident vertebral fractures did not modify results. 
Alternative explanations may be low vitamin D levels, which may lead to 
decreased BMD, as well as impaired lung function, or sarcopenia, and/or physical 
inactivity. COPD patients have a high prevalence of hypovitaminosis D and 
sarcopenia (33,34). Unfortunately, vitamin D levels were not available at baseline, 
but adjusting for disability index, which might be expected to associate with both 
low vitamin D and physical inactivity, did not change results. It was recently 
reported that the presence of anti-citrullinated protein antibodies is related to bone 
loss years before the occurrence of rheumatoid arthritis (35,36), while also being 
related to the development of airway abnormalities (37). This or other common 
factors might underlie our findings. Alternatively, a causal relationship between 
osteoporosis and (deaths from) other diseases like COPD cannot be ruled out since 
bone influences multiple other tissues and organs, eg, through its endocrine and 
immune-modulating properties as has been shown by multiple recent studies (38). 
Future studies should investigate a potential role of vitamin D, body composition, 
muscle strength, physical activity and potential common factors such as anti-
citrullinated protein antibodies. 
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Figure 2. All-cause (A) and chronic lung disease (B) mortality HRs for participants from 
RS-I, according to T-score, adjusted for age, BMI, and smoking status. *, P< .05; **, P< .001 
compared to normal T-score. x, P< .05; xx P< .001 osteoporosis compared to osteopenia.
Also, based on our findings it would be of public health importance to study fur-
ther whether treatment of osteoporosis in patients with COPD would influence 
their mortality and potential pulmonary function.
In both studies, we found that femoral neck BMD was significantly inversely 
related to overall mortality in males but not  in females. However, female subjects 
with osteoporosis also had increased risk of death. The relation between BMD and 
mortality in males was explained by an association with mortality from several 
causes, and similar findings  were seen  in females, except in the relation with 
cancer mortality. We found a decreased HR for cancer mortality with decreasing 
BMD in females, which may explain the absence of an association with overall 
mortality in females. A gender difference in cancer mortality was found in 
th NHANES I cohort (5), with a significantly increased HR for males but not 
females. Possible diverging associations between BMD and cancer mortality will 
have to be further investigated in well-powered studies.  
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We did not find a consistent association between BMD and CVD mortality, 
adding to the inconsistent literature findings of such a relationship. We found 
no association between BMD and dementia-related mortality. There is always 
the possibility that a low bone mass reflects a poor pre-existing health status, 
which may lead to increased mortality. We tried to account for this by excluding 
participants with mortality within the first 3 years of follow-up, but results were 
essentially the same.
This study has several limitations and strengths. A potential selection bias may 
have occurred since subjects who came to the research center at baseline for tests 
were healthier; however, if present, a dilution of the observed effects would be ex-
pected. Also, residual confounding cannot be excluded. Another weakness is that 
baseline COPD diagnosis was made based on clinical grounds and not in all cases 
on spirometry data, which is the “gold standard” method. Therefore, we cannot 
exclude the possibility of misclassification of COPD status at baseline, but it is not 
likely that this explains our finding. Also, we had no information on cumulative 
dose of corticosteroids in the past, only current use at baseline. Another potential 
limitation stems from the fact that the entire cohort is composed of European 
Caucasians, limiting the generalizability of our findings to other populations or 
ethnic groups.  
One  strength  is the availability of two large prospective and similarly well-cha-
racterized, population-based prospective studies with accurate determination of 
causes of death. In general, data of The Netherlands registers is recognized as 
reliable and consistent (39), and more than 85% of the death registries in these 
cohorts were coded with high certainty level. As with any survival analyses, the 
completeness of follow-up is important, because when low it produces biased 
estimates (40). For both cohorts, the corresponding values for completeness of 
follow-up were higher than 90%, reassuring us that effect estimates obtained are 
valid.
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In summary, we found an inverse relationship between BMD and all-cause 
mortality in males and an increased risk of death for male and female subjects 
with osteoporosis compared to those with normal BMD. This relationship was 
explained by several underlying causes, such as chronic lung disease mortality, 
trauma and other causes. A potential gender difference in the relation between 
BMD and cancer-related mortality with a positive association between BMD and 
cancer related mortality in females may explain the absence of an inverse relation 
between BMD and all-cause mortality in females. The consistent finding in both 
genders in both studies of an inverse and strong association between baseline 
BMD and chronic lung disease mortality has not been reported before and needs 
further study into the underlying pathophysiological mechanisms. 
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Abstract   
Objectives: Vascular calcification has been associated inconsistently to low bone 
mineral density and fractures. The aims of the present study were to investigate 
the associations between coronary artery calcification (CAC) and BMD change, 
BMD and fracture risk in elderly subjects of the population-based Rotterdam 
Study.
Methods: BMD was assessed through dual-energy X-ray absorptiometry and 
CAC through Electron-Beam Computed Tomography in 582 men and 694 women. 
We investigated the associations between BMD change (6.4 years follow-up) and 
CAC at follow-up and between BMD and CAC (measured simultaneously). In 
sensitivity analyses we stratified analyses for estradiol levels in women. The 
association between CAC and fracture risk (9 years follow-up) was tested through 
competing-risks models. Models were sex-stratified and adjusted for age, body 
mass index, smoking, bisphosphonate use and  age at menopause. 
Results: There was no association between BMD change and CAC in men. In 
women, each 1% increase in annual BMD loss was significantly associated with 
higher follow-up CAC [β=0.22 (0.06 – 0.38), p=0.006; prevalence ratio: 4%]. 
Stratified analyses showed significant associations between BMD loss and follow-
up CAC only in women with lower estradiol levels. We found no association 
between CAC and fracture risk and no association between BMD and  CAC 
cross-sectionally.
Conclusions: BMD loss was associated with higher follow-up CAC in women, 
which might be related to low estrogen levels. No association between CAC 
and BMD or fracture risk was found. Further studies are required to elucidate 
the mechanisms that might underlie the association between BMD change and 
coronary calcification in women.
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1. Introduction
Osteoporosis and cardiovascular disease (CVD) are common age-related diseases 
that have an increased co-existence independent of shared risk factors such as 
increased age, menopause, physical inactivity, alcohol intake and vitamin D 
deficiency [1]. Common pathophysiological mechanisms have been proposed 
such as inflammatory cytokines, oxidized lipids, increased homocysteine levels 
and decreased estrogen levels [1].
Vascular calcification is defined as the abnormal deposition of calcium in the 
vascular system [2]. Formerly considered a passive consequence of atherosclerosis, 
it is nowadays recognized as a highly active process associated with an increased 
risk of cardiovascular events independently of other traditional risk factors [3]. The 
resemblance that ectopic calcification shares with the normal calcification process 
of bone is remarkable and several studies [4,5] have verified the observation made 
by Virchow in 1863 that cardiovascular calcification is “an ossification, not a mere 
calcification”. [6]
 
The increased co-existence of vascular calcification with osteoporosis [7] is 
called the calcification paradox. It has motivated several investigators to evaluate 
whether bone mineral density (BMD) and vascular calcification (VC) in several 
vascular beds are associated beyond the aging process and independent of potential 
confounders [8-14]. Among studies with a cross-sectional design, an inverse 
relation between aortic or coronary artery calcification (CAC) and BMD has been 
reported by some [8.9] but not others [10,11]. In contrast, longitudinal studies 
have consistently shown that increased BMD loss is associated with increased 
aortic vascular calcification assessed through different imaging modalities, such 
as X-rays and radiogrammetry [12,13] as well as through computed tomography 
[14], this relation has not been explained by aging and other shared risk factors and 
has been found mainly in women. Longitudinal studies evaluating the association 
between bone turnover and CAC have been performed mainly in subjects with 
chronic kidney disease, and results have been inconsistent; while some studies 
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have shown that low bone turnover is associated with increased risk of CAC [15] 
others have not replicated such findings [16].
Studies addressing the association between vascular calcification and fracture risk 
have focused mainly on aortic calcification, and the results have been conflicting. 
While some of them have reported an increased fracture risk with increased 
vascular calcification [14,17], other studies have not found such results [11,18].
Since previous studies found an association in women between  BMD loss and 
aortic vascular calcification we aimed to investigate whether in the prospective 
population based Rotterdam study changes in BMD are associated with vascular 
calcification measured in the coronary arteries (CAC) in either sex and whether 
CAC is associated with incidental fractures and BMD. We also studied whether 
findings can be explained by hormonal status or bone turnover.
2. Materials and methods
2.1. Study population
The Rotterdam Study is a prospective cohort study of elderly men and women 
designed to investigate the incidence and determinants of chronic disabling 
diseases. Rationale and design have been described elsewhere [19]. The Rotterdam 
Study I cohort (RS-I) was initiated in 1990 and consisted of 7983 participants. 
All subjects were >55 years at recruitment and reside in Ommoord, a district 
in Rotterdam and they have been assessed at baseline and through four follow-
up visits. BMD was measured in all follow-up evaluations of the participants, 
and CAC scores were measured at RS-I-3 (third evaluation of the RS-I cohort). 
In total, 1276 subjects had available information on CAC levels, previous BMD 
measurements and incident fracture data (Fig. 1). The Rotterdam Study was 
approved by the Medical Ethics Committee of Erasmus MC.
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RS - I - 3
Third visit
1997 - 1999
BMD
LAB
BMD
CAC
BMD and CAC
cross-sectional
(n=1420)
CAC and fracture risk
( 9 y follow-up, n=1680)
BMD change and CAC
(6.4 y follow-up, n=1276)
BMD: femoral neck BMD assessment (DXA)
CAC: coronary artery calcification assessment ( electron-beam Computed Tomography)
LAB: laboratiry examination
RS - I - 1
Baseline
visit
1989 - 1993
Figure 1. Flowchart for time line, design and sample size for the analyses
2.2. DXA scanning
BMD was assessed using dual-energy X-ray absorptiometry (DXA). Trained 
radiographic technicians performed BMD measurements for participants at the 
first visit (1990-1993) and the third visit (1997-1999) with a GE Lunar DPX-L 
densitometer. For the longitudinal analysis of  BMD change  and its association 
with follow-up CAC, absolute annual percent BMD change at the femoral neck 
was calculated with the formula [100 * (BMDRS-I-1 – BMDRS-I-3)/(BMDRS-I-
1)*time length between measurements] [20], with a positive value reflecting BMD 
loss. Results are expressed per 1% increase in annual femoral neck BMD loss. 
Femoral neck BMD (from henceforth referred to simply as BMD) was chosen, 
as it is not affected by degenerative changes seen with age as lumbar spine BMD 
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and has been proposed for defining osteoporosis in epidemiologic studies [21]. For 
the cross-sectional analyses of BMD and CAC, BMD is expressed in sex-specific 
standard deviations (SD).
2.3. Coronary artery calcification assessment
At the third visit of the Rotterdam Study all participants who completed the 
third phase of the Rotterdam Study were invited to participate in the Rotterdam 
Coronary Calcification Study [22]. Epicardial coronary arteries calcification was 
detected by electron-beam Computed Tomography (EBT; C-150 Imatron Scanner, 
GE Healthcase, South San Francisco, CA). Before the subjects were scanned, 
they performed adequate breath-holding exercises. From the level of the root of 
the aorta through the heart, 38 images were obtained with a 100-ms scan time 
and a 3-mm slice thickness. During one breath hold, images were acquired at 
80% of the cardiac cycle by using echocardiographic triggering. Quantification 
of coronary calcification was performed with AccuImage software (AccuImage 
Diagnostics Corporation, South San Francisco, CA) displaying all pixels with a 
density >130 Hounsfield Units (HU). The presence of calcification was defined 
as a minimum of 2 adjacent pixels (area=0.65 mm2) with a density > 130 HU. 
Calcium scores were calculated by multiplying the area in mm2 of individual 
calcified lesions with a factor based on the peak density of the lesion. The total 
calcification score for the entire epicardial coronary vascular system comprised 
the sum of the scores for all individual lesions.
2.4. Fracture assessment
Fracture events were obtained from computerized records of general practitioners 
(GPs) in the research area (covering 80% of the cohort); additionally research 
physicians regularly followed participant information in the GP’s records outside 
the research area. All reported events were verified by two trained research 
physicians, who independently reviewed and coded the information. Finally, all 
coded events were reviewed by a medical expert for final classification according 
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to the International Classification of Diseases, tenth revision (ICD-10) [23]. 
Participants were followed from the date of the CAC scan until January 1, 2007, 
or until a first fracture or death occurred.
2.5. Covariates
Several covariates known to influence both BMD and coronary artery calcification 
scores (CACs) [4,24-26] were included in the regression models, particularly age, 
smoking, body mass index (BMI) and medication use (missingness <2%). BMI 
was calculated in kg/m2, from height and weight measured in standing position 
without shoes. BMI change was calculated as the absolute difference between 
measurements in the first and third visit of the Rotterdam Study. Smoking status 
was assessed by interview and coded as never-, former- and current smokers. 
Cigarette pack-years (for former and current smokers) were calculated as duration 
of smoking (in years) multiplied by the number of smoked cigarettes, divided 
by 20. Regarding medication use information, more than 99% of participants 
collected their drug prescriptions at seven regional pharmacies, which are 
fully computerized. Complete drug use information is available as of January 
1st, 1991. The pharmacy data include the Anatomical Therapeutical Chemical 
(ATC) code from the World Health Organization (WHO) Collaboration Centre 
for Drug Statistics Methodology, the collection dates, total amount of drug 
units and product names of the drugs. Adjustments in our analyses were done 
for bisphosphonate [2] and hormone replacement therapy (HRT) use [27] due to 
the fact that both medication types have potential beneficial effects on vascular 
calcification. Bisphosphonate use was defined as exposure to the antiresorptive 
medication of at least 365 cumulative days before the date of the CAC scan. 
Further adjustments were done for serum lipid reducing therapy (mainly statins) 
and diuretic use, due to its effects on BMD and potential influence in coronary 
artery calcification  [28].
Baseline comorbidity status was included in several models, namely prevalent 
diabetes mellitus, heart failure, peripheral artery disease and myocardial infarc-
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tion; definition of such cases has been previously described elsewhere [29-32].
Laboratory covariates included in the analyses were 17β-estradiol (pmol/L) and 
alkaline phosphatase (missingness of 78% and 21% , respectively). For these mea-
surements, non-fasting blood samples were drawn by venipuncture at the baseline 
visit between 0830 and 16 h. Platelets were removed by centrifugation and sam-
ples were stored at -80 C until measurements. 17β-estradiol (E2) was measured 
by direct immunoassay, and alkaline phosphatase (AP) was measured through 
an enzymatic colorimetric method. Other covariates included for further adjust-
ments were total cholesterol, creatinine, 25-hydroxyvitamin D, serum calcium 
and phosphate levels, measured from blood samples obtained at baseline as pre-
viously described [19]. Intake of dietary calcium and Vitamin D was assessed by 
interview at baseline for food intake assessment using an extensive semi quantita-
tive food frequency questionnaire (FFQ) at the study center by a trained dietician 
[19]. 
Additionally, analyses done for women were adjusted for age at menopause, co-
llected by interview in the first visit.
2.6.  Statistical analysis
Due to high skewness of the CAC measurements distribution that could not be 
completely corrected after log transformation, the association between BMD 
or BMD change and CAC scores was tested through generalized linear models, 
allowing Gaussian but also non-normal distributions for continuous variables. 
Log-transformed CAC scores (Ln(CAC+1)) were set as the dependent variable, 
with either BMD or BMD change as independent variables, adjusted for potential 
confounders. Fitness of different models was compared through the Akaike 
Information Criteria – AIC [33], models  with lower values corresponding to a 
better fit. For assessment of the CAC score  status in a binary fashion (yes/no), 
prevalence ratios were obtained with a log link instead of logit link, due to the 
fact that odds ratios overestimate the relative risks when the outcome is highly 
prevalent [34]. Assessments were made for BMD change  and prevalent CAC at 
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the third visit of the Rotterdam Study, between CAC and subsequent fractures, 
and cross-sectionally for BMD and prevalent CAC both measured during the 
third visit (see Fig. 1).  
As part of sensitivity analyses, we tested the significance of the interaction terms 
between BMD change with 17β-estradiol and alkaline phosphatase levels in those 
subsets with these measurements available (n=161 and n=556 with 17β-estradiol 
and alkaline phosphatase levels available, respectively) and performed stratified 
analysis according to 17β-estradiol (pmol/L) and alkaline phosphatase (U/L) 
levels, setting the cut-off point at the median value. Furthermore, analyses were 
performed after exclusion of participants with prevalent cardiovascular disease.
The association between CAC scores (at third visit) and incident fractures during 
follow-up was tested using competing-risks regression models which yield 
hazard ratio estimates and allow for informative censoring [35]. In this setting, 
the outcome of a fracture might not be seen because death occurs first, mainly 
because important risk factors for fracture incidence are shared for all-cause 
mortality [36]. For this analysis, the beginning of the follow-up period was set 
as the date of the CAC scan. The proportionality assumption was tested building 
interaction terms with time.
Analyses were performed with subjects with complete information on covariates, 
exposure and outcome.
SPSS (version 21.0, Armonk, NY: IBM Corp) and Stata (version 12, College 
Station TX: Stata Corp LP) were used for analyses. Statistical significance was 
defined as p<0.05.
3.  Results
General characteristics of the population with information available on BMD 
change and CAC are displayed in Table 1. Age and BMI were similar between 
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men and women. Men had higher BMD, lower BMD loss rate, heavier smoking 
habits, and almost six-times higher CAC scores than women. CAC prevalence 
was high in both men and women (more than 85%). 
The association between BMD change at the femoral neck (between baseline and 
third visit over an average of 6.4 y period) and follow-up CAC is depicted in Table 
2. We found no significant associations in men  [β= -0.02 (95%CI: -0.20 – 0.17), 
p=0.85); CAC prevalence ratio of 1%, p=0.16]. 
Table 1. General characteristics of the study population of 1276 men and women 
with information available on both BMD change and CAC 
Men (n=582) Women (n=694)
Visit 1 Visit 3 Visit 1 Visit 3
Age (y)a 64.1 
(59.9-68.2)
70.5 
(66.4-74.9)
63.7 
(59.8-68.2)
70.2 
(66.3-74.7)
BMI (kg/m2)a 25.9 
(24.2-27.9)
26.2 
(24.4-28.4)
25.9 
(23.6-29.0)
26.8 
(24.1-30.0)
BMD (g/cm2)b 0.93 (0.13) 0.91  (0.13) 0.86 (0.13) 0.81 (0.13)
Annual FNBMD
change (%)a
- 0.37 
(-0.18-0.86)
- 0.78 
(0.22-1.37)
Prevalent CAC (%) n/a 569 (98%) n/a 591 (85%)
CAC scorea n/a 271.5 
(58.3-925.8)
n/a 48.7 
(4.4-289.8)
Age at menopausea (y)  n/a n/a 50.0 (46-52)
Smoking (%)c 544 (93%) 535 (92%) 372 (54%) 369 (53%)
Prevalent CV diseased (%) 121 (21%) - 94 (13%) -
a Median and interquantile range
b Mean and standard deviation
c Current and former smokers
d Prevalent cardiovascular disease, defined as prevalent myocardial infarction, heart failure or 
peripheral artery disease
In women, we found that each 1% increase in annual BMD loss was signifi-
cantly associated with higher CAC score on follow-up [β= 0.22 (0.06 – 0.38), 
p=0.006] and with higher CAC prevalence ratio of 4% (p=0.007). Adjustment for 
bisphosphonate use (n=48 users among a total of 1276 analysed subjects) did not 
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essentially change results. Additionally, adjustments for prevalent diabetes 
mellitus status, lipid lowering therapy (mainly statins) use, diuretic use, and levels 
of 25 hydroxyvitamin D, calcium, phosphate, creatinine and total cholesterol and 
dietary intake of calcium and vitamin D at baseline yielded similar results (data 
not shown). These “full-model” analyses were performed in a smaller subset of 
participants with available information in all mentioned covariates (n=235 men 
and n=290 women).
We investigated a potential relation between CAC scores and any type of fracture 
(total number of events=254; Table 3). We found no associations for any type of 
fracture incidence in either sex (Table 3).
We performed a cross-sectional analysis of BMD and CAC scores at the third 
visit (see Fig. 1), and found no association for either sex (men: β= -0.03 (-0.20 
- 0.13), p=0.68; women: β= 0.01 (-0.16 - 0.19), p=0.89). Likewise, BMD was not 
associated with CAC prevalence in either sex in this cross-sectional analysis 
(Supplementary Table 1).
3.1. Sensitivity analysis
To further explore the association between BMD loss and follow-up CAC, we 
built interaction terms between BMD loss and two categories of respectively 
17β-estradiol (E2) and alkaline phosphatase (AP) stratified by the median values 
(n=161 and n=556 women with E2 and AP measurements available, respectively). 
The p value results for both interaction terms were suggestive (p=0.13); therefore 
we proceeded to stratify the analysis of BMD loss and CAC by median level of E2 
and AP. Table 4 shows that the associations between BMD loss and CAC seems 
to be confined to women with E2 levels below the median [β=0.55 (0.08-1.03), 
p=0.02] and to women with AP levels above the median [β=0.36 (0.12-0.60), 
p=0.003]. 
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In addition, we investigated the influence of HRT use (n=119 HRT users) and 
prevalent CVD (n=96 women) on the relationship between BMD change and fo-
llow-up CAC in women, and the results remained robust after these additional 
analyses (data not shown).
4.  Discussion
Overall we found that BMD loss (within an average period of 6.4 years follow-up) 
was significantly associated with higher follow-up CAC scores in women persis-
ting after adjusting for multiple factors. This relationship was not observed for 
men,  and we found no association of CAC scores with subsequent fractures in 
either sex.
Table 2.  Annual percent BMD change at femoral neck and CAC scores in RS-I-3 
Model I Model II
CAC as continuous variable
 n  β (95% CI)a p n β (95% CI)a p
Men 582 -0.02 (-0.20 - 0.17) 0.85 582 -0.02 (-0.21 – 0.17) 0.83
Women 694 0.22 (0.06 – 0.38) 0.006 694 0.23 (0.07 - 0.39) 0.005
CAC as binary variableb
n PR (95% CI)c p n PR (95% CI)c p
Men 582 1.01 (0.99-1.02) 0.16 582 1.01 (0.99-1.02) 0.16
Women 694 1.04 (1.01 – 1.07) 0.007 694 1.04 (1.01-1.07) 0.007
Statistically significant results are highlighted in bold.
Model I: adjusted for age, BMI, delta BMI, smoking; in women also age at menopause.
Model II: adjusted for covariates in Model I + bisphosphonate use before the date of the scan.
a β from linear regression for log CAC scores for 1% annual increase in BMD loss 
(100* [BMDRS-I-1 – BMDRS-I-3]/[BMDRS-I-1]*time length between measurements)
b CAC binary refers to presence/absence of CAC. Present CAC is defined as a CAC score above 0.
c Prevalence ratio of CAC for 1% annual increase in BMD loss.
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Table  3. Risk of incidence of all types of fracture as a function of CAC scores at 
RS-I-3 (third visit)
Model I Model II
no. of fxs HR (95% CI)a p no. of fxs  HR (95% CI)a p
All- fracture incidence
Men 83/808 1.01 (0.90-1.14) 0.80   64/615 0.96 (0.86-1.08) 0.48
Women 171/872 1.02 (0.95-1.10) 0.48 124/655 0.99 (0.91-1.07) 0.75
Hazard ratios derived from competing-risks regression models.
Model I. Adjusted for age, BMI and smoking at RS-I-3.
Model II. Adjusted for covariates in Model I + BMD at RS-I-3.
a Hazard ratios expressed per increase in log CAC.
Our results are in line with three previous longitudinal studies that reported a 
significant association between BMD loss and vascular calcifications in the 
aorta in women [12-14] but associations of BMD change with CAC have not 
been reported in the general population to the best of our knowledge. We hereby 
describe for the first time an association with CAC in a general population setting 
of elderly (aged over 55 years). The association we found was not confounded by 
age, smoking, changes in BMI or bisphosphonate treatment. 
The fact that BMD loss was associated with CAC among women only might su-
ggest involvement of underlying hormonal factors as potential mechanisms. Ex-
ploratory stratified analyses showed that the association of BMD loss with CAC 
scores was observed in those women with lower baseline estradiol suggesting that 
low E2 levels could be involved in the development of both coronary calcification 
and BMD loss. 
We found a significant association in the subgroup of women with higher AP levels, 
which may reflect higher bone turnover status induced by estradiol deficiency in 
the postmenopausal state [37]. AP induces the degradation of pyrophosphate (Pi), 
that plays a key role in ectopic calcification inhibition [38] that otherwise would 
occur in most tissues due to the fact that collagen, ubiquitously present, acts as 
a potent nucleating agent for the deposition of hydroxyapatite crystals [39]. The 
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increased AP levels in the postmenopausal state [40] may lead to lower Pi levels 
and therefore loss of inhibition of vascular calcification.
Vascular Smooth Muscle Cells (VSMC) can undergo differentiation towards an 
“osteoblast-like” phenotype, changing from a contractile to a synthetic state with 
subsequent secretion of extracellular matrix that eventually gets calcified [4,41]. 
There are several pathophysiological mechanisms that could explain the role 
that E2 plays in vascular calcification inhibition. In the first place, E2 prevents 
atherosclerotic plaque development [42], the only type of lesion that can get 
calcified in the coronary arteries as Mönckeberg’s medial calcification does not 
occur in this vascular bed [43]. 
Table 4.  Annual percent BMD change at femoral neck and CAC scores in RS-I-3 
(third visit) in women stratified by baseline 17β-estradiol (E2) and alkaline phos-
phatase (AP) levels
n    β (95% CI)a   p n   β (95% CI)a p
E2 >16.4 pmol/Lb E2 <16.4 pmol/Lb
Women 81 -0.03 (-0.49 – 0.42) 0.88 80 0.55 (0.08 – 1.03) 0.02
 AP <76 U/Lc AP >76 U/Lc
Women 278 0.06 (-0.22 – 0.34) 0.68 278 0.36 (0.12 – 0.60) 0.003
Models adjusted for age, BMI, delta BMI, and smoking 
a β from linear regression for log CAC scores for 1% annual increase in BMD loss                                                
(100* [BMDRS-I-1 – BMDRS-I-3]/[BMDRS-I-1]*time length between measurements)
b E2 corresponds to baseline 17β-estradiol levels. Cut-off point was set at median value
c AP corresponds to baseline alkaline phosphatase levels. Cut-off point was set at median value
It has been previously shown that the administration of E2 decreases VSMC 
proliferation in animal and human models, through activation of nitric oxide 
synthase [44] and through decreased mitogen-induced VSMC proliferation. In 
second place, VSMC and endothelial cells express RANK, RANKL and OPG, 
and therefore can respond to RANKL stimulation. RANKL induces VC through 
an increase in bone morphogenetic protein 2 (BMP-2, the main stimuli of AP) 
and a decrease in matrix Gla protein (MGP), an inhibitor of VC. Importantly, 
E2 is able to attenuate RANKL-induced VC [42]. Therefore, through differential 
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actions in the expression of key proteins, E2 preserves the original contractile 
VSMC features, decreasing trans-differentiation towards a calcifying phenotype 
[44].
The beneficial effects of E2 on the coronary bed have been reported only in 
women [45]. This observation may explain the absence of a significant association 
between BMD loss and CAC in men in our study, despite the fact that BMD 
loss in the aging men is also associated with estradiol deficiency [46]. Consistent 
with our results, Kiel and colleagues previously described a lack of association 
between BMD loss and aortic calcification in men from the Framingham cohort 
[12].
We observed no different association between  BMD loss and CAC regarding 
previous HRT use, suggesting that perhaps exogenous estradiol administration 
did not counterbalance the loss of atheroprotective effects associated with 
menopausal-related endogenous 17β-estradiol decrease. However, it should be 
emphasized that the age of HRT initiation or its duration in women from our 
cohort might not have been appropriate or long enough respectively to achieve 
a protective effect against coronary calcification, as the majority of HRT users 
reported a treatment length of less than 5 years and a previous RCT showed a 
beneficial effect of HRT after an average of 8.7 years of treatment in women aged 
50-59 y at enrollment [27]. Nevertheless, it is important to mention that the effects 
of estrogen in the vascular system are complex and robust evidence has proven 
that in general HRT lacks sufficient beneficial effects on cardiovascular disease in 
both primary and secondary prevention settings in postmenopausal women [47].
Similar to other prospective studies performed in aortic calcification [11,18], we 
found no significant association between CAC and all-fracture risk in either sex 
during a mean follow-up of 9 years. This analysis takes risk of death into account. 
Of note, significant associations between aortic calcification and fractures have 
been previously [17] reported in studies with cross-sectional designs or with 
utilization of odds ratios as estimates of relative risks precluding determination 
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of causality for the calcification process on fracture risk. Furthermore, different 
devices in assessing bone mineral density, diversity in covariates adjusted for 
or different cohort characteristics might limit the comparability of results from 
multiple studies. We used electron-beam CT, which is a high sensible device to 
identify calcification and is superior to fluoroscopic measures; this is one of the 
strengths of our study.
Further strengths of our study include the prospective design in BMD change and 
fracture assessment with high completeness of follow-up [48] (more than 95%) 
that allows a better determination of how the natural history of disease might 
occur. The availability of several important confounders aid to decrease the bias 
introduced by risk factors that influence BMD loss and CAC. The assessment of 
longitudinal measurements of BMD using the same device avoided the need for 
calibration. The stratified analyses according to 17β-estradiol, AP levels and HRT 
use provide a deeper insight into the mechanisms and suggest that low estradiol 
levels may underlie both increased BMD loss and higher CAC but since these 
results derive from small subgroup analyses they require replication in larger 
(cohort) studies. There are other limitations. The analyses were performed in a 
subsample of the Rotterdam Study with available data on CAC measurement. 
However, despite some minor differences, characteristics of the responders to 
the Rotterdam Coronary Calcification Study were highly similar to those of the 
nonresponders [22]. Another limitation of the study is the lack of availability of 
PTH and FGF23 serum levels. Nevertheless, an association between long-term 
exposure of high PTH and vascular calcification has been demonstrated mainly in 
patients with renal dysfunction [49] and FGF23 does not seem to induce vascular 
calcification [50]. Despite multiple adjustments, residual confounding cannot be 
discarded. The fact that the entire cohort is composed of European Caucasians 
limits the generalizability of our findings to other populations or ethnic groups. 
Besides, the relatively short follow-up time available for the incidental fracture 
analysis might have limited our ability to detect an association between CAC and 
fracture risk. Furthermore, the stratified analysis according to E2 and AP levels 
were performed only in a small subset of women with such information available. 
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In conclusion, we found that BMD loss is significantly associated with higher CAC 
scores on follow-up in women only and we found no association between CAC 
levels and subsequent fractures. Our findings suggest that endogenous estradiol 
deficiency might underlie both pathological processes and thus be a shared risk 
factor for BMD loss and CAC but further studies are required to replicate these 
findings. Further research is warranted to explain the mechanisms that might 
underlie the association between BMD loss and CAC in women.
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Abstract
Extreme phosphate levels (P) have been associated with mineralization defects and 
increased fracture risk. Whether P within normal range is related to bone health in 
the general population is not well understood. To investigate the association of P 
with bone mineral density (BMD) and fracture risk, we assessed two population-
based cohorts: the Dutch Rotterdam Study (RS-I, RS-II, RS-III; n = 6791) and the 
US Osteoporotic Fractures in Men (MrOS; n = 5425) study. The relationship of 
P with lumbar spine (LS) and femoral neck (FN) BMD was tested in all cohorts 
via linear models; fracture risk was tested in RS-I, RS-II, and MrOS through Cox 
models, after follow-up of 8.6, 6.6, and 10.9 years, respectively. Adjustments were 
made for age, body mass index, smoking, serum levels of calcium, potassium, 
25-hydroxyvitamin D, estimated glomerular filtration rate (eGFR), FN-BMD, 
prevalent diabetes, and cardiovascular disease. Additional adjustments were 
made for phosphate intake, parathyroid hormone, and fibroblast growth factor 
23 levels in MrOS. We further stratified by eGFR. Results were pooled through 
study-level metaanalyses. Hazard ratios (HR) and betas (β) (from meta-analyses) 
are expressed per 1 mg/dL P increase. P was positively associated with fracture 
risk in men and women from RS, and findings were replicated in MrOS (pooled 
HR all [95% CI]: 1.47 [1.31–1.65]). P was associated with fracture risk in subjects 
without chronic kidney disease (CKD): all (1.44 [1.26–1.63]) and in men with 
CKD (1.93 [1.42–2.62]). P was inversely related to LS-BMD in men (β: –0.06 
[–0.11 to –0.02]) and not to FN-BMD in either sex. In summary, serum P was 
positively related to fracture risk independently from BMD and phosphate intake 
after adjustments for potential confounders. P and LS-BMD were negatively 
related in men. Our findings suggest that increased P levels even within normal 
range might be deleterious for bone health in the normal population. 
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Introduction
Phosphorus is the main mineral in the bone, where it is deposited together 
with calcium.(1) The intracellular compartment contains approximately 14% of 
phosphorus, and only 1% circulates freely in plasma as phosphate (P).(2) Within 
bone, phosphorus accumulates in the form of hydroxyapatite.(3) Phosphorus 
bioavailability is crucial for appropriate mineralization; (4) conditions of low 
phosphate are characterized by defective mineralization and excessive amount of 
unmineralized bone, or osteoid, typical of rickets/osteomalacia.(5,6) On the other 
hand, extreme hyperphosphatemia induces tumoral calcinosis, characterized by 
ectopic calcifications but also by mineralization defects.(7–9)
The recent finding that P regulation is exerted also by the phosphatonins 
a-Klotho and the osteocyte-derived fibroblast growth factor 23 (FGF23)(7,10) has 
established the concept that bone is not only a P reservoir but also acts as an 
endocrine organ,(3) regulating P levels and mineralization. Therefore, a potential 
bidirectional relationship between P levels and bone can be postulated, in which 
adequate P availability allows bone mineralization,(1) while osteocytes regulate P 
levels through FGF23 synthesis and through master control of bone remodeling.
(11,12)
Despite this important role of P in bone, it is not known whether serum P is 
associated with bone mineral density (BMD) or fracture risk at the population 
level. This research has been scarce and assessed mostly in chronic kidney disease 
(CKD) patients.(13,14)
The aims of this research were to study the relation between P and BMD and 
fractures in two population-based cohorts, to study the influence of potential 
confounders, and to assess the existence of sex-specific effects, which have 
been previously described for some clinical outcomes mainly in the field of 
cardiovascular disease.(15,16)
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Materials and Methods
This research was performed in three cohorts from the Dutch Rotterdam Study(17) 
(RS-I, recruitment period 1989–1993, original n = 7983; RS-II, recruitment period 
2000–2001, original n = 3011; RS-III, recruitment period 2006–2008, original n 
= 3932; all subjects aged 45 years or older) and in the US Osteoporotic Fractures 
in Men (MrOS) study(18,19) (recruitment period 2000–2002, original n = 5994; all 
male subjects aged 65 years or older). Fasting serum P levels were measured in 
the third follow-up visit of RS-I and in baseline visits of RS-II, RS-III, and MrOS 
(Fig. 1). Fasting P levels were chosen because the fasting state might modify 
the association of P with clinical outcomes.(20) Fracture incidence was collected 
prospectively until January 1, 2007, in RS-I and RS-II, and until January 8, 2015, 
in MrOS. Fracture incidence was not assessed in RS-III. A total of 12,216 and 
11,196 participants were included for the BMD and fracture analyses, respectively, 
all with signed informed consent. The Rotterdam Study was approved by the 
Medical Ethics Committee of Erasmus Medical Center; MrOS was approved by 
the Institutional Review Board of each of the six clinical centers that enrolled 
participants.
Laboratory measurements
The Rotterdam Study
The concentration of phosphorus in serum corresponds to the inorganic fraction, 
or phosphate (P), based on the formation of ammonium phosphomolybdate.(1) 
Total calcium (Ca) determination was performed through a colorimetric 
o-cresolphthalein complexone method. Levels of 25-hydroxyvitamin D (25OHD) 
were determined through an electrochemiluminescence-based immunoassay 
(Elecsys Vitamin D Total, Roche Diagnostics, Mannheim, Germany); the test 
sensitivity was 10 nmol/L, the test range was 7.5 nmol/L to 175 nmol/L, the within-run
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/      /      /       /      /       /      /       /      /      /       /      /      /      /       /      /       /      /
2006 2007200019971989
RS - I - 1
First visit
1989 - 1993
LS - BMD
RS - I - 3
Third visit
1997 - 1999
LAB *
FN - BMD
P and BMD
cross - secional
(n = 2824)
Fasting P levels and fx risk
(8.6 y follow-up, n = 3304)
P and BMD
cross - secional
(n = 1956)
P and BMD
cross - secional
(n = 2011)
RS - II
First visit
2000 - 2001
LAB *
FN - BMD
LS - BMD
RS - III
First visit
2006 - 2008
LAB *
FN - BMD
LS - BMD
Fasting P levels and fx risk
(6.6 y follow-up, n = 2483)
Figure 1. Flowchart for time line, design, and sample sizes for the 
analyses of the Rotterdam Study cohorts. LAB* includes fasting phosphate levels.
FN-BMD = femoral neck BMD; LS-BMD = lumbar spine BMD; P = fasting phosphate levels; 
Fx risk = fracture risk.
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precision <6.5%, and the total precision <11.5%. We applied cosinor regressions 
to adjust 25OHD levels for season and year.(21) Creatinine was determined through 
a sarcosine-based colorimetric assay and standardized against isotope dilution 
mass spectrometry (ID-MS).
MrOS
Serum P, creatinine, and Ca were measured using a Roche COBAS Integra 800 
automated analyzer. P detectable range was 0.3 to 20.0 mg/dL, creatinine was 0.2 
to 15.0 mg/dL, and Ca was 0.1 to 20.0 mg/dL. Concentrations of 25OHD2 and 
25OHD3 were analyzed by liquid chromatography/tandem mass spectrometry 
(MS) in a subgroup (n = 2351) and added together to obtain total 25OHD levels 
using multiple reaction monitoring as previously described.(22) Additionally, free 
concentrations of 25OHD were measured in a subgroup (n = 541) by ELISA 
(DIAsource ImmunoAssays, Louvain-la-Neuve, Belgium) at Future Diagnostics 
Solutions (Wijchen, The Netherlands). This measurement was validated by 
comparison with equilibrium dialysis at 37°C in 15 normal samples, yielding a 
correlation of 0.83. The lower limit of detection was 1.9 pg/mL and its precision 
was less than 6%.(23) Serum 25OHD levels were adjusted by season. Measurements 
were performed at the Mayo Medical Laboratories in Rochester, MN, USA.
Parathyroid hormone (PTH) levels were completed using fasting morning blood 
samples, and samples were frozen until measurement. Immunoradiometric Assay 
from Scantibodies (3KG600) at Columbia University was used to measure total 
intact PTH (pg/mL). Fibroblast growth factor 23 (FGF23) levels were completed 
at the UC Davis Medical Center by two-site monoclonal antibody ELISA using 
the millipore method. The lower limit of detection was 3.3 pg/mL. Bone turnover 
markers were measured in a specialized laboratory (CCBR, Synarc, Lyon, 
France); type I collagen N-propeptide (PINP, Roche Diagnostics) was measured 
as marker of bone formation, with intra- and interassay coefficient of variation 
(CV) of <4.4%. For bone resorption, βC-terminal cross-linked telopeptide of type 
I collagen (βCTX, Roche Diagnostics) was measured, with intra-and interassays 
CVs <4.2%.(24)
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DXA scanning
Trained radiographic technicians performed BMD measurements using dual-
energy X-ray absorptiometry (DXA). RS-I participants were assessed at baseline 
(lumbar spine-LS-BMD, RS-I-1, 1989–1991) and at the third visit (femoral neck 
FN-BMD, RS-I, 1997–1999), whereas RS-II and RS-III participants were assessed 
at both skeletal sites at baseline visits (2000–2001; 2006–2008, respectively), as 
depicted in Fig. 1. A GE Lunar DPX-L densitometer was used in the assessments 
of RS-I and RS-II, and a Prodigy total body fan-beam densitometer(25) in RS-III 
(GE Lunar Corp, Madison, WI, USA). MrOS participants were assessed at both 
skeletal sites at the baseline visit; each US center used a DXA machine of the 
same model and manufacturer (QDR 4500, Hologic Inc, Waltham, MA, USA).(18) 
Machines across all six sites were cross-calibrated.
Fracture assessment
In the Rotterdam Study, information on incident clinical fracture events (of all 
skeletal sites) was obtained from computerized records of general practitioners 
(GPs) and hospital registries in the research area (covering 80% of the cohort), 
which are regularly checked by research physicians who review and code the 
fracture information according to ICD-10;(26) in addition, research physicians 
regularly followed participant information in the GP’s records outside the research 
area and made an independent review and encoding of all reported events.(27) All 
fractures are described by a radiologist, and in case of doubt the actual radiographs 
were reviewed. Finally, an expert in osteoporosis reviewed all coded events for 
final classification.(28,29)
Because access to medical specialists in The Netherlands is possible only through 
the GP, we do not anticipate that a considerable number of fractures could have 
been treated by orthopedic or traumatology surgeons without previous notification 
by GP. In The Netherlands, there is a 24-hour general practitioner evening and 
night center available after regular working hours and the GP is automatically 
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informed after discharge with a report about the diagnosis. Additionally, insurance 
companies do not cover expenses from the emergency room when patients have 
not been referred by the GP. Therefore, a significant underestimation of fractures 
is not anticipated in RS cohorts.
Incident fracture events were reported by participants in MrOS at 4-month 
intervals on brief mailed questionnaires.(30) The response rates exceeded 99%. 
Subsequently, study physicians centrally adjudicated reported fractures from 
medical records. Incident fractures were confirmed by radiology reports or 
radiographic images when reports were not available.(31) Only fractures that are 
confirmed by the adjudication process are included in MrOS data set. Health care 
service providers sent a film copy or digital image of the X-ray to the Coordinating 
Center for review and confirmation by a radiologist.
Fracture outcomes
Initially, we tested the association between P and all-fracture incidence; 
subsequently, we analyzed fractures located at the hip, vertebrae, wrist, humerus, 
and rib. We also included osteoporotic fractures, defined as fractures at any 
skeletal site except fingers, toes, skull, and facial fractures.(32)
Covariates
Because of previously reported differences in P levels for men and women,(33) 
we compared its distribution across sexes in the Rotterdam Study applying 
t tests. We assessed the distribution of potential confounders in subjects with 
FN-BMD information available across P quintiles, applying age-adjusted tests 
for trend. We included age, body mass index (BMI), smoking status, FN-BMD, 
prevalent diabetes mellitus, and levels of total Ca, 25OHD, potassium, creatinine, 
and estimated glomerular filtration rate (eGFR). Prevalent diabetes mellitus and 
cardiovascular disease were determined as previously described.(34) Alcohol intake 
was estimated at baseline through a validated food frequency questionnaire. 
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The Chronic Kidney Disease Epidemiology Collaboration equations based on 
creatinine levels(35) and the Modification of Diet in Renal Disease (MDRD) study 
equation(36) were applied to estimate eGFR (mL/min) in the Rotterdam Study and 
MrOS, respectively. Phosphate intake information collected at the same visit as 
fasting P was available in a subgroup from MrOS. This dietary information is 
from the Block Dietary Systems Food Frequency Questionnaire (FFQ), which 
was specially designed for the MrOS study as a brief FFQ for older adults, based 
on the NHANES III dietary recall data and including 69 items.
Statistical analyses
A potential association between P levels and BMD was tested through generalized 
linear models, allowing Gaussian but also non-normal distributions. BMD in sex-
specific standard deviations (SD) was set as the dependent variable, and P levels 
in mg/dL (1 mg/dL = 0.32 mmol/L) was set as the independent variable, adjusted 
for age, BMI, and smoking; site and race adjustments were included in MrOS. 
Betas (β) are expressed per 1 mg/dL increase in P levels. Fitness of different 
models was compared through the Akaike Information Criteria (AIC);(37) linear 
models with normal distributions displayed lower AIC values, corresponding to a 
better fit. The results from these analyses were meta-analyzed. LS-BMD was not 
measured simultaneously to P assessment in RS-I (Fig. 1).
We explored associations of P levels with fracture risk applying Cox models, 
testing the proportionality of the hazards through Schoenfeld residuals tests.
(38) Results from RS-I, RS-II, and MrOS were pooled through study-level meta-
analysis, applying a fixed-effects model because of the small number of studies 
involved.(39) The analysis time was set at the date of blood draw for fasting P 
levels. Subjects were followed until the first of the following events happened: 
first fracture, death, loss to follow-up, or censoring. Hazard ratios (HRs) are 
expressed per 1 mg/dL increase of P levels or in study-specific quintiles.
Adjustments were made first for a basic model including age, BMI, and 
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smoking;(40–42) site and race were also included in MrOS (Model I). Analyses in 
RS cohorts were also adjusted for a dummy variable to account for different DXA 
machines. We further adjusted the analyses for additional covariates included 
in a full model (Model II), composed of FN-BMD, calcium, potassium, eGFR, 
alcohol intake, and prevalent cardiovascular and diabetes mellitus; additionally, 
this model included season-corrected 25OHD adjustment in the full RS cohorts. 
We have adjusted for total 25OHD levels in MrOS in a subgroup with this 
information available.
Because of sex differences in P levels(33,43) and in the association of P with several 
outcomes,(15,16) we explored relations of P with bone traits in sex-combined and in 
sex-stratified models in RS cohorts.
Sensitivity analyses
To account for the potential confounding effect of renal impairment in the 
association between P levels and bone traits, we stratified the fracture analyses at 
an eGFR threshold of 58 mL/min, the estimated cut-off for P counterregulatory 
hormones triggering in early kidney disease.(44) In MrOS, subgroup analyses were 
performed in subjects with laboratory results of total and free 25OHD, PTH, and 
FGF23. Also in MrOS, we adjusted the fracture analyses for phosphate intake 
(available in 99.3% of the study population).
In addition, we repeated analyses including only subjects from both cohorts with 
P levels within normal range (0.81 to 1.45 mmol/L; 2.5 to 4.5 mg/dL).
Primary analyses were performed with subjects with complete information on 
covariates. The completeness of information on covariates for those participants 
with available P samples was more than 99% in MrOS (with the exception of 
subgroup analyses) and approximately 75% in the Rotterdam Study cohorts. 
Subsequently, missing values in the Rotterdam Study cohorts were imputed via 
multiple imputation with chained equations, following guidelines for imputation 
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for the Cox model.
Analyses were performed with SPSS (version 21.0, IBM Corp, Armonk, NY, USA), 
Stata (version 13, StataCorp LP, College Station, TX, USA), and Comprehensive 
Meta-Analysis (version 2.0).
Results
The distribution of relevant covariates across quintiles of P is depicted in Tables 1 
and 2. P and Ca levels were higher in women than in men in the three RS cohorts 
(p < 0.001). P levels lie within normal range (0.81 to 1.45 mmol/L; 2.5 to 4.5 mg/
dL) in the vast majority ( ~95%) of each study population. 
Phosphate is not associated with FN-BMD; it is negatively correlated with
LS-BMD in men from Rotterdam Study but not MrOS
Tables 3 and 4 show the relationship between P levels and BMD. We found no 
association between P and FN-BMD (Table 3) in men (pooled β [95% CI]) (β: 
–0.04 [–0.08 to 0.01], p = 0.096). In women, a negative association was found in 
the age-only adjusted model (β: –0.15 [–0.22 to –0.08], p < 0.001), but it became 
non-significant after adjustment for BMI.
We found a negative relationship between P levels and LS-BMD (Table 4) in the 
pooled results from men (β: –0.06 [–0.11 to –0.02], p = 0.007), which was driven 
by men from RS cohorts (β: –0.12 [–0.19 to –0.04], p = 0.002) and not significant 
in men from MrOS (β: –0.03 [–0.09 to 0.03], p = 0.360). In women, a negative 
association was found in the age-adjusted model (pooled β: –0.15 [–0.22 to –0.08], 
p < 0.001), but this became non-significant after adjustment for BMI. Therefore, 
the significant association between P levels and LS-BMD in sex-combined 
analysis (β: –0.06 [–0.09 to –0.02], p = 0.004) was driven by a significant negative 
association in men.
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Phosphate is associated with all-type fracture risk in men and women
Table 5 shows results from analyses of P levels and fracture risk in RS-I, RS-II, 
and MrOS after follow-up of 8.6, 6.6, and 10.9 years, respectively. During the 
follow-up period, a total of 1825 cases of incident fractures were recorded. In 
the basic model, each 1 mg/dL increase in P levels was significantly associated 
with an increase in all-type fracture risk in male subjects from the Rotterdam 
Study and in MrOS and borderline significantly in women. In the full model, 
the associations were statistically significant in all groups: Results for men were 
hazard ratio (HR) = 1.52 (1.34 to 1.74), p<0.001; results for women were 1.32 
(1.04 to 1.67),   p = 0.023; results for sex and study-combined analyses were 
HR = 1.47 (1.31 to 1.65), p <0.001. In MrOS, further adjustments for season-
corrected total 25OHD in the full model yielded similar results: HR = 1.49 (1.17 
to 1.90), p = 0.001; n = 2345). In both cohorts, adjustments for vitamin D (using 
different methods) did not influence results; furthermore, season adjustment in 
MrOS did not change results. In the full model, there was no statistical evidence 
for sex interaction in the association between P and fracture risk in RS cohorts 
(pheterogeneity = 0.258).
Phosphate in quintiles and fracture risk
Analyses of P in quintiles and fracture risk suggested a dose-effect relation in 
both RS-I (the RS cohort with more fracture events) and MrOS (Tables 6 and 7). 
After adjustments in Model I, data from RS-I showed a significant trend for in-
creasing P and fracture risk in both men (HRs for the fourth quintile = 2.07 [1.21 
to 3.57], p = 0.008, and for the fifth quintile = 2.27 (1.33 to 3.90), p = 0.003 against 
the first quintile; ptrend<0.001) and women (HRs for the fourth quintile = 1.50 [1.08 
to 2.09], p = 0.016, and for the fifth quintile = 1.47 [1.05 to 2.05], p = 0.026, against 
the first quintile; ptrend = 0.022). A similar trend was observed in MrOS (HRs for 
the fourth quintile = 1.23 [1.01 to 1.49], p = 0.040, and for the fifth quintile: 1.59 
[1.32 to 1.93], p<0.001, against the first quintile; ptrend<0.001).
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Subtypes of fractures
Results of different subtypes of fractures can be found in Supplemental Table S1. 
In studies and sexes combined we found that P levels were related to all types of 
fractures. 
Although effects sizes could not be compared due to the difference in numbers 
of fractures, it appeared that the strongest associations were found for (clinical) 
vertebral fractures in men while women displayed a stronger association for 
humerus fractures.
Sensitivity analyses
The stratified fracture analyses according to eGFR (Supplemental Table S2) 
showed that the association between P and fractures was not abolished after 
restricting the analyses to subjects with eGFR >58 mL/min (pooled results for 
sex and studies combined: Model I HR = 1.43 [1.27 to 1.61], p < 0.001; Model II 
HR = 1.44 [1.26 to 1.63], p < 0.001).
Additionally, men with eGFR <58 mL/min from both populations displayed a 
significant relation between P and fracture risk in both the basic and full models 
(RS men, Model I HR = 2.24 [1.01 to 4.98], p = 0.048; Model II HR = 4.05 [1.38 
to 11.9], p = 0.011; men from MrOS, Model I HR = 1.90 [1.40 to 2.58], p < 0.001; 
Model II HR = 1.81 [1.32 to 2.49], p < 0.001). The pooled result for men yielded: 
Model I HR = 1.94 (1.46 to 2.58), p < 0.001, and Model II HR = 1.93 (1.42 to 2.62), 
p < 0.001.
Women with eGFR <58 mL/min displayed no significant association between P 
and fracture risk.
Results for P and fracture risk after excluding subjects with abnormal values of 
P were significant in men (RS men HR = 1.79 [1.26 to 2.56], p = 0.001; MrOS 
men: 1.55 [1.33 to 1.81], p = 0.001) (data not shown). The pooled results yielded 
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HR = 1.59 (1.38 to 1.83), p < 0.001. In women, the relation between normal P and 
fracture risk was not statistically significant (HR = 1.12 [0. 89 to 1.40], p = 0.330). 
In study and sex-combined analyses, the results were HR = 1.44 (1.28 to 1.62), 
p < 0.001.
Analyses after applying multiple imputation did not substantially modify the re-
sults obtained in the analyses with the complete cases (data not shown).
Additional adjustments in MrOS
The additional adjustments for total and free 25OHD, FGF23, and PTH 
levels in a subgroup of men from MrOS (Supplemental Table S3) did not 
substantially modify the significant association between serum P and fracture 
risk (PTH-adjusted HR = 1.50 [1.18 to 1.90],  p = 0.001; FGF23-adjusted HR 
= 1.69 [1.25 to 2.29], p = 0.001; total 25OHD-adjusted HR = 1.49 [1.18 to 
1.89], p = 0.001; free 25OHD-adjusted HR = 1.73 [1.16 to 2.59], p = 0.008). 
The multivariate analyses showed no modification in the results either.
Table 7. Risk of Incidence of All Types of Fractures as a Function of Phosphate 
Levels Categorized in Quintiles in Men From MrOS
Men
P levelsa HRb,c
mean (range) Events/no. risk (95% CI) p
2.6 (1.8–2.8) 188/1085 1.00 (reference)
2.9 (2.8–3.0) 206/1081 1.14 (0.94–1.39) 0.194
3.2 (3.1–3.3) 190/1081 1.06 (0.87–1.30) 0.558
3.4 (3.3–3.5) 213/1083 1.23 (1.01–1.49) 0.040
3.8 (3.5–6.8) 249/1079 1.59 (1.32–1.93)  <0.001
ptrend <0.001
a P levels expressed in mg/dL.
b Hazard ratios are age, body mass index, smoking, site, and race adjusted; first quintile was set 
as reference. 
c Hazard ratios are derived from Cox models.
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The same pattern was observed after stratification by kidney function (GFR 58 
mL/min; Supplemental Table S4) in both strata.
Further adjustments for dietary phosphate intake in men from MrOS did not 
change results (Model I HR = 1.53 [1.33 to 1.76], n = 5394, Model I adjusted 
for dietary phosphate, calcium, and energy intake HR = 1.53 [1.33 to 1.76], n = 
5394; Model II HR = 1.48 [1.16 to 1.89] n = 2333, Model II adjusted for dietary 
phosphate, calcium, and energy intake HR = 1.48 [1.16 to 1.89], n = 2333).
Additional analyses performed in MrOS in a subset (n = 988) with bone turnover 
markers available did not change results: Model I HR = 1.34 (0.94 to 1.90) n = 937, 
Model I adjusted for PINP and βCTX HR = 1.34 (0.94 to 1.90), n = 933; Model 
II HR = 1.35 (0.94 to 1.95), n = 933, Model II adjusted for PINP and βCTX HR = 
1.36 (0.94 to 1.97), n = 933.
Discussion
In these population-based cohorts, serum P levels were positively and significantly 
associated with fracture risk in both sexes. These associations were independent of 
BMD and not explained by multiple potential confounders. Although associations 
appeared stronger in men than in women in the Rotterdam Study, there was no 
statistical evidence for a sex difference. P was inversely associated with LS-BMD 
only in men from the Rotterdam Study, although in combined analyses of sexes 
and cohorts, this association remained significant. No associations were found 
with FN-BMD. In women, a relation between P and BMD at both skeletal sites 
was completely explained by a previously described association of P with BMI.(43)
The results from fracture analyses with P in categories suggested a potential 
threshold of P (3.3 mg/dL [1.1 mmol/L] in men—consistent in both cohorts—
and 3.7 mg/dL [1.2 mmol/L] in women) above which fracture risk was increased. 
However, trend analysis suggests that risk may start to increase even at lower 
levels. Analyses restricted to subjects with P levels within normal range still 
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showed a significant relation between P and fracture risk, although results were 
statistically significant in men only.
Previous cross-sectional studies reported P levels to be higher in elderly subjects 
and in CKD patients on hemodialysis with previous fragility fractures(13,14,45) 
compared with subjects without fractures, but to the best of our knowledge, no 
prospective studies have been reported at the population level.
Regarding the mechanisms underlying the relation between P levels and bone 
traits, several potential pathways can be hypothesized, namely: 1) effects through 
P regulatory hormones; 2) direct effects of P on BMD and or bone quality 
(and vice versa) and/or fracture risk; and 3) P as a reflection of bone turnover. 
Regarding the first possibility, P levels are regulated by a complex set of 
hormones that play an important role in bone metabolism, such as FGF23, PTH, 
and 1,25-hydroxyvitamin D. Abnormal FGF23 levels have been associated with 
impaired mineralization,(6,7,46,47) through P-dependent and independent effects.(48) 
However, consistent with previous research,(49) adjustments for FGF23 levels did 
not influence the association of P with fracture risk in men from MrOS.
High PTH levels in hypovitaminosis D may also increase fracture risk.(50) 
Nevertheless, we found that adjustments for 25OHD in RS cohorts and additionally 
for total and free 25OHD and PTH levels in a subgroup of men from MrOS did 
not basically modify the association between P and fracture risk. The exclusion 
of subjects with CKD yielded similar results both in men and women; therefore, 
we conclude that our findings are not likely explained by secondary elevations of 
FGF23 or PTH in CKD or by vitamin D deficiency.
On the other hand, we also observed a strong relation between P and fracture 
risk in men from RS cohorts with CKD, which was replicated in men from 
MrOS. These results are consistent with an increased gradient of risk for 
fracture stemming from the increased P load that patients with CKD display,(51) 
even without overt hyperphosphatemia. This finding was not abolished or even 
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attenuated after adjustment for FGF23 and PTH levels in MrOS, suggesting that 
high P itself and not underlying hormonal disturbances may explain the increased 
fracture risk in this group. As a potential therapeutic possibility, the feasibility 
of a multicenter randomized trial testing whether P lowering is able to decrease 
several clinical outcomes in patients with CKD, including bone pain and fracture 
risk, is currently being evaluated.(52) In contrast, the association between P and 
fracture risk in women with CKD was not statistically significant.
Regarding our findings of a negative association between P levels and LS-BMD in 
the pooled results from men, which was driven by men from RS cohorts, we can 
only speculate whether this is a chance finding or related to the fact that LS-BMD 
contains more trabecular than cortical bone. It has been previously described 
that FGF23 expression differs across human bone tissue(53) and that it tends to 
cluster in osteocytes near the trabecular periphery and the lacuna-canalicular 
systems,(54–58) in contrast to the expression pattern of other osteocytes (DMP1 
osteocytes), which are diffusely located throughout bone. This observation needs 
to be tested in other cohorts,(59) and if confirmed, it deserves further research. 
Because  LS-BMD measurements can be affected by degenerative changes,(60) more 
accurate techniques for trabecular volumetric bone assessment might be desirable 
as well as novel methods to assess more accurately bone microarchitecture that 
might be influenced by serum phosphate.(7,8)
It is also possible that P may have direct effects on bone metabolism. P itself exerts 
key roles in growth plate maturation, secondary ossification center formation, and 
osteoblast differentiation.(2,4) Moreover, high P diets have been shown to increase 
bone resorption and development of osteoporosis in senescent mice.(61–63) Studies 
on rats fed high P showed disturbances in P homeostasis and reduced bone 
mineralization over short- and long-term periods.(64) Therefore, a direct negative 
effect of increased P intake on bone is quite well possible. In MrOS, adjustment 
for dietary phosphate intake did not influence the associations between P and 
fracture risk, but it is currently difficult to accurately estimate phosphorus intake 
for example, because phosphorus additives from processed food are often not 
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labeled on food products.(65) But if a relation can be shown between dietary 
phosphate intake and (bone) health, this may have implications in light of the 
increasing use of P additives in our diet.(65)
It is important to emphasize that fracture risk was found to be increased within 
normal values of serum phosphate, suggesting that for bone health the current 
upper limit may be too high. It has been shown that high dietary intake of P is 
related to postprandial elevation of serum P,(66) which may not be reflected as 
fasting P. Indeed, there was no association between dietary P intake and fasting 
serum P levels in MrOS. Interestingly, the same threshold above which fracture 
risk was increased in men from both populations (3.3 mg/dL) was previously 
related to increased cardiovascular risk.(67) To the best of our knowledge, this is 
the first report to describe this association in a prospective fashion,(13,14) and it may 
have important clinical consequences for subjects with and without CKD.
In addition, we cannot exclude the possibility that high serum P is merely a 
reflection of high bone turnover, although we think this is not very likely because 
under normal circumstances, P exchange with the skeleton yields a neutral 
balance and bone turnover abnormalities rarely give rise to clinically relevant 
disturbances in P homeostasis.(11,68,69) Also, the results from adjustments for 
bone turnover markers in MrOS suggest that bone turnover does not explain the 
association between P and fracture risk.
Lastly, we cannot rule out that P levels were associated with fracture risk through 
non-skeletal effects, but an effect through falling appears to be unlikely because 
P levels were also strongly related to vertebral fractures and these fractures are 
often not preceded by a fall. Nevertheless, we cannot discard that other potential 
mechanisms through muscle mass or function might play a role in our findings.
Although there was no statistical evidence for an interaction by sex in the main 
analysis, the relations between P and bone traits seemed stronger in men than in 
women with larger effect sizes. Such an observation has been reported before for 
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other clinical outcomes, such as all-cause mortality, subclinical atherosclerosis, 
CKD progression, and incident coronary disease.(15,16,70) More research is needed 
to fully elucidate if the relation of P and fractures (and other outcomes) is indeed 
stronger in men.
Our study has some limitations. LS-BMD and fasting P levels were not assessed 
simultaneously at RS-I and only 75% of individuals from RS cohorts had complete 
data for all covariates of interest. But results were similar after applying multiple 
imputation. There are several strengths, though, namely the availability of 
several well-characterized and large cohorts with BMD and prospective fracture 
information and the ability to replicate the association between P and fracture risk 
in another large population-based cohort. Although no DXA cross-calibration 
between MrOS and RS cohorts was performed, statistical adjustments to account 
for use of different machines did not materially change results.
Additionally, the association between P and fracture risk was significant despite 
multiple adjustments, including levels of FGF23 and PTH in men from MrOS. 
Therefore, we consider it unlikely that our results are explained by residual con-
founding.
In conclusion, we found that in two population-based studies, increasing P 
levels were positively associated with fracture risk in men and women. These 
results were independent from BMD, although there was an inverse association 
between P and LS-BMD in men. The association between P and fractures was 
also independent of dietary phosphate intake. Results were also not explained 
by serum levels of calcium, 25OHD, PTH, FGF23, or by comorbidity, including 
CKD, but associations between P and fractures were also found in men with 
CKD. The association between P and fractures calls for future research testing 
whether lowering of serum P or reducing P intake may reduce the risk of fracture. 
Additionally, further well-powered studies are needed to clarify if there is a sex 
difference in the relation between P and bone traits.
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The findings of our study also suggest that the current upper limit of serum P may 
be too high and they call for more research into the effects of high P diets and the 
use of P as food additives on bone health.
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Abstract
Hyperphosphatemia has been associated with increased mortality in chronic 
kidney disease but the nature of such a relation in the general population is 
unclear. To investigate the association between phosphate (P) levels and all-
cause and causespecific mortality, we assessed two cohorts from the Rotterdam 
Study, with follow-up of 14.5 (RS-I) and 10.9 (RS-II) years until January 2012 
with availability of fasting phosphate levels. Deaths were classified according 
to International Classification of Diseases into 7 groups: cardiovascular, cancer, 
infections, external, dementia, chronic lung diseases and other causes. Sex-
stratified Weibull and competing-risks models were adjusted for age, BMI and 
smoking. Hazard ratios are expressed per 1 mg/dL increase in phosphate levels. 
The total number of participants included 3731 (RS-I, 2154 women) and 2494 
(RS-II, 1361 women) subjects. The main outcome measures were all-cause and 
cause-specific mortality. A significant positive association was found between 
phosphate and all-cause mortality in men (pooled HR (95% CI): 1.46 (1.26–
1.69)) but not in women (0.90 (0.77–1.05)). In men, higher phosphate increased 
the risk for cardiovascular mortality (1.66 (1.29–2.14)), other causes (1.67 (1.16–
2.40)) and chronic lung disease mortality (1.94 (1.02–3.72)), the latter driven by 
mortality due to chronic obstructive pulmonary disease (COPD) (4.44 (2.08–
9.49)). No relations were found for mortality due to infections, cancer, dementia 
or external causes. In conclusion, serum P is associated with increased all-cause, 
cardiovascular and COPD mortality in men but not women. The association with 
COPD mortality is novel and needs further research on underlying mechanisms.
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Introduction
Phosphorus is the sixth most common element in the human body and the second 
mineral in abundance [1]. It plays an important structural role in hard tissues, such 
as bone, and exerts critical regulatory roles in metabolic and signaling pathways 
[1].
The majority of phosphorus is stored in bone (85%) where it is complexed with 
calcium in the form of hydroxyapatite, whereas 15% of phosphorus is located 
in the intracellular compartment while less than 1% is present in extracellular 
fluids. In blood, phosphorus exists in two main forms: a) an organic form bound 
to proteins (70%), b) an ionized form (30%), known as inorganic phosphorus, or 
phosphate, that circulates freely [1].
Traditionally, phosphate homeostatic mechanisms have been ascribed to the actions 
of parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) 
[1, 2]. Recently, an equally important new axis of phosphate regulators was 
discovered [2, 3], composed of the so-called phosphatonins: fibroblast growth 
factor 23 (FGF23), synthesized mainly in osteocytes, and its co-receptor α-Klotho 
[3, 4]. The FGF23/α-Klotho axis increases P urinary excretion [5].
Monogenic disorders causing extreme phosphate concentrations are associated with 
rickets in severe hypophosphatemia and calcinosis in severe hyperphosphatemia 
[5]. Recently, milder hyperphosphatemia was shown to increase cardiovascular 
mortality in chronic kidney disease (CKD) [6]. Subsequently, this association 
was reported also in non-CKD population [7–10]. Interestingly, sex differences 
have been described with associations found in men but not women for all-cause 
mortality and subclinical atherosclerosis [9]; the underlying reasonsare not 
understood. In addition to serum phosphate levels (P), high P intake has recently 
been found to increase mortality [11].
The objectives of this study were to assess the association of P with all-cause 
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and, in detail, cause-specific mortality within two cohorts of the population-based 
Rotterdam Study, and to test for potential sex differences in these associations.
Materials and methods
Study population
The Rotterdam Study is a prospective study of men and women designed to inves-
tigate the incidence and determinants of chronic disabling diseases. Rationale and 
design has been described elsewhere [12]. This research was performed in two co-
horts within the Rotterdam Study, the Rotterdam Study I cohort (RS-I), initiated 
in 1990 in 7983 subjects, and the Rotterdam Study II cohort (RS-II) initiated in 
2000 in 3011 subjects. All participants were 55 years or more at recruitment and 
have been assessed at baseline and through several follow-up visits. P was measu-
red in the non-fasting state at baseline visit of RS-I (referred to as RS-I-1) and in 
the fasting state at the second follow-up visit of RS-I (RS-I-3, referred to as RS-I) 
and the baseline visit of RS-II (Fig. 1). The fasting state may modify the associa-
tion between P and mortality [10]. Therefore, our main analysis was based on data 
from RS-I3 and RS-II because P was assessed in the fasting state; subsequently 
we checked if the observed results followed similar patterns in RS-I-1, where 
non-fasting samples are available. A total of 3731 participants from RS-I and 2494
from RS-II were included for these analyses, all of them with signed informed 
consent and available phosphate levels. The Rotterdam Study was approved by 
the institutional review board (Medical Ethics Committee) of the Erasmus Medi-
cal Center and by the review board of the Netherlands Ministry of Health, Welfare 
and Sports. The approval has been renewed every 5 years.
Laboratory measurements
The amount of phosphorus determined in blood corresponds to the inorganic 
fraction, or phosphate (mg/dL), assessed with a method based on the formation of 
ammonium phosphomolybdate [1].
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Total calcium determination (mg/dL) was done through a colorimetric 
o-cresolphthalein complex one method (Merck Diagnostica, Amsterdam, 
The Netherlands, for RSI-1; and Roche, Mannheim, Germany, for RS-I and 
RS-II). Levels of 25-hydroxyvitamin D (nmol/L) were determined through an 
electrochemiluminescence immunoassay. We applied cosinor regressions to 
adjust 25-hydroxyvitamin D for season and year. After testing for seasonality 
applying the dickey fuller test, we proceeded to perform a time transformation on 
sine and cosine terms (sin(2*pi*time/12)). Afterwards, we proceeded to regress 
the serum vitamin D levels on those terms to get the mesor, that is, the mean value 
of the cosinor regression. We then computed the difference between the mean of 
each season and the mesor, and adjusted every individual value accordingly [13, 
14]. Levels of 1,25-dihydroxyvitamin D3 were assessed in a subset of participants 
from RS-I-1 through 125I-radioimmunoassay (IDS, Boldon, UK). Creatinine was 
determined through a sarcosine-based colorimetric assay and standardized against 
isotope dilution mass spectrometry (ID-MS). Cystatin C was assessed through 
particle enhanced immunoturbidimetric assay. C-reactive protein (CRP) levels 
were measured through an agglutination method with antibodies. Magnesium 
(Mg) levels were determined with a colorimetric method based on xylidyl blue. 
Glucose and cholesterol levels were determined by standard enzymatic methods 
[12].
Covariates
We assessed the distribution of potential confounders across P quintiles, such 
as age, body mass index (BMI), smoking status, calcium, 25-hydroxyvitamin 
D levels, creatinine, estimated glomerular filtration rate (eGFR), C-reactive 
protein (CRP), glucose, magnesium, total cholesterol to HDL cholesterol ratio 
and prevalent diabetes mellitus and cardiovascular disease (CVD). BMI, 
smoking status, prevalent diabetes mellitus and prevalent CVD were assessed 
as previously described [12]. The diagnoses of prevalent and incident chronic 
obstructive pulmonary disease (COPD) cases was based on an obstructive pre-
bronchodilator spirometry (FEV1/FVC<0.7), according to GOLD guidelines [15].
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Figure 1. Flowchart for time line, design and sample size for the analyses
P intake at baseline visit (RS-I-1) was collected in a subsample of participants 
through a validated semiquantitative food frequency questionnaire. The Chronic 
Kidney Disease Epidemiology Collaboration equations based on creatinine [16, 
17] were applied to estimate eGFR (mL/min). Additionally, cystatin C-based 
eGFR was estimated for subjects with creatinine-based eGFR less than 60 mL/
min, as previously recommended [16].
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Assessment of all-cause and cause-specific mortality
Information on vital status is obtained continuously from the municipal authorities 
in Rotterdam. The cohorts are monitored for mortality through computerized 
linkage of the study database to medical files of general practitioners. Two 
research physicians independently coded the mortality events according to 
ICD-10. Medical specialists in the respective field reviewed and confirmed the 
diagnosis. Information on cause-specific mortality was available until January, 
2012.
Different causes of mortality were recorded according to ICD-10 codes and firstly 
grouped into cardiovascular diseases (CVD), cancer and other causes. To perform 
comprehensive analyses, the group of other causes was further categorized into 
external causes, dementia, infections, chronic lung disease and other causes in the 
strict sense, as previously described [18].
 
Statistical analysis
Subjects with fasting P measurements from RS-I and RS-II were analyzed 
separately and in a meta-analysis. Additionally, we analyzed subjects with non-
fasting P from RSI-1.
Due to sex differences in P [19] and in its association with health outcomes [9], we 
built sex-stratified analyses.
We compared the distribution of potential confounding factors applying age-ad-
justed tests of trend across P quintiles. We estimated P levels across smoking 
categories applying ANOVA and post hoc (Tukey’s) tests. Initially, the association 
of P with mortality was assessed through Cox models, testing the proportiona-
lity assumption of the hazards via the Schoenfeld residuals test. All significant 
HRs from Cox’ models were found to be constant over follow-up time; therefore, 
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we found no evidence for a time-dependent effect of P levels on mortality. In a 
second step, we compared the semi-parametric Cox model with parametric models, 
and found that Weibull regression models—albeit with highly similar results 
to Cox regressions— provide better statistical fit to the data than Cox models. 
Weibull models provided also better fit than the rest of parametric models. We 
applied Cox-Snell residuals graphs and Akaike (AIC) and Bayesian information 
criteria (BIC) to compare among models, as previously recommended [20]. 
Models with lower AIC and BIC correspond to a better fit. Therefore, the results 
reported in this manuscript correspond to Weibull regression models. Finally, we 
also performed competing-risks regressions models which allow for informative 
censoring due to the multiple possible causes of death [21]; these models provide 
an estimate of the effect of the exposure on the probability of developing the 
outcome over time [22].
Hazard ratios (HRs) are expressed per increase in 1 mg/ dL (0.32 mmol/L) of P 
or in quintiles; the latter were built to explore a potential dose–effect relationship 
between phosphate levels and mortality.
The analysis time was set at the date of blood drawing. Subjects were followed 
until the first of the following events happened: death, lost to follow-up, or 
censoring by 1st January, 2012.
Adjustments were made firstly for age, BMI and smoking because they are related 
to mortality and P; subsequently other covariates that have been associated with 
mortality were added to the model and retained if they changed the beta estimate 
more than 10%, including eGFR, glucose, hsCRP, Mg levels, cholesterol to HDL 
cholesterol ratio, calcium, 25-hydroxyvitamin D and prevalent cardiovascular 
disease.
Results from RS-I and RS-II were meta-analyzed using fixed-effect model.
Primary analyses were done with subjects with complete information on 
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covariates. Subsequently, missing values were imputed via multiple imputation 
with chained equations, allowing missingness at random. We followed specific 
guidelines for imputation for survival analysis.
Sensitivity analyses
We repeated analyses including only subjects with normal P (2.5–4.5 mg/dL; 
0.81–1.45 mmol/L). We further adjusted the analyses for phosphate dietary intake 
and 1,25- dihydroxyvitamin D3 levels in a subset of participants from RS-I-1 
(n = 4046).
Additionally, we performed stratified analyses according to smoking categories.
We used SPSS (version 21.0, Armonk, NY: IBM Corp), Stata (version 13, College 
Station TX: Stata Corp LP) and Comprehensive Meta-Analysis (version 2.2, 
Biostat, Englewood, NJ). A two-sided p<0.05 was considered significant.
Results
Serum phosphate correlates
A general descriptive summary of main continuous covariates is depicted in Table 
1. The distribution of relevant covariates and risk factors across even quintiles of 
P for RS-I and RS-II is depicted in Table 2. P was higher in women than men in 
both cohorts (pdifference<0.001). P levels were different across smoking categories 
in both sexes and cohorts (ANOVA p <0.001); this difference was due to higher 
P in current smokers (Tukey’s tests  >0.05 between former and never smokers).
P was within normal range in 95.5 and 94.9% of participants in the fasting state 
(RS-I and RS-II, respectively) and in 89.7% of participants in the non-fasting state 
(RS-I-1).
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Serum phosphate and all-cause mortality
During 14.5 year (median) and 10.9 year (mean) follow-up a total of 1631 and 
469 fatal events occurred in RS-I and RS-II, respectively. We found a significant 
interaction between P and sex for all-cause mortality in RS-I (pinteraction<0.001) and 
performed sex-stratified analyses. The results for the comparison of goodness-of-
fit between parametric models and the semiparametric Cox model are displayed 
in Supplementary Table 1 (AIC and BIC criteria) and in Fig. 2 (Cox-Snell residuals 
plot). Both methods showed that Weibull models provide a better fit to our data
among the parametric and semiparametric models.
The associations between P and all-cause mortality are depicted in Table 3. Results 
from RS-I and RS-II were meta-analyzed (pooled HR (95% CI)). A significant 
association between P and all-cause mortality was found in men (1.46 (1.26–1.69)) 
but not in women (0.90 (0.77–1.05)).
Table 1. General characteristics of subjects in RS-I and RS-II with serum 
phosphate levels, BMI and smoking information available, stratified by sex.
Men Women
Mean (SD) 
(n: 1577)
Min. Max. Mean (SD) 
(n: 2154)
Min. Max.
(I) RS-I
Age (year) 71.8 (6.53) 61.4 96.7 72.5 (7.06) 61.4 100.9
BMI (kg/m2) 26.3 (3.18) 17.6 41.1 27.3 (4.37) 15.2  47.9
Calcium (mg/dL) 9.65 (0.39) 6.26 11.6 9.79 (0.41) 6.98 12.9
Phosphate (mg/dL) 3.15 (0.44) 1.91 7.62 3.62 (0.43) 2.28 5.25
25(OH)D (nmol/L) 61.4 (25.5) 8.99 173.8 47.9 (22.5) 5.14 134.4
CRP (mg/L) 4.24 (7.22) 0.20 115.0 3.93 (6.66) 0.20 145.0
Glucose (mmol/L) 6.06 (1.62) 4.10 20.5 5.87 (1.46) 1.60 19.5
Creatinine (µmol/L) 92.4 (33.6) 43.0 1107.0 72.1 (14.8) 34.0 263.0
eGFR (mL/min) 73.8 (14.4) 3.55 108.8 73.8 (13.9) 14.9 113.7
Mg (mmol/L) 0.85 (0.06) 0.60 1.13 0.85 (0.06) 0.58 1.17
Chol to HDL ratio 4.69 (1.32) 1.52 10.2 4.30 (1.30) 1.19 14.1
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Men (n: 1133) Women (n: 1361)
(II) RS-II
Age (year) 64.3 (7.48) 55.1 93.9 64.9 (8.17) 55.1 95.3
BMI (kg/m2) 26.9 (3.36) 16.8 40.5 27.4 (4.46) 15.9  50.5
Calcium (mg/dL) 9.57 (0.34) 8.58 11.8 9.68 (0.34) 8.70 11.3
Phosphate (mg/dL) 3.09 (0.44) 1.39 4.66 3.54 (0.44) 1.82 5.12
25(OH)D (nmol/L) 65.7 (27.9) 0.25 175.0 58.9 (27.5) 5.84 162.5
CRP (mg/L) 2.37 (4.60) 0.30 51.8 2.33 (4.16) 0.00 65.5
Glucose (mmol/L) 6.17 (1.78) 3.90 22.1 5.87 (1.47) 3.80 25.9
Creatinine (µmol/L) 87.8 (18.7) 53.0 349.0 69.2 (11.8) 40.0 165.0
eGFR (mL/min) 80.9 (13.9) 14.0 111.6 80.6 (13.7) 26.8 108.4
Mg (mmol/L)  0.83 (0.06) 0.34 1.02 0.83 (0.06) 0.43  1.06
Chol to HDL ratio 4.77 (1.34) 1.83 12.4 4.23 (1.22) 1.52 11.1
BMI body mass index, 25(OH)D 25-hydroxyvitamin D levels, CRP C-reactive protein, eGFR 
estimated glomerular filtration rate, Mg magnesium, Chol to HDL ratio total 
cholesterol to HDL cholesterol ratio
Conversion to SI Units: to convert 25-hydroxyvitamin D levels to ng/mL multiply by 0.4; 
to convert glucose to mg/dL multiply by 18.02; to convert creatinine  to  mg/dL 
multiply by 0.011; to convert magnesium to mg/dL multiply by 2.43
Min: minumum. Max: maximum
Adjustments in a full model composed of age, BMI, smoking, prevalent 
cardiovascular disease and levels of calcium, 25-hydroxyvitamin D, eGFR, 
CRP, Mg, glucose and total cholesterol to HDL cholesterol ratio levels did not 
substantially modify results (men: 1.49 (1.27–1.74); women: 0.92 (0.79–1.07)).
Similarly, results from RS-I-1 with non-fasting phosphate showed a significant 
association of phosphate with all-cause mortality in men (1.12 (1.02–1.23); 
no events = 1389), but not in women (0.99 (0.91–1.08); no events = 1779).
To explore whether there was a dose–response pattern in the association we found 
in men, we analyzed P in even quintiles and all-cause mortality in RS-I, the 
cohort with most events, (Table 4) and set the first quintile (lowest) as reference. 
We observed a significant trend for increasing P and mortality (ptrend˂0.001) with 
significant HRs for the fourth (1.35 (1.08–1.69)) and fifth quintile (1.49 (1.19–1.86)) 
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compared with the first quintile.
Sensitivity analyses
Results after excluding subjects with abnormal P were similar to the unrestricted 
analyses (men: 1.44 (1.21–1.70); women: 0.87 (0.74–1.03)). Adjustments for 
phosphate and energy intake in men from RS-I-1 did not modify the results 
between non-fasting phosphate and all-cause mortality (1.13 (1.02–1.24); 
no events = 1117). Further adjustments for 1,25 dihydroxyvitamin D3 levels in a 
subset from RS-I-1 did not modify results (data not shown).
Serum phosphate and cause-specific mortality in men
We did not observe associations between P and cause-specific mortality in 
women (data not shown). In contrast, the pooled results in men (Table 5) showed 
a significant positive relation between P and CVD mortality (1.66 (1.29–2.14)). 
Exclusion of male subjects with prevalent CVD disease yielded similar results 
(1.69 (1.28–2.23)).
We also found an association between higher P and chronic lung disease mortality 
(1.94 (1.02–3.72)). Most of these cases clustered within COPD mortality. Therefore, 
we further investigated such a relation (Table 6), and found a significant association 
(4.44 (2.08–9.49)). Most likely due to power constraints, this association was not 
significant in RS-II (05 cases in contrast to 28 cases in RS-I) but there was no 
evidence for statistical difference between both estimates (pheterogeneity = 0.780). 
141
Chapte r  5
Ta
bl
e 
2.
 G
en
er
al
 c
ha
ra
ct
er
is
ti
cs
 o
f 
su
bj
ec
ts
 in
 R
S
-I
 a
nd
 R
S
-I
I 
ac
co
rd
in
g 
to
 q
ui
nt
ile
s 
of
 f
as
ti
ng
 p
ho
sp
ha
te
 le
ve
ls
M
en
W
om
en
Ph
os
ph
at
e 
in
 q
ui
nt
il
es
Ph
os
ph
at
e 
in
 q
ui
nt
il
es
1
2
3
4
5
p*
1
2
3
4
5
p*
(I
) 
R
S
-I
  N
 (m
g/
dL
) 
31
5
   
(2
.5
6)
31
5
   
(2
.9
2)
31
6
   
(3
.1
5)
31
5
   
(3
.3
7)
31
6
   
(3
.7
7)
43
1
   
(3
.0
2)
43
1
   
(3
.4
0)
43
1
   
(3
.6
2)
43
1
   
(3
.8
3)
43
0
   
(4
.2
1)
  A
ge
 (
ye
ar
) 
71
.6
72
.4
71
.4
71
.9
71
.8
0.
96
8
73
.0
72
.3
72
.8
72
.4
71
.9
0.
04
9
  B
M
I 
(k
g/
m
2 )
  
26
.7
26
.4
26
.2
26
.2
26
.0
0.
00
5
29
.0
27
.5
27
.2
26
.7
25
.9
< 
0.
00
1
  E
ve
r 
sm
ok
e 
(%
)
90
%
87
%
92
%
92
%
95
%
0.
00
8
47
%
47
%
50
%
53
%
51
%
0.
09
1
  C
al
ci
um
 (m
g/
dL
)
9.
59
9.
66
9.
62
9.
66
9.7
2
< 
0.
00
1
9.7
7
9.
80
9.7
6
9.7
9
9.
84
0.
02
6
  2
5 
(O
H
) 
D
 (n
m
ol
/L
)
62
.8
62
.6
62
.7
59
.1
59
.9
0.
03
4
45
.4
48
.9
46
.8
48
.6
50
.1
0.
03
5
  C
R
P
 (m
g/
L)
  
4.
57
3.
62
4.
15
3.
79
5.
12
0.
34
0
4.
92
4.
06
3.
79
3.
60
3.
23
< 
0.
00
1
  G
lu
co
se
 (m
m
ol
/L
)
6.
09
5.
96
6.
04
6.
04
6.
15
0.
52
9
6.
18
5.
79
5.
87
5.
77
5.
77
< 
0.
00
1
  P
re
va
le
nt
 D
M
 (
%
)
14
%
12
%
13
%
14
%
15
%
0.
42
4
17
%
10
%
12
%
9%
9%
0.
00
1
142
PART I. Bone traits and phosphate in relation to health & survival
  C
re
at
in
in
e 
(µ
m
ol
/L
)
91
.4
92
.7
90
.2
91
.3
96
.2
0.
16
7
72
.4
72
.7
71
.5
71
.9
71
.9
0.
65
2
  e
G
F
R
 (m
L
/m
in
)
73
.9
72
.0
75
.0
74
.2
73
.7
0.
43
2
73
.1
73
.1
74
.2
74
.1
74
.4
0.
35
6
  M
g 
(m
m
ol
/L
) 
 
0.
84
0.
84
0.
85
0.
85
0.
86
0.
00
2
0.
84
0.
85
0.
85
0.
85
0.
86
< 
0.
00
1
  C
ho
l t
o 
H
D
L 
ra
tio
4.
75
4.
93
4.
75
4.
56
4.
47
< 
0.
00
1
4.
41
4.
42
4.
33
4.
17
4.
18
< 
0.
00
1
  P
re
va
le
nt
 C
V
D
 (
%
)
7%
9%
8%
7%
10
%
0.
22
1
4%
2%
2%
4%
3%
0.
71
2
(I
I)
 R
S
-I
I
  N
 (
m
g/
dL
) 
22
6
  (
2.
49
)
22
7
  (
2.
86
)
22
6
  (
3.
07
)
22
7
  (
3.
31
)
22
7
  (
3.
71
)
27
2
  (
2.
92
)
27
2
  (
3.
32
)
27
2
  (
3.
54
)
27
2
  (
3.
77
)
27
3
 (
4.
14
)
  A
ge
 (
ye
ar
) 
 
63
.8
64
.4
65
.0
64
.7
63
.8
0.
88
4
65
.4
66
.2
64
.4
65
.2
63
.1
< 
0.
00
1
  B
M
I 
(k
g/
m
2 )
  
27
.1
26
.7
26
.8
26
.7
27
.3
0.
48
2
29
.1
27
.9
27
.4
26
.8
26
.0
< 
0.
00
1
  E
ve
r 
sm
ok
e 
(%
)
86
%
81
%
80
%
87
%
 
89
%
0.
14
2
57
%
62
%
57
%
58
%
63
%
0.
64
2
  C
al
ci
um
 (
m
g/
dL
)
9.
50
9.
59
9.
53
9.
58
9.
64
< 
0.
00
1
9.
64
9.
66
9.
70
9.
68
9.
75
0.
00
1
  2
5 
(O
H
)D
 (
nm
ol
/L
)
66
.6
68
.0
65
.1
65
.7
62
.8
0.
10
3
57
.1
57
.2
58
.3
58
.9
63
.2
0.
07
1
  C
R
P 
(m
g/
L
) 
2.
41
2.
22
2.
42
1.
88
2.
93
0.
47
9
2.
82
2.
54
1.
92
2.
34
2.
01
0.
03
7
  G
lu
co
se
 (
m
m
ol
/L
)
6.
08
5.
98
6.
24
6.
06
6.
50
0.
01
3
6.
10
5.
84
5.
79
5.
78
5.
84
0.
04
9
143
Chapte r  5
  P
re
va
le
nt
 D
M
 (
%
)
11
%
9%
15
%
11
%
21
%
0.
00
2
12
%
9%
10
%
9%
7%
0.
16
4
   
C
re
at
in
in
e 
(µ
m
ol
/L
)
87
.6
87
.4
88
.7
86
.8
88
.2
0.
91
5
69
.5
70
.0
68
.4
69
.2
68
.9
0.
92
3
   
eG
F
R
 (
m
L
/m
in
)
80
.9
81
.3
79
.2
81
.3
81
.7
0.
47
5
79
.7
79
.1
81
.6
80
.5
81
.8
0.
69
1
  M
g 
(m
m
ol
/L
) 
0.
83
0.
83
0.
83
0.
83
0.
84
0.
29
0
0.
82
0.
83
0.
83
0.
83
0.
84
< 
0.
00
1
  C
ho
l t
o 
H
D
L 
ra
tio
4.
93
4.
71
4.
62
4.
66
4.
93
0.
90
6
4.
35
4.
20
4.
31
4.
15
4.
12
0.
04
2
  P
re
va
le
nt
 C
V
D
 (
%
)
8%
11
%
13
%
9%
13
%
0.
35
1
3%
3%
 
3%
 
3%
1%
0.
60
8
St
at
is
ti
ca
ll
y 
si
gn
ifi
ca
nt
 p
-v
al
ue
s 
(<
0.
05
) 
ar
e 
hi
gh
li
gh
te
d 
in
 b
ol
d 
fo
nt
*P
 v
al
ue
s 
co
rr
es
po
nd
s 
to
 a
ge
-a
dj
us
te
d 
si
gn
ifi
ca
nc
e 
of
 t
re
nd
 a
cr
os
s 
qu
in
ti
le
s
BM
I 
bo
dy
 m
as
s 
in
de
x,
 2
5(
O
H
)D
 2
5-
hy
dr
ox
yv
ita
m
in
 D
 l
ev
el
s, 
C
RP
 C
-r
ea
ct
iv
e 
pr
ot
ei
n,
 p
re
va
le
nt
 D
M
 p
re
va
le
nt
 d
ia
be
te
s 
m
el
lit
us
, 
eG
FR
es
ti
m
at
ed
 g
lo
m
er
ul
ar
 fi
lt
ra
ti
on
 r
at
e,
 M
g 
m
ag
ne
si
um
, 
C
ho
l 
to
 H
D
L 
ra
tio
 t
ot
al
 c
ho
le
st
er
ol
 t
o 
H
D
L 
ch
ol
es
te
ro
l 
ra
tio
, 
pr
ev
al
en
t 
C
V
D
 p
re
va
le
nt
ca
rd
io
va
sc
ul
ar
 d
is
ea
se
C
on
ve
rs
io
n 
to
 
SI
 
U
ni
ts
: 
to
 
co
nv
er
t 
25
-h
yd
ro
xy
vi
ta
m
in
 
D
 
le
ve
ls
 
to
 
ng
/m
L 
m
ul
tip
ly
 
by
 
0.
4;
 
to
 
co
nv
er
t 
gl
uc
os
e 
to
 m
g/
dL
 m
ul
tip
ly
 b
y 
18
.0
2;
 t
o 
co
nv
er
t 
cr
ea
tin
in
e 
to
 m
g/
dL
 m
ul
tip
ly
 b
y 
0.
01
1;
 t
o 
co
nv
er
t 
m
ag
ne
si
um
 t
o 
m
g/
dL
 m
ul
tip
ly
 b
y 
2.
43
144
PART I. Bone traits and phosphate in relation to health & survival
Figure 2. Cox-Snell residuals plot for parametric models in the association between serum 
phosphate levels and all-cause mortality in men
Table 3. Serum phosphate levels and all-cause mortality in RS-I and RS-II, 
adjusted for age, BMI and smoking, follow-up until year 2012
Men Women
no events HR* (95% CI) p no events HR* (95% CI) p
RS-I 810/1577 1.58 (1.34–1.87) < 0.001 821/2154 0.85  (0.71–1.00) 0.056
RS-II 262/1133 1.14 (0.85–1.53) 0.378 207/1361 1.14 (0.81–1.60) 0.439
Studies combined† 1072/2710 1.46 (1.26–1.69) < 0.001 1028/3515 0.90 (0.77–1.05)  0.176
Statistically significant p-values (<0.05) are highlighted in bold font
*Hazard ratios from Weibull models, expressed per 1 mg/dL (0.32 mmol/L) increase in phosphate 
levels
†Studies combined from meta-analyses using fixed-effect models
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Table 4. Serum phosphate levels in quintiles and all-cause mortality in men from 
RS-I, adjusted for age, BMI and smoking, follow-up until year 2012
Quintile 
Phosphate concentrations 
mean (range)*
no events/no risk HR
† (95% CI) p
1 2.56 (1.91–2.81) 139/315 1 (reference)
2 2.92 (2.81–3.02) 154/315 1.09 (0.87–1.38) 0.439
3 3.15 (3.02–3.27) 154/316 1.05 (0.83–1.33) 0.660
4 3.37 (3.27–3.49) 172/315 1.35 (1.08–1.69) 0.008
5 3.77 (3.52–7.62) 191/316 1.49 (1.19–1.86) <0.001
ptrend <0.001
Statistically significant p-values (˂ 0.05) are highlighted in bold font
*Phosphate levels in mg/dL
†Hazard ratios from Weibull models; first quintile was set as reference
Table 5. Serum phosphate levels and cause-specific mortality in men from RS-I 
and RS-II, adjusted for age, BMI and smoking, follow-up until year 2012
Individual cohorts Studies combined
Cohort n HR* (95% CI) p HR† (95% CI) p
CVD  RS-I 266 1.80 (1.35–2.39) <0.001 1.66 (1.29–2.14) <0.001
RS-II 77 1.25 (0.73–2.15) 0.412
Cancer RS-I 243 1.41 (1.04–1.90) 0.025 1.23 (0.95–1.58) 0.112
RS-II 98 0.88 (0.55–1.40) 0.586
External RS-I 18 1.58 (0.50–5.02) 0.439 0.94 (0.36–2.46) 0.902
RS-II 9 0.29 (0.05–1.62) 0.159
Infectious RS-I 56 1.02 (0.53–1.98) 0.943 0.97 (0.53–1.80) 0.929
RS-II 9 0.71 (0.13–3.84) 0.691
Dementia RS-I 52 1.83 (0.93–3.60) 0.081 1.70 (0.92–3.15) 0.092
RS-II 13 1.18 (0.26–5.37) 0.826
Lung RS-I 42 2.07 (0.97–4.42) 0.058 1.94 (1.02–3.72) 0.044
RS-II 15 1.64 (0.47–5.72) 0.441
Other RS-I 133 1.58 (1.04–2.41) 0.032 1.67 (1.16–2.40) 0.006
RS-II 40 1.98 (0.96–4.11) 0.066
Statistically significant p-values (<0.05) are highlighted in bold font
*Hazard ratios from Weibull models, expressed per 1 mg/dL (0.32 mmol/L) increase in 
phosphate levels
†Studies combined from meta-analyses using fixed-effect models
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Further adjustments for glomerular filtration rate did not abolish the association 
between P and COPD mortality (4.16 (2.05–8.43)). Furthermore, the association 
was found to be consistent in subjects without chronic kidney disease (CKD) (6.58 
(2.59–16.7)); whereas we found no association in subjects with CKD (1.14 (0.20–
6.63)), although the latter analysis is constrained due to low number of events and 
driven only by RS-I. Non-fasting phosphate levels and COPD mortality in men from 
RS-I-1 also displayed a significant association (1.54 (1.05–2.27), no events = 69). 
P was also found to be positively associated with mortality from other causes 
(1.67 (1.16–2.40))
Table 6. Serum phosphate levels and chronic obstructive pulmonary disease 
(COPD) mortality in men from RS-I and RS-II, adjusted for age, BMI and 
smoking, follow-up until year 2012
Individual cohorts Studies combined
n HR* (95% CI) p HR† (95% CI) p
RS-I 28 4.62 (2.06–10.3) < 0.001 4.44 (2.08–9.49) < 0.001
RS-II 05 3.29 (0.35–30.7) 0.296
Statistically significant p-values (˂ 0.05) are highlighted in bold font
*Hazard ratios from Weibull models, expressed per 1 mg/dL (0.32 mmol/L) increase in phosphate 
levels
†Studies combined from meta-analyses using fixed-effect models
We found no significant associations between P and death due to cancer, infections, 
dementia or external causes.
Results from competing-risks regression models were similar to Weibull models 
and showed a significant association between P and mortality due to CVD (1.50 
(1.12–2.02)), other causes (1.40 (1.01–1.93)) and COPD (2.42 (1.62–3.63)); no other 
significant associations were found (Supplementary Tables 2 and 3).
Analyses after applying multiple imputation yielded significant associations for P 
and all-cause, CVD, COPD and other causes of mortality in men (data not shown).
Missingness of covariates of interest was less than 6%.
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Sensitivity analyses
Results after excluding male subjects with abnormal P were similar to 
the unrestricted analyses (Supplementary Tables 4 and 5). Likewise, our 
findings remained essentially unaltered after adjustments for calcium and 
25-hydroxyvitamin D levels; and were only slightly attenuated after further 
adjustments for levels of calcium, 25-hydroxyvitamin D and eGFR (CVD 1.65 
(1.27–2.14), COPD 3.79 (1.87–7.69), other causes 1.76 (1.21–2.56)). Similar 
results were obtained after adjustments for cystatin-based eGFR. Additionally, 
the analyses after exclusion of male subjects with eGFR <60 mL/min showed 
a positive association between P and mortality due to other causes  (1.72 (1.13–
2.61)) and COPD (6.58 (2.59–16.7)) - as previously mentioned - and a borderline 
association between P and CVD mortality (1.36 (1.00–1.85)).
Smoking adjustment did not attenuate the association between P and CVD or 
COPD mortality (data not shown). The results from the stratified analyses 
according to smoking categories (Supplementary Tables 6 and 7) showed that in 
studies combined the associations between P and all-cause and CVD mortality 
were in the same direction and did not show statistical evidence for a difference 
across categories (pheterogeneity = 0.752 for all-cause mortality and pheterogeneity = 0.796 
for CVD mortality). The relation between P and COPD mortality in men from 
RS-I (RS-II excluded due to few events) was not statistically different among 
former and current smokers (pheterogeneity = 0.494).
As previously mentioned, analyses in men from RS-I-1 showed that non-fasting 
phosphate levels were also associated with chronic lung disease mortality 
and COPD mortality, and these associations were not abolished after further 
adjustments for phosphate and energy intake: chronic lung disease mortality: 1.79 
(1.19–2.68); no events = 59; COPD mortality: 1.87 (1.20–2.91), no events = 49.
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Discussion
This prospective population-based cohort study among elderly demonstrated 
that P was positively associated with all-cause mortality in men but not in 
women, supporting an effect modification by sex previously described [9]. When 
analyzing in detail cause-specific mortality in men, we found that this association 
was driven by mortality due to CVD, COPD and other causes. The association 
between increasing P and the composite endpoint of fatal and nonfatal CVD 
incidence in non-CKD population in sex-combined analyses has been reported 
before but is still scarce [7–9]. Our results provide evidence of an association 
between higher P - even within normal range - and death due to CVD in men. 
On the other hand, to the best of our knowledge the association we found with 
COPD mortality is novel. These results remained significant after adjustments for 
several potential confounders, were observed also after restricting the analyses to 
subjects with normal P and showed no heterogeneity between cohorts.
Several mechanisms have to be considered when analyzing P and mortality, 
including phosphate being a marker of another risk factor or through direct 
pathogenic pathways. 
First, P levels are regulated by a complex interplay of factors that have been linked 
to mortality, such as 1,25-dihydroxyvitamin D3, PTH and FGF23. Low levels 
of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D3 have been found to be 
associated with increased mortality [23]. Nevertheless, the vitamin D adjustments 
did not modify our results.
PTH abnormalities have also been associated with mortality. Primary excess of 
PTH is associated with increased cardiovascular mortality [24], but in this context 
P tends to be low. Secondary elevations of PTH in impaired kidney function have 
been inconsistently associated with mortality. This compensatory mechanism in 
CKD is triggered when eGFR falls below 47 mL/min [25]. Although PTH levels 
were not available, the proportion of patients in our cohorts with eGFR below that 
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threshold was considerably low (4% in RS-I and 2% in RS-II) suggesting that 
secondary hyperparathyroidism is unlikely to explain our findings. Nevertheless, 
PTH values seem to rise within normal range in the general population without 
CKD [26] at higher thresholds of decreasing eGFR (<120 mL/min); whether 
increasing PTH values within normal range are associated with all-cause mortality 
in the long term is unclear [27].
Other important players in P homeostasis that might underlie its associations with 
mortality are the phosphatonins FGF23 and α-Klotho [3, 4]. FGF23 is synthesized
mainly in osteocytes [5] and requires the presence of α-Klotho to bind to its 
receptor with high affinity and for signaling [28]. FGF23/α-Klotho axis decreases 
P through increased urinary phosphate excretion and both molecules are anti-
ageing factors [5]. Primary causes of excess FGF23, such as in hereditary 
hypophosphatemic rickets, have been associated with cardiovascular calcification 
in cases of excessive phosphate treatment. Secondary FGF23 elevation occurs in 
CKD at earlier stages than PTH [3, 25] in response to P retention, and it has been 
linked to increased mortality [29, 30]. Similar to PTH, FGF23 elevations within 
normal range have been described at high thresholds of eGFR in population 
without CKD [26]; FGF23 levels have also been associated with mortality in this 
setting [31]. Nevertheless, FGF23 seems not to induce vascular calcification in 
most studies [4, 32, 33].
Recently, soluble klotho has been linked to increased mortality in CKD patients 
[34] although the lack of a validated assay for its measurement might be a concern 
for some [30].
Another potential confounder could be smoking. Similar to previous reports [7], 
P was found to be higher in current smokers. Although adjustments for smoking 
did not alter our analyses, due to heavy current and former smoking in men it is 
difficult to fully dissect its effects. Nevertheless, in studies combined the stratified 
analyses by smoking status showed that the associations between P and all-cause
and CVD mortality appeared to be of the same direction and similar magnitude 
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across smoking categories. The group of former smokers - who had similar P as 
never smokers - displayed the most statistically significant associations possibly 
due to larger number of subjects in this category. Specifically, P was related to 
COPD mortality comparably in current and former smokers men from RS-I but 
only significant in the latter group; a relation in non-smokers could not be tested 
due to low numbers in this subgroup. Therefore we do not anticipate that current
smoking explains the association between P and COPD mortality.
Regarding direct effects, P itself is able to induce vascular calcification, a process 
with high resemblance to bone ossification and that increases mortality [33, 35]. 
Several pathways are known such as (a) differential gene expression in vascular 
smooth muscle cells with up-regulation of markers critical for mineralization 
[36]; and (b) elastin degradation, thought to be mediated by P induction of matrix 
metalloproteinase (MMP)-9.
The association we found between P and COPD mortality has never been described 
in humans before; interestingly there is additional evidence for the pathogenicity 
of high P stemming from rodent models with fgf23 or klotho knockout. These 
animals display similar phenotypes characterized by severe hyperphosphatemia 
and features of premature aging, such as osteoporosis, ectopic calcifications, 
pulmonary emphysema and short life span [37–39]. Heterozygous klotho mice 
also display emphysematous lungs. Remarkably, a low phosphate diet is able to 
alleviate or rescue the phenotype - including the lung emphysema; and a high 
phosphate diet worsens it [40], strongly suggesting that phosphate itself  accelerates 
ageing [41] and induces alveoli destruction, and that this process can be modified 
by diet manipulation [40].
A new concept of phosphotoxicity as a risk factor for mammalian ageing has 
emerged lately [3, 40] and there are concerns that increasing phosphate intake 
through food additives may negatively influence multiple aspects of health [42]. 
Indeed it has been shown that high absolute P intake was positively related to all-
cause mortality - not explained by CVD mortality [11]. Recently, a healthy diet 
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- according to the Alternate Healthy Eating Index (2010) score - was associated 
with lower risk of COPD in humans [43]; interestingly in men but not women 
this beneficial association was driven mostly by a drastic reduction in red and 
processed meat consumption, expected to contain high phosphate [42]. A positive 
relation between cured meat intake and COPD risk has previously been reported 
in cross-sectional (NHANES III) and prospective studies [44, 45]. Importantly, 
when spirometric definitions for lung volumes and COPD have been applied, 
cured meat intake has been shown to be negatively associated with lung function, 
and positively related with COPD risk [44, 46]; the latter study showed that these 
associations were found predominantly in men. Cured meat consumption has 
also been shown prospectively to increase the hospital readmission rate in COPD 
patients [47].
From a mechanistic point of view, previous research [48] has shown that phosphate 
is able to directly induce injury in mice and human lung epithelial cells through
increased DNA oxidative stress and apoptosis; indeed phosphate medium is used 
experimentally to induce oxidative lung injury. Interestingly, α-Klotho exerts 
protective antioxidant effects against lung injury induced by P [48], hyperoxia, 
and acute α-Klotho deficiency [49]. These data show that lung tissue is a target 
for phosphotoxic insult. Remarkably, increased P intake down-regulates α-Klotho 
expression in rodents [41]; therefore low P diet may be a therapeutic strategy to 
increase Klotho [3].
A genetic variant associated with low FGF23 was found to be associated with 
emphysema in smokers with COPD. More studies are needed to elucidate further 
the underlying mechanisms, especially considering that COPD ranks high in the 
most common causes of death worldwide.
The reasons for the sex difference between P and mortality are not clear. 
Interestingly, the vascular calcification induction by P is attenuated by 
17β-estradiol, suggesting a potential hormonal reason for this difference 
[50]. Despite the fact that menopause is characterized by low estradiol levels, 
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hormone replacement therapy-naïve postmenopausal women with higher 
17β-estradiol levels display lower coronary calcification scores than those with 
lower 17β-estradiol [51]. Additionally, coronary infusion of 17β-estradiol exerts 
vasodilation in postmenopausal women, but not men [52]. Testosterone and 
estradiol play important roles as P regulators [19].
Although men had a less healthy profile at baseline than women, multiple 
adjustments did not abolish our results. Moreover, a previous study showed that 
P is associated with subclinical atherosclerosis in men (but not women) without 
prevalent cardiovascular and cerebrovascular disease at baseline [53].
This study has several limitations. 1,25-dihydroxyvitamin D3 levels were 
available only in a subgroup. PTH and FGF23 measurements were not available 
and it is known that kidney function in elderly can be misclassified even by eGFR. 
Our findings cannot be generalized to other ethnicities other than European 
Caucasians. Nevertheless, there are several strengths, such as the availability of 
two well-characterized cohorts with long follow-up, the detailed information on 
cause-specific mortality and the availability of multiple potential confounders. The 
completeness of follow-up was high (94 and 92% in RS-I and RS-II) indicating 
that obtained estimates are valid.
In conclusion, we found that higher P is associated with increased all-cause 
mortality and cause-specific mortality due to CVD, COPD and other causes in 
elderly men but not in women, adding more evidence for a modification of these 
associations by sex. We hereby provide evidence to support that the concept 
of phosphotoxicity also among non-CKD general population deserves further 
attention and, if causally related, it occurs independently of vitamin D levels and 
kidney function. Our study suggests that moderation of phosphate intake might be 
relevant also in non-CKD population for healthy ageing. Finally, we consider that 
the available evidence calls for a review of the currently accepted normal range of 
P. Further research is needed to clarify the underlying mechanisms, especially for
COPD mortality, and to elucidate the reasons for the sex difference in the 
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association of P with mortality.
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Supplementary Material 
Supplementary Table 1. Goodness of fit among parametric and 
semiparametric models for the association between serum phosphate levels 
and mortality in men from RS-I, according to AIC and BIC criteria:
AIC BIC
Parametric models
Weibull 3060.27 3097.81
Exponential 3246.42 3278.59
Gompertz 3065.36 3102.9
Lognormal 3194.43 3231.97
Loglogistic 3106.07 3143.62
Generalized gamma 3060.31 3103.22
Semiparametric model
Cox 10865.15 10891.96
AIC: Akaike information criteria; BIC: Bayesian information criteria   
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Supplementary Table 3. Competing-risks results for serum phosphate levels 
and COPD mortality in men from RS-I and RS-II, adjusted for age, BMI and 
smoking, follow-up until year 2012:
Individual cohorts Studies combined
n SHR* (95% CI) p SHR*,† (95% CI) p
RS-I 28 2.42 (1.61-3.65) <0.001
2.42 (1.62-3.63)    <0.001
RS-II 05 2.54 (0.20-32.8) 0.475
* Subhazard ratios from competing risks models, interpreted as the relative increase in the incidence 
of the event of interest per 1 mg/dL (0.32 mmol/L) increase in serum phosphate in the presence of 
competing risks.
† Studies combined from meta-analyses using fixed-effect models
Supplementary Table 4. Serum phosphate levels within normal range and 
cause- specific mortality in men from RS-I and RS-II, adjusted for age, BMI and 
smoking, follow-up until year 2012:
Individual cohorts Studies combined
Cohort n HR* (95% CI) p HR† (95% CI) p
CVD RS-I 249 1.72 (1.22-2.42) 0.002
1.60 (1.19-2.16)  0.002
RS-II 73 1.27 (0.68-2.37) 0.449
Cancer RS-I 230 1.41 (0.99-2.01) 0.056
1.33 (0.98-1.80)     0.066
RS-II 82 1.13 (0.63-2.01) 0.681
External RS-I 18 1.24 (0.33-4.59) 0.750
0.80 (0.25-2.58)     0.703
RS-II 8 0.14 (0.01-1.84) 0.134
Infectious RS-I 54  0.61 (0.28-1.34) 0.220
0.58 (0.28-1.20)    0.142
RS-II 9 0.37 (0.04-.3.04) 0.358
Dementia RS-I 51 1.61 (0.75-3.47) 0.222
1.63 (0.81-3.27)      0.171
RS-II 12 1.72 (0.32-9.33) 0.530
Lung RS-I 39 2.88 (1.21-6.89) 0.017
2.31 (1.11-4.83)    0.026
RS-II 15 1.32 (0.33-5.32) 0.691
Other RS-I 127 1.53 (0.94-2.50) 0.085
1.66 (1.09-2.53)    0.018
RS-II 38 2.11 (0.93-4.82) 0.075
* Hazard ratios from Weibull models, expressed per 1 mg/dL (0.32 mmol/L) increase in phosphate
levels constrained to normal values (2.5-4.5 mg/dL; 0.81-1.45 mmol/L)
† Studies combined from meta-analyses using fixed-effect models
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Supplementary Table 5. Serum phosphate levels within normal range and 
chronic obstructive pulmonary disease (COPD) mortality in men from RS-I and 
RS-II, adjusted for age, BMI and smoking, follow-up until year 2012:
 Individual cohorts Studies combined
n HR* (95% CI) p HR† (95% CI) p
RS-I 27 7.18 (2.53-20.4) <0.001
6.22 (2.39-16.2)  <0.001
RS-II 05 2.98 (0.28-31.9) 0.367
* Hazard ratios from Weibull models, expressed per 1 mg/dL (0.32 mmol/L) increase in phosphate
 levels constrained to normal values (2.5-4.5 mg/dL; 0.81-1.45 mmol/L)
† Studies combined from meta-analyses using fixed-effect models
Supplementary Table 6. Serum phosphate levels and all-cause and CVD 
mortality in men from RS-I and RS-II stratified by smoking status, adjusted for 
age and BMI, follow-up until year 2012:
All-cause mortality CVD mortality
n HR*(95% CI) p n HR*(95% CI) p
RS-I
Never smoker 57 2.11 (1.04-4.26) 0.038 16 1.17 (0.28-4.88) 0.827
Former smoker 543 1.66 (1.36-2.04) <0.001 184 1.80 (1.28-2.52) 0.001
Current smoker 210 1.36 (0.99-1.86) 0.059 66 1.97 (1.11-3.51) 0.021
RS-II
Never smoker 29 0.95 (0.37-2.47) 0.923 08 1.45 (0.25-8.25) 0.674
Former smoker 162 1.11 (0.76-1.63) 0.570 47 1.65 (0.81-3.33) 0.165
Current smoker 71 1.31 (0.76-2.26) 0.331 22 0.74 (0.27-2.05) 0.563
Studies combined†
Never smoker 86 1.59 (0.90-2.80) 0.109 24 1.27 (0.42-3.85) 0.667
Former smoker 705 1.52 (1.27-1.82) <0.001 231 1.77 (1.30-2.40) <0.001
Current smoker 281 1.35 (1.02-1.77) 0.032 88 1.55 (0.94-2.56) 0.085
* Hazard ratios from Weibull models, expressed per 1 mg/dL (0.32 mmol/L) increase in  phosphate 
levels
† Studies combined from meta-analyses using fixed-effect models
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Supplementary Table 7. Serum phosphate levels and COPD mortality in men 
from RS-I stratified by smoking status, adjusted for age and BMI, follow-up 
until year 2012:
COPD mortality
n HR* (95% CI) p
RS-I
Never smoker 01 n/a
Former smoker 20 5.59 (2.21-14.1) <0.001
Current smoker 07 2.64 (0.38-18.3) 0.326
* Hazard ratios from Weibull models, expressed per 1 mg/dL (0.32 mmol/L) increase 
in phosphate levels
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Summary
Plastin 3 (PLS3), a protein involved in the formation of filamentous actin 
(F-actin) bundles, appears to be important in human bone health, on the basis 
of pathogenic variants in PLS3 in five families with X-linked osteoporosis and 
osteoporotic fractures that we report here. The bone-regulatory properties 
of PLS3 were supported by in vivo analyses in zebrafish. Furthermore, in an 
additional five families (described in less detail) referred for diagnosis or ruling 
out of osteogenesis imperfecta type I, a rare variant (rs140121121) in PLS3 was 
found. This variant was also associated with a risk of fracture among elderly 
heterozygous women that was two times as high as that among noncarriers, which 
indicates that genetic variation in PLS3 is a novel etiologic factor involved in 
common, multifactorial osteoporosis.
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Osteoporosis is a prevalent disorder characterized by low bone mass and 
microarchitectural deterioration of bone tissue, which results in bone fragility 
and fractures.1 It is diagnosed clinically and often confirmed by measuring bone 
mineral density (BMD).1,2 An understanding of the causes of osteoporosis is 
important for its prevention, diagnosis, and treatment. The investigation of rare 
mendelian disorders with decreased BMD as a key diagnostic feature constitutes 
a strategy for identifying genetic determinants of osteoporosis.3-7
We identified families with X-linked osteoporosis and fractures among patients 
with negative tests for the genes encoding collagen type Iα1 and type Iα2 
(COL1A1 and COL1A2, respectively) who had been referred to us for diagnosis 
or ruling out of osteogenesis imperfecta type I. Osteoporosis with fractures as 
an X-linked trait has been reported by Sillence.8 We now report data from five 
families with X-linked osteoporosis and fractures related to pathogenic variants 
in the gene for plastin 3 (PLS3), provide functional evidence that PLS3 is a bone-
regulatory protein, and describe a rare variant or single-nucleotide polymorphism 
(SNP) associated with decreased BMD and an increased risk of fracture among 
heterozygous women in the general population.
Methods
Families
The pedigrees and clinical characteristics of Families 1 through 5 are provided in 
Figure 1 and Table 1, and Figure S1 and Table S1 in the Supplementary Appendix, 
available with the full text of this article at NEJM.org. Five additional families, 
designated Families 6 through 10, were also included in the study and are 
mentioned in less detail (Fig. S2 and Table S2 in the Supplementary Appendix).
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Genetic studies
Three patients with osteoporosis and fractures from Family 1 (Patients 1.III-2, 
1.IV-3, and 1.IV-7) underwent X-linked whole-exome sequencing.9,10 We then 
performed Sanger sequencing of all PLS3 exons in 95 affected male patients 
without COL1A1 or COL1A2 mutations who had been referred for diagnosis 
or ruling out of osteogenesis imperfecta type I. Complementary DNA (cDNA) 
analysis was performed in Patients 1.III-2 and 3.II-1 and the index patient from 
Family 9. Linkage analysis was conducted in Families 1 and 2. Methodologic 
and other details of the studies performed are described in the Supplementary 
Appendix.
Epidemiologic studies
The rs140121121 SNP was genotyped in three cohorts (RS-I, RS-II, and RS-III) of 
the prospective, population-based Rotterdam Study, which has analyzed, among 
other topics, the association of genetic factors with BMD and incident fractures in
Dutch men and women 45 years of age or older.11 Details of these studies are 
provided in the Supplementary Appendix.
Functional studies
Electrophoresis of type I collagen and Western blot analysis for PLS3 were 
performed in affected Patients 1.III-2, 1.IV-2, 1.IV-7, 1.IV-8, 3.II-1, and 4.II-1 and 
the index patients from Families 7 and 9. PLS3, belonging to the family of plastins, 
is involved in the formation of F-actin bundles.12 The effect of PLS3 deficiency 
on F-actin cytoskeleton was investigated in dermal fibroblasts with the use of 
immunofluorescence microscopy. We hypothesized that PLS3 may be involved 
in mechanosensing of osteocytes. Mechanical loading in the form of fluid shear 
stress increases the production of nitric oxide in bone cells,13 periodontal ligament, 
and gingival fibroblasts.14 
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In the absence of bone tissue from patients, we investigated the response to 
fluid shear stress of dermal fibroblasts from six patients with PLS3 mutations, as 
compared with three patients with molecularly confirmed osteogenesis imperfecta 
type I and eight controls. To characterize the effect of loss of PLS3 on bone 
morphology, we performed morpholino-mediated knockdown of the zebrafish 
homologue (National Center for Biotechnology Information [NCBI] Reference 
Sequence [RefSeq], NM_001002326.1). Since cartilaginous pharyngeal arches 
are the earliest formed craniofacial skeletal elements, we used a col1a1:eGFP 
(enhanced green fluorescent protein under the control of a col1α1-promoter) 
transgenic zebrafish line to monitor skeletal development.15 Details of these 
studies are provided in the Supplementary Appendix.
Results
Genetic studies
Identification of Pathogenic Variants in PLS3
We discovered a single deleterious hemizygous frameshift, c.235delT;p.
(Tyr79Ilefs*6), in exon 3 of PLS3 (NCBI Reference Sequence, NM_005032.5; 
Mendelian Inheritance in Man number, 300131; chromosome-map location, Xq23) 
in Patients 1.III-2, 1.IV-3, and 1.IV-7 (Fig. S3A through S3F in the Supplementary 
Appendix). Sanger sequencing confirmed the presence of this variant in six 
affected male patients and its absence in one unaffected male patient (Fig. 1).
Sanger sequencing of all PLS3 exons in 95 affected male patients without COL1A1 
or COL1A2 mutations yielded four pathogenic variants in Families 2 through 5 
(Fig. 1). In Family 2, a nonsense mutation, c.1471C→T;p.(Gln491*), in exon 13 was 
identified in Patients 2.III-3 and 2.III-7. In Families 3, 4, and 5, three pathogenic 
variants were identified: a splice-site variant, c.748+1G→A, in exon 7 (in Patient 
3.II-1); an insertion, c.759_760insAAT;p.(Ala253_Leu254insAsn), in exon 8 (in 
actin-binding domain 1, conserved from human down to tetraodon) (in Patient 
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4.II-1); and a frameshift variant, c.1647delC;p.(Ser550Alafs*9), in exon 15 (in 
Patient 5.II-3). To our knowledge, none of these variants are described in current 
databases of human sequence variants: data from the 1000 Genomes Project, the 
Single Nucleotide Polymorphism database (dbSNP, build 137), or data from the 
GO Exome Sequencing Project (ESP) of the National Heart, Lung, and Blood 
Institute (http://evs.gs.washington.edu/EVS).
In addition, a c.321T→A variant in exon 4b (Fig. S3F in the Supplementary 
Appendix), listed in dbSNP as rs140121121, was identified in 5 patients (from 
Families 6 through 10) among the 95 male patients referred to us for possible 
osteogenesis imperfecta type I (allele frequency, 0.05) (Table S2A in the 
Supplementary Appendix). For this rare variant, the allele frequency was 0.01 
among 1872 men in the ESP and 0.02 among the 5189 men in the Rotterdam Study, 
results that differ significantly from the frequency among our 95 male patients 
(P=0.006 and P=0.04 by two-tailed Fisher’s exact test for the two comparisons, 
respectively).
cDNA Analysis
In Family 3 (Patient 3.II-1), a partial skipping of exon 7 and use of a cryptic splice 
site, c.748+36, was detected (Fig. S4A and S4B in the Supplementary Appendix).
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Figure 1. Pedigrees of Families 1 through 5 with Mutations in the Gene for Plastin 
3 (PLS3). 
We identified five pathogenic variants in PLS3 in hemizygous male family members in 
Families 1 through 5, associated with osteoporosis and osteoporotic fractures of the axial and 
appendicular skeleton developing in childhood. Patient 1.IV-1 had a mild phenotype with a
forearm fracture at the age of 8 years, mild osteopenia at the age of 13 years, and two vertebral
compression fractures diagnosed at the age of 21 years. Patient 4.II-1 received a diagnosis of
osteoporosis and osteoporotic fractures in adulthood. Physical examination did not reveal 
abnormalities,  and specifically, no extraskeletal features of osteogenesis imperfecta 
were observed. Apart from a waddling gait in two brothers (Patients 1.IV-7 
and 1.IV-8), which disappeared for unknown reasons, no neuromuscular abnormalities 
were reported. Available radiographs did not show abnormalities in bone size 
or shape. Serum calcium and phosphate levels were normal in all affected
male family members, as was urinary calcium excretion, which was 
measured in several of the affected patients. No consistent decrease
or increase in bone-turnover markers was observed. The clinical picture in heterozygous 
female members in Families 1 and 2 was varied, ranging from normal bone mineral density 
and an absence of fractures to early-onset osteoporosis. Osteopenia and osteoporosis
were diagnosed by means of dual-energy radiographic absorptiometry according to World Health 
Organization criteria. Squares represent male family members, circles female family members, 
and slashes deceased family members. Arrows indicate the probands. Additional clinical details 
from Families 1 through 5 are available in Tables S1, S2, and S3 in the Supplementary Appendix.
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Use of this cryptic splice site leads to an in-frame insertion of 36 nucleotides in the 
messenger RNA (mRNA) and an insertion of 12 amino acids in PLS3: p.(Glu249_
Ala250ins12) (NCBI RefSeq, NP_001129497.1) in the highly conserved actin-
binding domain 1. The in-frame insertion is consistent with the results of Western 
blot analysis, which showed a detectable but reduced PLS3 level (the difference 
in molecular weight of the proteins of approximately 1 kD is not detectable on 
Western blot testing) (Fig. S5 in the Supplementary Appendix). In fibroblasts 
from Family 9 with the c.321T→A exon 4 variant, cDNA with primers for exons 
4 (forward) and 7 (reverse) was normal.
Linkage Analysis
The combined LOD score in Families 1 and 2 was 3.40 (2.35 in Family 1 and 
1.05 in Family 2). Thus, it is very likely that the identified variants in PLS3 were 
causative.
Epidemiologic Studies
The minor allele frequencies of the rs140121121 SNP in men and women, 
respectively, in the RS-I, RS-II, and RS-III cohorts were 0.022 and 0.016, 0.024 
and 0.017, and 0.012 and 0.016. To investigate the relationship of this variant with 
fracture risk, we performed sex-combined analyses for X- linked inheritance with 
adjustment for age and bodymass index but not sex, treating men as homozygous
women.16
In the two cohorts with fracture information (RS-I and RS-II cohorts; 8638 
persons) heterozygous female carriers of the minor (A) allele had a significantly 
increased risk of fracture as compared with the risk among noncarriers of the A 
allele. The odds ratio in the RS-I cohort was 1.74 (95% confidence interval [CI], 
1.19 to 2.55; P = 0.004), and the odds ratio in the RS-II cohort was 2.99 (95% CI, 
1.44 to 6.20; P = 0.003). In a combined analysis of the RS-I and RS-II cohorts 
in a fixed-effect model, the odds ratio was 1.95 (95% CI, 1.39 to 2.74; P<0.001) 
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(Table 2). We observed no statistical indication of sex-specific effects (P>0.05 
for heterogeneity), although associations between carrier status and fracture risk 
among men in the RS-I cohort were not significant and no fractures were observed 
in the very small number of male A-allele carriers in the RS-II cohort, which had 
a shorter follow-up.
Analyses of individual study data for an association with BMD did not show 
consistent effects. Combined analyses of BMD in the three cohorts showed a 
small but significantly decreased BMD at the lumbar spine and femoral neck in 
heterozygous women (P=0.008 and P=0.04, respectively), whereas no significant 
difference was observed in men (Table 3), again without statistical evidence 
of heterogeneity between sexes. Correction for BMD in the fracture analysis 
restricted to the group with BMD and fracture information resulted in a minor 
decrease in the fracture risk among women.
Functional studies
Electrophoresis of Type I Collagen
No decreased production or overmodification of type I collagen was observed.
Western Blot Analysis 
No PLS3 was detected on Western blots in the fibroblast lysates from Patients 
1.III-2, 1.IV-2, 1.IV-7, and 1.IV-8, who had the c.235delT variant (Fig. S5 
in the Supplementary Appendix). PLS3 production in Patient 3.II-1, who 
had the c.748+1G→A variant, was decreased. In Patient 4.II-1, who had the 
c.759_760insAAT variant, and in the index patients from Families 7 and 9 who 
had the c.321T→A variant, the production of PLS3 was similar to that in controls.
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Immunofluorescence Microscopy
Staining with rhodamine phalloidin (Fig. S6 in the Supplementary Appendix) 
visualizes stress fibers, a specific type of contractile F-actin bundles. An 
investigator who was unaware of the clinical and molecular genetic data observed 
no clear differences in the quantity or quality of stress fibers in patients with the 
pathogenic c.235delT PLS3 variant, as compared with controls.
Mechanosensitivity Studies
All cell lines produced a small amount of nitric oxide in response to fluid shear 
stress. Statistical analysis with the use of the Mann–Whitney U test showed no 
significant differences among controls, patients with osteogenesis imperfecta, and
patients with pathogenic PLS3 variants.
In Vivo Characterization of pls3 Knockdown in Zebrafish
Zebrafish with pls3 knockdown had severe dysplasia of craniofacial skeletal 
elements (Fig. S7A and S7B, Fig. S8A and S8B, and Fig. S9C in the Supplementary 
Appendix). Gross morphologic abnormalities were observed in the knockdown 
zebrafish larvae, which were specific and could be reversed dose-dependently 
by injection of human PLS3 mRNA (Fig. S7C and S7D, Fig. S8C and S8D, Fig. 
S9A and S9B, and Fig. S10 in the Supplementary Appendix). Furthermore, the 
muscle tissue in the knockdown larvae, characterized by a predominance of 
F-actin, was also deformed (Fig. S8A and S8B in the Supplementary Appendix). 
Immunohistochemical colocalization experiments revealed a distinct actin-
bundling function of pls3 in the developing bone structure (Fig. S11 in the 
Supplementary Appendix).
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Discussion
We identified five pathogenic variants in PLS3 in Families 1 through 5, with 
osteoporosis and osteoporotic fractures manifested in childhood in the majority 
of hemizygous male family members. The clinical picture in heterozygous 
women from Families 1 and 2 ranged from normal bone density and an absence 
of fractures to early-onset osteoporosis. Factors such as differences in overall and 
local X-chromosome inactivation, postmenopausal status, and immobility could 
play a role.
In addition, we identified a rare variant in PLS3, c.321T→A in exon 4 (SNP 
rs140121121) in Families 6 through 10. The prevalence of this variant was 
significantly increased in our group of  95 male patients without COL1A1 
or COL1A2 mutations who had been referred for diagnosis or ruling out of 
osteogenesis imperfecta type I. The clinical symptoms of patients in Families 
6 through 10 were generally less severe and had a later onset (absent in one 
case) than those in Families 1 through 5 with loss-of-function variants in PLS3. 
We hypothesized that the rs140121121 SNP may be associated with fractures, 
decreased BMD, or both in the general population.
A combined analysis of two cohorts (RS-I and RS-II) of  8638 elderly Dutch 
persons showed that heterozygous women had an increased odds of fracture of 
1.95 (95% CI, 1.39 to 2.74) and that the SNP was significantly associated with 
decreased BMD. However, the association with fracture risk was not fully 
explained by BMD, which suggests that other factors leading to decreased bone 
strength may be involved. Associations in hemizygous men were not significant, 
a finding that may be due to the small size of this group or may indicate that 
additional (possibly genetic) factors play a role. The associations of the SNP 
with fractures and BMD in the general population need to be replicated in larger 
cohorts worldwide.
Our findings indicate that PLS3 has bone-regulatory properties. Overexpression 
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of PLS3 has been reported to act as a protective modifier of spinal muscular 
atrophy, facilitating axonal growth and presynaptic F-actin-dependent processes 
at the neuromuscular junction.17,18 A knockdown of pls3 in zebrafish was used in 
an investigation of motor axon development.17 Since no other animal models were 
available, we used this model17 to analyze the role of PLS3 in skeletal development. 
Malformations of developing craniofacial bone structure, body axis, and tail 
were present and could be reversed dose-dependently by the administration of 
human PLS3 mRNA. Muscles that contained F-actin appeared to be deformed 
as well, which is notable because the formation of pharyngeal cartilage and the 
formation of muscle occur simultaneously.19 Immunohistochemical colocalization 
experiments confirmed a distinct actin-bundling function of pls3 in developing 
bone structure. Taken together, the in vivo data suggest that PLS3 may be a 
regulator of bone development.
The exact mechanism by which PLS3 mutations cause osteoporosis and fractures 
is unknown. Fimbrin, the chicken homologue of PLS3,20 is abundant in osteocyte 
dendrites.21-23 These dendrites are important for mechanosensing (converting 
mechanical signals into intracellular biochemical signals to osteoblasts and 
osteoclasts).24 The loss of sensor-cell mechanosensitivity has been proposed as 
a cause of osteoporosis.25 We hypothesize that PLS3 mutations lead to decreased 
mechanosensing of osteocytes, with subsequent dysregulation of bone modeling 
or remodeling, which results in osteoporosis and fractures. Bone tissue from 
patients with PLS3 mutations will be needed for investigation of mechanosensing 
in osteocytes.
In conclusion, we identified loss-of-function variants in PLS3 as a monogenetic 
cause of X-linked osteoporosis and osteoporotic fractures. We propose diagnostic 
analysis of PLS3 in boys and men who have clinical or radiologic signs of an 
inherited bone disorder with low BMD and fractures, early-onset osteoporosis, 
or a presumptive diagnosis of osteogenesis imperfecta type I without COL1A1 or 
COL1A2 mutations. Among elderly study participants, we identified a rare PLS3 
variant, which was associated with decreased BMD and a risk of fracture among 
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heterozygous women that was two times as high as that among noncarriers, 
indicating genetic variation in PLS3 as a novel factor involved in common, 
multifactorial osteoporosis.
Supported by grants to the Rotterdam Study from Erasmus Medical Center 
and Erasmus University, Rotterdam; the Netherlands Organization of Scientific 
Research (NWO) Investments (175.010.2005.011 and 911-03-012); the Research 
Institute for Diseases in the Elderly (014-93-015 and RIDE2); the Ministry of 
Education, Culture, and Science; the Ministry for Health, Welfare, and Sports; 
Directorate-General XII of the European Commission; the Netherlands Genomics 
Initiative and NWO Project (050-060-810); the Netherlands Consortium of 
Healthy Aging; and the Municipality of Rotterdam. The zebrafish studies were 
supported by grants from the European Union Program FP7 Program (2012 
305121), Deutsche Forschungsgemeinschaft (Wi945-14/1, to Dr. Wirth), and 
SMA-Europe (to Dr. Riessland). The col1a1:eGFP transgenic line was a gift from 
Dr. Shannon Fisher to Dr. Hammerschmidt’s laboratory. 
Disclosure forms provided by the authors are available with the full text of this 
article at NEJM.org.
We thank the participants and the research center staff in the Rotterdam study; the 
contributors of the fracture data set, Mr. Pascal Arp for genotyping rs140121121, 
Dr. Fernando Rivadeneira for advice and help with the statistical analyses in 
the Rotterdam study, Mr. Seyyed Mohsen Hosseini-Barkooie for generating the 
PLS3- RNA expression vector, Dr. Birgit de Witte for help with the statistical 
analyses of the mechanosensitivity experiments, Dr. Jan M. Cobben for assistan-
ce with the linkage analysis, and Dr. René J.P. Musters for advice on the immu-
nofluorescence experiments.
184
PART III. Genetic studies in relation to bone and phosphate
References
1. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. 
The diagnosis of osteoporosis. J Bone Miner Res 1994; 9:1137-41.
2.  Laine CM, Koltin D, Susic M, et al. Primary osteoporosis without fea-
tures of OI in children and adolescents: clinical and genetic characteristics. Am J 
Med Genet A 2012;158A:1252-61.
3.  Hartikka H, Mäkitie O, Männikkö M, et al. Heterozygous mutations 
in the LDL receptor-related protein 5 (LRP5) gene are associated with primary 
osteoporosis in children. J Bone Miner Res 2005;20:783-9.
4.  Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide me-
ta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated 
with risk of fracture. Nat Genet 2012;44:491-501.
5.  Laine CM, Joeng KS, Campeau PM, et al. WNT1 mutations in ear-
ly-onset osteoporosis and osteogenesis imperfecta. N Engl J Med 2013;368:1809-
16.
6.  Keupp K, Beleggia F, Kayserili H, et al. Mutations in WNT1 cause 
different forms of bone fragility. Am J Hum Genet 2013; 92:565-74.
7.  van Dijk FS, Dalgleish R, Malfait F, et al. Clinical utility gene card for: 
osteogenesis imperfecta. Eur J Hum Genet 2013;21: 698-9.
8.  Sillence DO. Bone dysplasia: genetic and ultrastructural aspects with 
special reference to osteogenesis imperfecta. Ann Arbor, MI: University Microfil-
ms, 1980.
9.  Ameziane N, Sie D, Dentro S, et al. Diagnosis of Fanconi anemia: mu-
tation analysis by next-generation sequencing. Anemia 2012;2012:132856.
10.  Clarke L, Zheng-Bradley X, Smith R, et al. The 1000 Genomes Pro-
ject: data management and community access. Nat Methods 2012;9:459-62.
11.  Hofman A, van Duijn CM, Franco OH, et al. The Rotterdam Study: 
2012 objectives and design update. Eur J Epidemiol 2011;26:657-86.
12.  Delanote V, Vandekerckhove J, Gettemans J. Plastins: versatile mo-
dulators of actin organization in (patho)physiological cellular processes. Acta 
Pharmacol Sin 2005;26:769-79.
185
Chapte r  6
13.  Bacabac RG, Smit TH, Van Loon JJWA, Doulabi BZ, Helder M, 
Klein-Nulend J. Bone cell responses to high-frequency vibration stress: does the 
nucleus oscillate within the cytoplasm? FASEB J 2006;20: 858-64.
14.  van der Pauw MTM, Klein-Nulend J, van den Bos T, Burger EH, 
Everts V, Beertsen W. Response of periodontal ligament fibroblasts and gingival 
fibroblasts to pulsating fluid flow: nitric oxide and prostaglandin E2 release and 
expression of tissue non-specific alkaline phosphatase activity. J Periodontal Res 
2000;35:335-43.
15.  Kague E, Gallagher M, Burke S, Parsons M, Franz-Odendaal T, Fi-
sher S. Skeletogenic fate of zebrafish cranial and trunk neural crest. PLoS One 
2012;7(11): e47394.
16.  Clayton D. Testing for association on the X chromosome. Biostatistics 
2008;9: 593-600.
17.  Oprea GE, Kröber S, McWhorter ML, et al. Plastin 3 is a protective 
modifier of autosomal recessive spinal muscular atrophy. Science 2008;320:524-7.
18.  Ackermann B, Kröber S, Torres-Benito L, et al. Plastin 3 ameliorates 
spinal muscular atrophy via delayed axon pruning and improves neuromuscular 
junction functionality. Hum Mol Genet 2013;22:1328-47.
19.  Shwartz Y, Farkas Z, Stern T, Aszódi A, Zelzer E. Muscle contraction 
controls skeletal morphogenesis through regulation of chondrocyte convergent 
extension. Dev Biol 2012;370:154-63.
20.  de Arruda MV, Watson S, Lin CS, Leavitt J, Matsudaira P. Fimbrin is 
a homologue of the cytoplasmic phosphoprotein plastin and has domains homolo-
gous with calmodulin and actin gelation proteins. J Cell Biol 1990;111:1069-79.
21.  Bonewald LF. The amazing osteocyte. J Bone Miner Res 2011;26:229-38.
22.  Tanaka-Kamioka K, Kamioka H, Ris H, Lim SS. Osteocyte shape is 
dependent on actin filaments and osteocyte processes are unique actin-rich pro-
jections. J Bone Miner Res 1998;13:1555-68.
23.  Kamioka H, Sugawara Y, Honjo T, Yamashiro T, Takano-Yamamoto 
T. Terminal differentiation of osteoblasts to osteocytes is accompanied by dra-
matic changes in the distribution of actin-binding proteins. J Bone Miner Res 
2004;19:471-8.
186
PART III. Genetic studies in relation to bone and phosphate
24.  Weinbaum S, Duan Y, Thi MM, You L. An integrative review of me-
chanotransduction in endothelial, epithelial (renal) and dendritic cells (osteo-
cytes). Cell Mol Bioeng 2011;4:510-37.
25.  Mulvihill BM, Prendergast PJ. Mechanobiological regulation of the 
remodelling cycle in trabecular bone and possible biomechanical pathways for 
osteoporosis. Clin Biomech (Bristol, Avon) 2010;25:491-8.
187
Chapte r  6

7
Osteoporotic Vertebral 
Fractures During
Pregnancy:
Be Aware of a Potential 
Underlying Genetic
Cause
190
PART III. Genetic studies in relation to bone and phosphate
191
Chapte r  7
Osteoporotic Vertebral Fractures During Pregnancy:
Be Aware of a Potential Underlying Genetic Cause
Authors:
Natalia Campos-Obando, Ling Oei, Lies H. Hoefsloot, Rosalie M. Kiewiet,
Caroline C. W. Klaver, Marleen E. H. Simon, and M. Carola Zillikens
Status: 
Published in J Clin Endocrinol Metad 2014;99:1107-11
192
PART III. Genetic studies in relation to bone and phosphate
Context: Although the baby growing in its mother’s womb needs calcium for 
skeletal development, osteoporosis and fractures very rarely occur during 
pregnancy.
Case Presentation: A 27-year-old woman in the seventh month of her first 
pregnancy contracted midthoracic back pain after lifting an object. The 
pain was attributed to her pregnancy, but it remained postpartum. Her past 
medical history was uneventful, except for severely reduced vision of her left 
eye since birth. Family history revealed that her maternal grandmother had 
postmenopausal osteoporosis and her half-brother had three fractures during 
childhood after minor trauma. Her height was 1.58 m; she had no blue sclerae or 
joint hyperlaxity. Laboratory examination including serum calcium, phosphate, 
alkaline phosphatase, creatinine, β-carboxyterminal cross-linking telopeptide of 
type I collagen, 25-hydroxyvitamin D, and TSH was normal. Multiple thoracic 
vertebral fractures were diagnosed on x-ray examination, and dual-energy x-ray 
absorptiometry scanning showed severe osteoporosis (Z-scores: L2–L4, -5.6 
SD; femur neck, -3.9 SD). DNA analyses revealed two compound heterozygous 
missense mutations in LRP5. The patient’s mother carried one of the LRP5 
mutations and was diagnosed with osteoporosis. Her half-brother, treated with 
cabergoline for a microprolactinoma, also had osteoporosis of the lumbar spine 
on dual-energy x-ray absorptiometry and carried the same LRP5 mutation. The 
patient was treated with risedronate for 2.5 years. Bone mineral density and back 
pain improved. She stopped bisphosphonate use 6 months before planning a 
second pregnancy.
Conclusion: Our patient was diagnosed with osteoporosis pseudoglioma 
syndrome/familial exudative vitreoretinopathy. Potential underlying genetic
causes should be considered in pregnancy-associated osteoporosis with 
implications for patients and relatives. More studies regarding osteoporosis 
treatment preceding conception are desirable. 
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Pregnancy- and lactation-associated osteoporosis (PLO) with the occurrence of 
fragility fractures mainly of the vertebral bodies was first described as a syndrome 
by Nordin and Roper (1) in 1955. It is most commonly observed in the third 
trimester or early postpartum in women presenting with severe and prolonged 
back pain and sometimes height loss. The prevalence is unknown, and so far 
about 120 case reports have been reported (2). The etiology is also not known, 
although a role of calciotropic hormones such as PTHrP has been suggested (3, 
4). Most of the cases have been reported in primigravid women (3). There are no 
guidelines for treatment due to the lack of controlled trials.
Table 1. Laboratory and Imaging Studies
Lab Values
Reference
Values
Index
Patient, 
III:2
Patient’s
Mother, 
II:2
Patient’s
Half-brother, 
III:3
Serum
   Calcium, mmol/L 2.25–2.65 2.35 2.26 2.31
   Phosphate, mmol/L 0.8 –1.4 1.39 0.96 1.19
   Creatinine, µmol/L 55–90 67 66 82
   TSH, mU/L 0.4 – 4.3 1.26 4.10 0.55
   ALP, U/L <97 83 76 71
   Bone-specific ALP, g/L <20.1 22.6 N/A 21.8
   25-Hydroxyvitamin D, nmol/L  >50 59 101 46
   bCTX, µg/L <0.56 0.11 N/A 0.88
Urine
   24-h calcium, mmol/24 h 2.5–7.5 1.9 7.2 N/A
   Urine spot sample, mmol/L 3.55
DXA scan
Cut-off for 
osteoporosis
   Lumbar spine L2--L4 (T-score) < – 2.5 SD – 5.7 – 3.2 – 1.4
   Lumbar spine L2--L4 (Z-score) < – 2.0 SD – 5.6 – 2.8 – 2.1
   Femoral neck (T-score) < – 2.5 SD – 3.9 – 0.5 0.0
   Femoral neck (Z-score)  < – 2.0 SD – 3.9 0.0 – 0.8
Abbreviations: ALP, alkaline phosphatase; bCTX, β-carboxyterminal cross-linking telopeptide
 of type I collagen; N/A, measurement not available.
Values outside of reference range are marked bold.
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Another form of rare pregnancy-associated osteoporosis is called transient 
osteoporosis of pregnancy. Transient osteoporosis of pregnancy usually presents 
in the third trimester of pregnancy, sometimes with very severe pain while 
walking or standing, usually localized in the hip, and sometimes leading to hip 
fracture (5). Radiographs can show severe localized loss of bone mass, whereas 
only edema  may be visible in magnetic resonance imaging in early stages. 
This condition usually fades within a few months after delivery. Additionally, 
pregnancy and lactation might lead to bone loss in patients with pre-existent 
osteoporosis attributable to genetic causes of low bone mineral density (BMD). 
As a consequence, these patients may become clinically manifest and develop 
fractures during this period. In this case report, we describe the clinical picture 
of a 27-year-old woman diagnosed with vertebral fractures and osteoporosis 
shortly after pregnancy. We will discuss potential causes of pregnancy-associated 
osteoporosis, its clinical consequences, and issues to take into account concerning 
patient management.
Case Presentation
A 27-year-old Caucasian woman in the seventh month of her first pregnancy 
complained of midthoracic back pain after bending over to lift a nonheavy object. 
The pain remained with differing intensity and was attributed to her pregnancy. 
After the delivery of a healthy child, the back pain prevented her from lifting her 
baby. She breastfed her baby for about 4 weeks. Because physical therapy had no 
effect on the pain, she was referred to an internist about 3 months after delivery. 
Her past medical history was uneventful without fractures, but she reported a 
severely reduced vision of her left eye since birth of unknown etiology, treated 
unsuccessfully with patches on the right eye. She consumed two to three dairy 
products daily. There was no history of abnormal menstrual cycle, smoking, 
alcohol, or medication use (such as corticosteroids) except for over-the-counter 
calcium and vitamin D supplements. Family history revealed that her maternal 
grandmother had postmenopausal osteoporosis, her grandfather had ankylosing 
spondylitis, and her only sibling (a half-brother) had experienced three fractures 
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during childhood after minor trauma. On physical examination, her height was 
1.58 m (5 ft 2 in), her weight was 53 kg (117 lb), and she had no blue sclerae and 
no joint or skin hyperlaxity. Her maximally corrected visual acuity was 0.16 + 
+ left (S-6.50 = C-2.75 X 22) and 1.0– right (S-5.75 = C-1.25 X 170). Further 
ophthalmological examination revealed amblyopia in the left eye and changes 
compatible with a mild form of familial exudative vitreoretinopathy (FEVR) in 
both eyes. There was normal form and function of the spinal column, which was 
slightly painful during flexion and extension. Except for an increase in bone-
specific alkaline phosphatase and low urinary calcium excretion, there were no 
abnormalities on laboratory examination (Table 1). Spinal x-ray showed end-plate 
compressions of thoracic vertebrae (T7, -9, -10, and -12; Figure 1). Dual-energy 
x-ray absorptiometry (DXA) scanning performed approximately 3 months after 
delivery showed severe osteoporosis (Z-scores: L2–L4, –5.6 SD; femur neck, 
–3.9 SD) (Table 1). A biopsy of the iliac crest revealed coarse trabeculae with 
loss of connectivity and a strongly increased bone turnover, but no evidence for 
mastocytosis or osteomalacia. After obtaining informed consent, DNA analysis 
was performed and showed no mutations in the COL1A1 or COL1A2 genes, only a 
polymorphism in the COL1A1 gene that has been reported in juvenile osteoporosis 
but also in nonaffected family members. 
Figure 1. Lateral spinal x-ray image of the index patient. 
The black arrows show end-plate compressions of thoracic 
vertebrae at T7, T9, T10, and T12.
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This makes a mild form of osteogenesis imperfecta unlikely. It is important, 
however, to notice that 10% of patients with clinical osteogenesis imperfecta 
have no detectable mutations in the exons for COL1A1 and COL1A2 (6). DNA
analyses of the LRP5 gene revealed two compound heterozygous mutations, 
c.1519G >A (p.Gly507Ser) and c.3758G >T (p.Cys1253Phe). Subsequently, family 
screening with DXA and DNA analyses were performed (Figure 2). The 
mother of the patient, recently postmenopausal, is a carrier of the LRP5
c.3758G> T mutation and was diagnosed with osteoporosis on a DXA scan 
(Z-scores: lumbar spine, –2.8 SD; femoral neck, +0.0 SD). Spine radiography 
showed mild anterior wedging (less than 25%) of three thoracic vertebrae. The 
patient’s half-brother, treated with cabergoline for a microprolactinoma, carried 
the same LRP5 c.3758G> T mutation.  He also had osteoporosis on the DXA scan 
(Z-scores: lumbar spine, -2.1 SD; femoral neck, +0.0 SD) and had sustained three 
fractures after minimal trauma at a young age, as described before. He had no
vertebral fractures on spine radiography. The mother and half-brother had no v 
isual impairments. The father of the patient was deceased and could therefore not 
be tested. Surprisingly, the c.3758G >T mutation was not detected in DNA from 
the  maternal grandmother with osteoporosis. This indicates that the mutation 
was inherited from the maternal grandfather or a de novo mutation and that the 
grandmother may have had common osteoporosis. The patient was treated with 
risedronate for 2.5 years. BMD and back pain improved. She stopped the use of 
bisphosphonate 6 months before planning a second pregnancy.
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Figure 2. Pedigree and genotypes of the family. Index patient (III:2) is indicated with an 
arrow. She is compound heterozygous for the c.1519G> A and the c.3758G >T mutations. 
Subjects II:2 and III:3 are carriers of the c. 3758G> T mutation. Black squares within 
cicles and square represent low BMD (below left) and mild exudative vitreoretinopathy 
(above right).
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Discussion
In this case report we describe the clinical picture of a young woman without a 
history of fractures. She presented in the third trimester of her first pregnancy with 
disabling back pain that persisted after delivery and was caused by fractures of
multiple thoracic vertebrae. She had a severely reduced BMD on DXA scanning. 
We considered the diagnosis of PLO, but we identified a genetic cause underlying 
her condition. PLO is a rare heterogeneous disorder of unknown etiology. It is 
characterized by the occurrence of fragility fractures mostly in the spine and 
severe back pain presenting typically in the third trimester of gestation or early 
postpartum period (3). In PLO, whereas some patients improve spontaneously after 
giving birth or stopping lactation, others need medical treatment and continue to 
have decreased BMD (7). Pre-existing secondary causes of osteoporosis, such 
as vitamin D deficiency, celiac disease, anorexia nervosa, mastocytosis, and 
hyper(para)thyroidism, should always be ruled out. Pregnancy and lactation may 
lead to up to 5–10% loss of mainly trabecular bone, especially during breast-
feeding. However, almost complete recovery occurs in most cases within 6 to 12 
months (8) and thus cannot explain the verylow BMD in our patient unless BMD 
was already compromised before pregnancy due to other reasons. In patients with 
PLO, a high prevalence of fractures has been reported in their mothers (9) and 
of osteopenia in their offspring (10), leading to the suggestion of an underlying 
(genetically determined) low peak bone mass (8, 9).
In our patient, we suspected an underlying monogenetic bone disease due to the 
severity of her osteoporosis. Analysis of her half-brother and mother confirmed a 
familial component. The history of severely reduced vision in one eye since birth 
led to suspicion of osteoporosis pseudoglioma (OPPG) syndrome, an autosomal 
recessive disorder characterized by early onset osteoporosis and blindness 
(OMIM no. 259770). OPPG is a rare disease with an estimated incidence of 
1/2 000 000 and a carrier frequency of 1/700 (11), caused by biallelic loss of function 
mutations in LRP5 (12). LRP5 (low-density lipoprotein receptor-related protein 
5) is a cell-surface protein receptor that plays a key role in several intracellular 
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signaling pathways, mainly Wnt and Norrin signaling (12). Mutations in LRP5 
are also involved in FEVR (13) (FEVR/ exudative vitreoretinopathy 4, OMIM 
no. 133780), a hereditary blinding disorder with a highly variable phenotype even 
within the same family (14). Both autosomal recessive and autosomal dominant 
inheritance can occur. FEVR caused by LRP5 mutations is associated with low 
bone mass, in contrast to FEVR caused by mutations in other genes (eg, FZD4 or 
NDP) (14). OPPG and FEVR caused by LRP5 mutations are therefore disorders 
with an overlapping phenotype. It has been suggested by Qin et al (14) that OPPG 
and FEVR caused by mutations in LRP5 are part of a single phenotypic spectrum 
with both ocular and bone manifestations. DNA analysis in our patient showed 
compound heterozygosity for two missense mutations in the LRP5 gene.  The 
c.1519G >A (p.Gly507Ser) mutation is predicted to induce a minor chemical change 
of an evolutionary strongly conserved amino acid with introduction 
of an alternate splice acceptor site, and when present in homozygous 
state induces OPPG with very low BMD levels (15). On the other hand,
c.3758G >T (p.Cys1253Phe) is  predicted to induce a major chemical change of 
an evolutionary strongly conserved amino acid and has been previously described 
in recessive FEVR (13). Because most patients with OPPG are congenitally blind 
or become blind by the age of 25 years (11, 15–17), it is remarkable that our 
patient had relatively mild signs of exudative vitreoretinopathy, and a diagnosis of 
recessive FEVR might be considered as well (18), although osteoporosis is usually 
less severe than in OPPG (11, 14, 15). The mother and half-brother carrying the 
LRP5 c.3758G >T mutation that  has been previously described in recessive FEVR 
also had decreased BMD. Although OPPG follows an autosomal recessive pattern 
of inheritance, heterozygous carriers can exhibit mildly reduced BMD (19).
Heterozygous mutations in LRP5 are associated with primary osteoporosis in 
children (20). Moreover, in genome-wide meta-analyses the LRP5 locus was 
significantly associated with BMD and fracture risk (21), broadening the spectrum 
of bone abnormalities related to genetic variation in LRP5.
We treated our patient with risedronate after she told us she did not want to get 
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pregnant for at least 2 years, and she continued the use of oral contraceptives. 
Bisphosphonates are contraindicated in pregnancy. Animal studies with high 
doses have shown maternal and fetal toxicity, and there is concern of treating 
premenopausal women with these drugs because they are retained in bone for 
several years (22). A recent study of the literature that identified 78 cases of 
pregnancies involving exposure to bisphosphonates before conception or during 
pregnancy did not demonstrate serious adverse effects. Despite this, cases 
of increased spontaneous abortions, shortened gestational age, low neonatal 
birth weight, and transient hypocalcemia of the newborn were reported (23). 
Although bisphosphonates share the same core structure, their binding affinity 
to hydroxyapatite crystals varies among them; those with higher affinity display 
longer skeletal retention. It has been found that the ranking order for hydroxyapatite 
affinity from highest to lowest is zoledronate  > alendronate  > ibandronate = 
risedronate  > etidronate (24). We chose a bisphosphonate with relatively low 
skeletal retention. We advised the patient to stop treatment at least 6 months 
before stopping birth control because risedronate levels have not been detected 
in urine 5 months after cessation of therapy (25). We would nevertheless advise 
close monitoring of pregnancy and intrauterine growth, check for neonatal 
hypocalcemia, and report on outcome. Also, we advised our patient to limit or 
avoid lactation after a subsequent pregnancy to prevent further maternal bone loss 
associated with breast-feeding (8). Alternatively, newer medications without long-
term bone retention could be considered as off-label treatment in premenopausal 
women at very high risk for fractures who wish to become pregnant. However, 
in theory, stopping these drugs before becoming pregnant could lead to increased 
bone loss during pregnancy.
Conclusion
We report the clinical picture of a 27-year-old woman who suffered from 
disabling back pain during pregnancy and was diagnosed with multiple vertebral 
fractures and severe osteoporosis after delivery. We made the diagnosis of severe 
osteoporosis due to compound heterozygous mutations in the LRP5 gene with mild 
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exudative vitreoretinopathy as part of a spectrum of diseases named “osteoporosis 
pseudoglioma syndrome” and “familial exudative vitreoretinopathy.” Thus, 
our patient was genetically predisposed, and pregnancy further exacerbated 
her osteoporosis, resulting in vertebral fractures. We propose screening for 
an underlying monogenetic bone disorder in patients with PLO and one of the 
following features: a severely reduced BMD (Z-scores < –2.0 SD); a family 
history of osteoporosis or fragility fractures, joint hypermobility, blue sclerae, 
congenital blindness, or severely reduced vision; or a history of fractures before 
pregnancy (eg, testing for mutations in collagen 1A1 and 1A2 genes, LRP5, WNT1 
[26], and LGR4 [27], and for the recently reported PLS3 gene [28]). A genetic 
diagnosis has implications for the patient and relatives. More studies regarding 
bisphosphonate treatment and newer osteoporosis drugs preceding conception are 
desirable.
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Title: The Annunciation.
Author: Fra Angelico.
Chronology: 1425-1428.
Style: Quattrocento (Renaissance)
Technique: Tempera on wood.
Location: Currently in the Prado Museum.
Título: La Anunciación.
Autor: Fra Angélico.
Cronología: 1425-1428.
Estilo: Quattrocento (Renacimiento)
Técnica: Témpera sobre tabla.
Ubicación: Actualmente en el Museo del Prado.
"In the sixth month the Angel GABRIEL was sent by GOD to a town in 
Galilee... to a VIRGIN betrothed to a man named JOSEPH,  
and the VIRGIN'S name was MARY. He went in and said to her, 
'Rejoice, you who enjoy GOD's favour! The LORD is with you.'"
"Al sexto mes fue enviado por DIOS el Ángel GABRIEL a una ciudad de 
Galilea... a una VIRGEN desposada con un hombre llamado JOSE; 
el nombre de la VIRGEN era MARIA. Y entrando, le dijo: 
«Alégrate,  llena de GRACIA, el SEÑOR está contigo.»"
 [ST. LUKE (HOLY GOSPEL) 1:26-28]
[SAN LUCAS (SANTO EVANGELIO) 1:26-28]
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Discussion
The aims of this thesis were threefold: 1) to investigate the relation of bone-related 
traits, such as bone mineral density (BMD) and serum phosphate (P), with several 
health outcomes – including all-cause and cause-specific mortality, fractures 
and coronary calcification; 2) to study sex differences in these associations as 
well as in serum calcium and phosphate levels; and 3) to discover underlying 
genetic variants for human serum phosphate levels and for monogenetic forms 
of osteoporosis. These aspects of my work will be discussed here. In addition, an 
outlook to future research in this area will be highlighted at the end.
Part I. Bone traits and phosphate in relation to health & survival
Bone mineral density and mortality: update in the Rotterdam Study
The Rotterdam Study has been one of the leading cohorts in reproducing an 
incipient and interesting finding noticed in few other research groups since 1991 
and in describing that low BMD is related to mortality independently of fractures 
(1-3). Indeed, the knowledge of fracture events as an important factor in excess 
mortality was by then well established (4,5), but the novel concept of low BMD 
influencing survival beyond skeletal boundaries posed in itself a challenge from 
both the epidemiological and the biological perspectives.
It was originally proposed that this association could be suffering from confounding 
and that a low BMD was only reflecting a cumulative load of noxious stimuli 
throughout life (1,6). Despite this initial interpretation, there was a continuous 
growth of research articles suggesting that a low bone mass, a compromised 
bone microarchitecture – or a combination of both - was playing a potential role 
in decreasing survival in the general population (7-11). Gradually, the studies 
were more extensive until they reached the threshold for meta-analyses, which 
confirmed an epidemiological association between low BMD and all-cause 
mortality (12). Subsequently, the research question arose about the nature of the 
disease (s) underlying this relation.
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In parallel to the acknowledgment of the role of BMD in survival beyond fracture-
mortality, a new term arose in the literature to denote a joint condition of low 
BMD and arterial calcification (AC). The first description of the “calcification 
paradox” (13) was echoed by abundant heterogeneous reports, some showing an 
inverse relation between BMD and AC (especially in postmenopausal women) 
(14) but others found no such link (15). It became apparent that the source of 
heterogeneity was partly driven by sex, age, and the skeletal site (16), as lumbar 
spine BMD seemed to provide a more consistent evidence of the association, 
especially in men (17).
Despite low consistency, the relation BMD-AC acquired importance as AC 
constitutes an independent risk factor for CVD mortality. In a landmark report, 
Block et al. (18) were among the first to correctly hypothesize the ominous 
prognosis that AC conferred to chronic kidney disease (CKD) patients in 
hemodialysis. This was later replicated in CKD patients not on dialysis (19) until 
the evidence became so strong at the population level that a prominent position 
statement from the American Heart Association acknowledged the crucial role of 
arterial calcification in increasing cardiovascular disease and mortality, especially 
in the coronary bed (20).
Following this evidence and a relation between low BMD and stroke mortality (1), 
a possible link between BMD and CVD mortality was thoroughly investigated. 
However, the heterogeneity across studies precluded a confirmatory association. 
Indeed, the last available meta-analysis (21) describes an inverse relation between 
BMD and CVD mortality, but the authors highlighted the strong evidence 
of publication bias to the point of nullifying the results. In other words, a 
considerable amount of research that had not reached publication has not found 
BMD to be related to CVD mortality (22). Of note, the pooled evidence lacks 
stratified analysis according to skeletal site (12, 21), which is an important aspect 
as different compartments in bone can display specific properties and metabolic 
activities (23).
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In 2003 Mussolino et al. from NHANES I noticed that the association of low 
hand BMD with allcause mortality in both black and white subjects was related to 
non-CVD mortality (9). In 2008, this finding was also described in NHANES III 
(including the addition of Mexican-Americans) where a strong relation between 
low total femoral BMD and non-CVD & non-cancer mortality was found (8). 
These findings were followed by a report by Johansson et al. (7) from MrOS 
Sweden: the authors described an association of total hip BMD with mortality in 
men which was multifactorial but mainly driven by causes other than CVD and 
cancer.
In the Rotterdam Study, it has been previously reported that a low femoral 
neck BMD (FN-BMD) was related to decreased overall survival in men (not 
in women), but the cause was not identified (3). Therefore, our first aim was to 
investigate the type of disease underlying the relation between a low BMD and 
decreased survival. Our second aim was to investigate if BMD was associated 
with calcification in the coronary arteries. 
For both research questions we chose FN-BMD to facilitate the comparison with 
previous reports. FN-BMD can be classified into categories of normal BMD, 
osteopenia and osteoporosis (24), although this classification is also possible from 
BMD at other skeletal sites.
In Chapter 2 (25), we present the analysis of this relation in 7.834 participants 
from the first two cohorts of the Rotterdam Study (RS-I & RS-II) followed now 
for more than 10 years (17 years on average) and we reproduced the findings 
previously described by our colleagues with a follow-up of 5.4 years (3): each 
standard deviation (SD) decrease of FN-BMD (i.e., approx. 0.14 g/cm2) is related 
to an increased all-cause mortality in men (but not women) by 9% [pooled HR 
men: 1.09 (1.04-1.15)]. Importantly, this result was not explained by fracture-
related mortality.
With the purpose of improving the inference, the analyses were repeated excluding 
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subjects with fatal events within the first three years of follow-up. We found no 
evidence that early mortality attenuated our findings.
These results answer our first question:
Q1a. Is femoral neck BMD still related to all-cause mortality in a longer follow-up 
study? 
Low BMD is related to increased all-cause mortality. In particular, we observed 
this relationship in men but not in women. The association described previously 
seems not to vanish with time, nor is it explained by early mortality. This argues 
against reverse causation – an argument commonly applied to justify the 
associations of bone with health outcomes other than fractures.
We also found that a low FN-BMD was especially related to chronic lung disease 
mortality in men from both cohorts and in women from RS-I. Each SD decrease 
of FN-BMD was related to an increased lung mortality of 80% in men from both 
cohorts [HR: 1.80 (1.40-2.31)] and of 72% in women from RS-I [HR: 1.72 (1.16-
2.57)].
When we analyzed the results using T-scores of BMD (26) we found the following:
	 	Men with osteopenia at baseline had a hazard of dying from chronic 
lung disease during the 10-year follow-up of 121% compared with men with 
normal FN-BMD [HR: 2.21 (1.34- 3.62)];
	 	Men with osteoporosis at baseline had a hazard of dying from chronic 
lung disease during the 10-year follow-up of 1560% compared with men with 
normal FN-BMD [HR: 16.6 (5.84-47.0)];
	 	 Women with osteoporosis at baseline had a hazard of dying from 
chronic lung disease during the 10-year follow-up of 490% compared with women 
with normal FN-BMD [HR: 5.91(1.20-2.90)].
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Chronic obstructive pulmonary disease (COPD) (27) was the main cause among 
the lung mortality group. We found that each SD decrease in FN-BMD increased 
COPD mortality in 130% in men [HR: 2.30 (1.72-3.09)] and in 76% in women [HR: 
1.76 (1.13-2.75)]. FN-BMD was found to influence COPD mortality independently 
of age, body mass index, smoking, inflammation, proxies of 25-hydroxyvitamin 
D status, vertebral fractures and prevalent COPD.
In our analyses, COPD mortality drove almost all of the association of low 
BMD with all-cause mortality in men from both cohorts, while we did not find 
associations with mortality due to cardiovascular diseases, dementia, infections, 
trauma or cancer.
A special emphasis in our analyses was given to assess the potential influence 
of vertebral fractures, as they are closely related to low FN-BMD (28). Vertebral 
fractures can induce pain and progressive kyphosis; both mechanisms are 
compatible with a restrictive pattern of lung function which is characterized by a 
decreased movement of the thorax with subsequent reduced lung volumes (such as 
vital capacity and total lung capacity) (29-33). In addition, these type of fractures
can increase mortality in COPD patients (29,34). Nevertheless, we found no 
evidence for prevalent or incident vertebral fractures as an underlying mechanism 
for the relation between low BMD and COPD mortality. Nor did baseline COPD 
and glucocorticoid use influence our results.
	 	Bone mineral density and COPD mortality: an update in NHANES III
An important support for the causal inference of our results in Rotterdam 
Study was provided by AC Looker in 2014, who replicated in NHANES III an 
association between low FN-BMD and COPD mortality in non-Hispanic white 
men and women (35). The author also found low FN-BMD to be related to 
COPD prevalence. Progressive adjustments did attenuate somewhat the relation. 
Nevertheless, Looker concluded that there was enough evidence that confounding 
could not fully explain these results and, intriguingly, that the link between 
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low BMD and COPD appeared to be initiated many years before overt COPD 
development.
As previously mentioned, NHANES researchers had already in 2008 been able 
to identify that a low (total proximal) femoral BMD was related to all-cause 
mortality, not driven by CVD or cancer (8): subjects in the lowest BMD quartile 
displayed a 104% increased mortality due to a non-CVD & non-cancer cause 
[RR: 2.04 (1.24-3.35)].
After 16 years and in line with our data from Rotterdam, Looker identified this 
disease process to be COPD (32).
These findings answer the second part of our first set of questions:
Q1b. Can we identify a specific disease through which survival is impaired by 
a condition of low BMD and explain this relationship, or is it all explained by 
fractures?
COPD is the disease (identified in the Rotterdam Study and NHANES cohorts) for 
which survival is strongly influenced by a low BMD and that, in fact, drives most 
of the association between low BMD and all-cause mortality in men; this latter 
association is not explained by fracture-related mortality.
BMD and coronary artery calcification (CAC): rationale for this research in the 
absence of an association linking BMD and CVD mortality
In contrast to the absence of evidence of a relation between BMD and CVD 
mortality (21), metaanalyses assessing an association with arterial calcification 
(AC) had less heterogeneity, allowing the conclusion that BMD is inversely related 
to AC (36, 37). Most studies of this sort have been, however, cross-sectional and 
composed of post-menopausal women only.
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As previously mentioned, AC is an independent CVD risk factor for fatal and non-
fatal events (13, 20, 38, 39). Although the morphology and location of calcified 
lesions exert a crucial role in plaque stability (40), AC assessment provides useful 
clinical information for re-classification and risk management, especially for 
patients in intermediate risk categories (20).
Therefore, to answer our second set of research questions, we analyzed whether 
markers of bone health (FN-BMD; FN-BMD loss) (41) were related to calcification 
in the coronary epicardial arteries (CAC) in the Rotterdam Study. Previously, 
BMD loss in cortical compartments  (metacarpal bone) has been related to aortic 
calcification progression in post-menopausal women from Framingham Study and 
from a Dutch population from Zoetermeer (42, 43); however, whether a similar 
relation could be identified between BMD loss and coronary calcification was 
uncertain.
In this context, it is important to note that excluding advanced CKD and severe 
primary hyperparathyroidism (44, 45), CAC occurs mainly in the intima and 
therefore reflects atherosclerotic burden.
In Chapter 3 (46), we describe the relation between BMD and BMD loss and 
CAC through cross-sectional, prospective and “hybrid” approaches. In the 
first approach, we tested whether FN-BMD was related to CAC; in the second 
approach, we assessed if CAC scores were related to fracture risk; and in the third 
approach, we analyzed whether FN-BMD loss (assessed in two points in time) 
was related to CAC (assessed in one point in time).
We found no cross-sectional association between FN-BMD and CAC. After 
applying competing risks models, CAC scores were not a risk factor for fractures. 
But in line with previous data (42,43), in 1.276 participants we found the following: 
a) each 1% annual FN-BMD loss was related to increased CAC scores in women 
(but not men) assessed both continuously [β: 0.22 (0.06-0.38)] and categorically 
[prevalence ratio (PR): 4% (1% - 7%)]; and b) the relation between FN-BMD loss 
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and CAC was constrained to women in the lowest 17β-estradiol levels (<16.4 
pmol/L) and in the highest alkaline phosphatase levels (>76 U/L), suggesting a 
condition of marked hypoestrogenism and increased bone turnover as underlying 
factors for the association.
The consistent evidence of (mainly cortical) BMD loss and arterial calcification 
progression in women from our study and from previous research (42,43) requires, 
however, a careful interpretation. Through an elegant experiment, a Japanese 
group showed (47) that the bone-related proteins osteoprotegerin (OPG) and the 
Receptor Activator of Nuclear Factor κβ (RANK) are also expressed in human 
aortic endothelial and smooth muscle cells, reflecting the potential vascular 
responsiveness to RANK ligand (RANKL). RANKL increases the synthesis 
of bone morphogenetic protein 2 (BMP-2) in endothelial cells, stimulating the 
expression of osteogenic genes, such as ALPL (alkaline phosphatase), in smooth 
muscle cells and therefore favoring transdifferentiation into osteoblast-like cells 
(48). Therefore, RANKL increases calcification in vascular cells. Importantly, 
estradiol attenuates RANKL-induced calcification partly through an increase in 
Matrix Gla Protein, a calcification inhibitor that blocks BMP-2.
Consequently, the clinical context of marked hypo-estrogenism increases RANK/
RANKL activation that induces a) osteoclast activation and mineral resorption in 
bone tissue (49) and b) BMP-2 activation and subsequent calcification induction 
in endothelial and smooth muscle cells (47).
Remarkably, the authors showed evidence that it is not serum (i.e., bone-derived) 
RANKL but instead locally expressed RANKL which is the underlying source 
for the described events (47).
A potential explanation for our findings that hypo-estrogenism appeared to 
underlie both processes of bone loss and AC in women but not in men could be 
the absent role for 17β-estradiol in AC  process in men – as shown in a series of 
sequential experiments by Fitzpatrick et al. (50,51). On the other hand, serum 
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estradiol levels are much lower in postmenopausal women than men of the same 
age.
Moreover, there is clinical evidence supporting the crucial role of 17β-estradiol as 
an inhibitor of arterial calcification in women: a previous randomized controlled 
trial has provided evidence that hormone replacement therapy (HRT) decreases 
coronary calcification (52). However, estrogen exerts complex effects at the 
vascular level. Importantly, it must be added that HRT cannot be considered a 
therapy to decrease overall CVD risk, as the landmark HERS & WHI studies and 
Cochrane meta-analyses have shown the opposite to be true (53-55).
We conclude that our findings support an absent primary role for bone in the 
association between cortical bone loss and coronary calcification in women; 
instead, the available data suggest the mediation of low 17β-estradiol as the trigger 
agent for both pathological processes.
Therefore, the answer to our second set of question is as follows:
Q2a. Is femoral neck BMD related to coronary artery calcification? Q2b. In 
addition, is femoral neck bone loss related to coronary artery calcification? Q2c. 
Is there evidence that the presence of coronary calcification increases fracture 
risk?
We found no evidence for an association between FN-BMD and CAC. However, in 
longitudinal analyses, there was a relation between FN-BMD loss and CAC which 
was evident only in women with the lowest levels of 17β-estradiol, suggesting its 
role as a mediator. In addition, our results do not support an association between 
coronary calcification and fracture risk.
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P, BMD and fracture risk in the Rotterdam Study and MrOS: rationale for 
assessing bone outcomes
Albright and colleagues were among the first researchers to describe the 
phenotype of a child affected with walking difficulty, bone deformities, and 
multiple non-healing fractures, despite high doses of vitamin D, as the underlying 
rickets were induced by X-linked hypophosphatemia (56). The literature has been 
productive (57-59) since then in the description of similar cases and their clinical, 
biochemical and genetic profiles not only in hypophosphatemic disorders but also 
in their hyperphosphatemic counterpart (60, 61).
However, aside from Mendelian disorders, the association of P with bone outcomes 
has been remarkably absent in the literature, perhaps reflecting a tacit assumption 
that P levels not lying in the extremes of its distribution are not related to bone 
disorders.
Recently, the diagnosis of mineral and bone disorder in chronic kidney disease 
(CKD-MBD, previously renal osteodystrophy) has emerged as an exception 
to this gap in knowledge (62). CKD-MBD is composed of a dual condition of 
high P load (overt hyperphosphatemia in advanced stage) (63) and a severely 
increased fracture risk in comparison with subjects with normal kidney function. 
Depending on the CKD stage, fracture risk can increase fourfold, sixfold and 
even tenfold  (64). Several authors have provided evidence for an important role 
of P in increasing fracture risk in CKD patients (65, 66).
In contrast to studying the role of P in CKD, whether P is related to BMD and 
fracture risk in the general population has been largely unexplored. This is despite 
a) the discovery of FGF23 in the year 2000 (67), b) the identification of osteocytes 
as the main site for FGF23 synthesis in the year 2003 (68, 69), and c) the overlooked 
concept that osteocytes compose 95% of bone cells (69).
More recently, FGF23 and α-klotho proteins have been considered the most 
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important axis to control serum P (or P load), even more so than PTH (70, 71).
In Chapter 4 (72), we present the results from a joint analysis from the Rotterdam 
Study I and II and the MrOS USA cohorts, where we found the following results:
 
 a) P was not related to FN-BMD; it was negatively related to LS-BMD in 
men from the Rotterdam Study and in combined analysis.
 b) P was positively associated with all-fracture risk with a stronger 
estimate in men but no evidence of sex-interaction. Each 1 mg/dL increase in 
P increased fracture risk in 52% in men [(HR: 1.52 (1.34-1.74)] and in 32% in 
women [HR: 1.32 (1.04-1.67)].
 c) Higher P levels in men increased predominantly vertebral and wrist 
fracture risk and to a lesser extent hip and rib fracture risk; in women P increased 
humerus fracture risk as the only skeletal fracture site (Table 1).
 d) In men only, normal serum P was consistently related to increased 
fracture risk.
 e) Our joint data suggest a P threshold of 3.3 mg/dL (1.1 mmol/L) in 
men and 3.7 mg/dL (1.2 mmol/L) in women above which fracture risk starts to 
increase.
 f) In men, P was associated with increased fracture risk across the entire 
range of kidney function and consistently also in CKD. In women, this relation 
was significant only in the group with normal kidney function (Table 2).
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Table 1. Phosphate and fracture risk according to skeletal site and sex: pooled 
results from the Rotterdam Study and MrOS cohorts [source (72)]
Men Women
Fracture site fx/total n HR (95% CI) p fx/total n HR (95% CI) p
Wrist 104/7439 1.90 (1.20-2.99) 0.006 105/2497 1.18 (0.74-1.89) 0.477
Vertebral 219/7447 1.73 (1.27-2.37) 0.001 116/2543 1.16 (0.73-1.83) 0.533
Rib 246/7441 1.40 (1.05-1.88) 0.022 21/2556 1.09 (0.37-3.23) 0.873
Hip 265/7443 1.36 (1.02-1.82) 0.037 77/2548 1.12 (0.65-1.93) 0.687
Humerus 83/6568 1.61 (0.99-2.62) 0.055 42/2539 2.16 (1.06-4.40) 0.035
Table 1 highlights the differences for P in fracture risk according to sex and fracture 
site. In men, P increased fracture risk predominantly in trabecular-enriched bones, 
such as vertebra and wrist, where a rapid gradient of increasing trabecular bone 
content along the radius axis (e.g from <5% to >80%) has been shown (73, 74).
Apart from differences in power for the analysis across sexes, 
women displayed increased fractures with increasing P but this 
association was of weaker magnitude than in men and it reached
statistical significance only at the humeral bone (75-77).
Table 2. Phosphate and fracture risk according to eGFR and sex: pooled results 
from the Rotterdam Study and MrOS cohorts [source (72)]
Men Women
eGFR fx/total n  HR (95% CI) p fx/total n HR (95% CI) p
>58 mL/min 1046/6435 1.46 (1.26-1.69) <0.001 349/2107 1.37 (1.06-1.77) 0.016
<58 mL/min 167/946 1.93 (1.42-2.62) <0.001 46/235 1.10 (0.55-2.18) 0.790
Table 2 highlights the differences for P in fracture risk according to sex and 
CKD status. This relation in men was not only consistent also in CKD, but even 
stronger (I2 across eGFR strata~60%) (78). In women, P was related to increased 
fracture risk only in those without CKD, although the small number of fractures 
prevents the drawing of definite conclusions.
From a physiologic perspective, a clear distinction must be made between the 
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association of P and fracture risk in participants without CKD (general setting) 
and P and fracture risk in patients who fulfill the diagnosis of CKD (CKD setting).
In the general setting, the findings in men of P being related to increased 
fracture risk at predominantly trabecular-enriched bones, and their consistency 
after constraining the analyses to normal P, allow the formulation of “osteocyte 
deficiency” as a potential underlying mechanism. This concept was coined by 
JESUS Delgado-Calle et al. (79), who showed that patients with hip fracture had a 
marked decrease (~95%) in FGF23 expression in trabecular osteocytes in relation 
to decreased bone mass and/or increased osteocyte apoptosis.
Similarly, a condition of decreased “osteocyte density” (80) has been postulated 
where impaired fatigue microdamage detection and reduced canalicular flow can 
increase bone fragility independently of BMD.
In the CKD setting, different mechanisms can be postulated. The distinct eGFR 
threshold applied for CKD classification in our manuscript (58 mL/min instead 
of 60 mL/min) stems from evidence that at an eGFR of 58 mL/min several 
compensatory mechanisms in CKD progression are triggered, especially FGF23 
release (81). As a result, hyperphosphatemia is a late phenomenon in CKD; 
however, there are adverse consequences of this “secondary hyperphosphatonism”, 
including impaired bone mineralization and decreased 1,25 dihydroxyvitamin D 
synthesis (82,83).
Therefore, for the same P level across eGFR categories, the clinical context is 
different as a “normal P” within a CKD diagnosis implies that several complex 
compensatory networks with adverse consequences in bone have already been 
recruited.
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	 	P and fractures: a note of caution on the interpretation of results after 
adjustment for FGF23 serum levels
The almost null modification after adjusting our findings for FGF23 levels do 
not imply an absent role of FGF23 in the association between P and fracture 
occurrence. It has been shown that there is an important discordance between 
FGF23 expression and serum levels: even a decrease in FGF23 expression in bone 
cells by almost half does not translate into changes of serum FGF23 levels (79, 
84). This discordance has to be taken into account wherever serum FGF23 levels 
adjustments are applied to avoid oversimplification and incorrect interpretations.
According to our data, we can answer the third question as follows:
Q3a. Is serum P related to BMD in the general population? Are there differences 
according to skeletal site? Q3b. Is P related to fracture risk –even within normal 
ranges? If so, can a particular pattern in fracture-site be identified? Q3c. Are 
there sex differences for any of these outcomes?
P was negatively related to LS-BMD in men. P was related to increased fracture 
risk, with a potential sex dimorphism in the fracture site, since there appeared 
to be a predominant effect in trabecular-enriched sites in men based on our 
data from Rotterdam and MrOS. Increasing P within the normal range was 
significantly related to fracture risk in men only, in whom a consistent relation 
was also shown in CKD. Replication of our findings regarding sex-differences in 
these relations is needed as well as more research into underlying mechanisms.
Phosphate and mortality: beyond CVD mortality
In Chapter 5 (85), we analyzed prospectively the relation of P with all-cause and 
cause-specific mortality in the Rotterdam Study I and II cohorts spanning more 
than 10 years of follow-up. In line with previous data (86, 87), we found that: a) 
P was associated with increased all-cause mortality in men [46% per 1 mg/dL 
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increased P (HR: 1.46 (1.29-1.69))] and b) despite having 15% higher P levels than 
men, P did not influence mortality in women.
The assessment of cause-specificity replicated previous evidence (87) of P as a 
risk factor for increased CVD mortality in men [66% per 1 mg/dL increased P 
(HR: 1.66 (1.29-2.14))].  Intriguingly, P was also found to be related to increased 
COPD mortality in men [344% per 1 mg/dL increased P (HR: 4.44 (2.08-9.49))].
The findings of P as a factor increasing all-cause and CVD mortality have been 
published previously (86, 88) and confirmed in meta-analysis (87). Furthermore, 
the sex difference has also been highlighted previously, especially by Onufrak 
and his group (86, 89).
Yet, we were able to identify for the first time in humans an association between P 
and lung disease mortality, which proved to be completely driven by COPD and, 
despite a smaller sample size than other causes of mortality within our data sets, 
showed a larger magnitude than CVD mortality (p heterogeneity=0.016). This finding 
was not attenuated by multiple adjustments and was consistently observed after 
constraining the analyses to participants with normal serum P levels.
As current smoking was related to increased P levels, in addition to smoking 
adjustments, we stratified analyses and found that each 1 mg/dL increase in P was 
related to an increase of 459% in COPD mortality in former smokers [HR: 5.59 
(2.21-14.1)]. Although the analysis was constrained to a smaller sample size, we 
found no significant relation in current smokers [HR: 2.64 (0.38-18.3)].
	 	Potential underlying mechanisms
For COPD mortality:
Although the relation between P and COPD mortality is novel in human 
epidemiology, a similar observation has been described in basic research since 
the discovery of the klotho gene. In fact, it has been systematically documented 
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that lung emphysema is a key component of the premature ageing phenotype 
of rodents with genetically-induced severe hyperphosphatemia (90-94). Normal 
klotho expression is required for postnatal alveolar integrity (93). Both fgf23-/- 
and klotho-/- mice (phenocopies) develop postnatal emphysema that remarkably, 
can be rescued with restoration of normophosphatemia, either through genetic 
(NaPi2a-/-) or dietary interventions (90). Importantly, sex-differences in rodent 
models have been described in the phenotype rescue: while normophosphatemia 
rescues the aging phenotype in male mice, it has no effect on female mice (91).
In addition, animal models and cell culture experiments have shown that a high P 
medium [3-5 mM] directly induces oxidative stress and apoptosis in human lung 
epithelial cells; of note αKlotho protects against this damage (95, 96). In physi 
logical conditions, high phosphorus intake decreases expression of klotho (91), 
which is required for alveolar integrity as its absence induces lung emphysema 
(93). KLOTHO expression has been recently described in humans tissue (97), 
especifically in lung tissue (98) and found to be decreased (99) in COPD patients 
versus smokers (p<0.05) and versus non-smokers (p<0.001).
For CVD mortality:
There is evidence from basic (48), epidemiologic (18) and clinical research (100) 
that high P can induce arterial calcification (AC), especially in the media. Such an 
association has been extensively shown in CKD (101) but scarcely investigated in 
the general population (102). High phosphorus intake acutely leads to calciprotein 
particles formation (103), one of the first steps in AC. In addition, compensatory 
FGF23 rise in CKD induces myocardial hypertrophy (104). Nevertheless, whether 
an increased but within normal range P can induce AC has been unclear, but 
recent research from our group has found evidence for normal P to be causally 
related to AC in the general population (Chapter 6; unpublished data).
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With these cumulative results, we can answer the following lines to the fourth 
question:
Q4a. Is there evidence that higher P levels - but within normal range – are 
associated with all-cause mortality in data from Rotterdam? If so, what specific 
diseases are involved, or is it driven by cardiovascular mortality? If not, is there 
evidence of P influencing other causes of mortality, as suggested from findings in 
animal studies? Q4b. Are there sex differences in our results?
We found evidence that P, even at normal levels, was related to decreased survival 
in men. As previously shown, P was associated with increased CVD mortality, 
but, in addition, our data showed a consistent relation of P with COPD mortality 
- not seemingly explained by confounders. This observation is novel for human 
studies but not for animal models with severe hyperphosphatemia. Once more, 
our results displayed marked sex differences, with no associations seen in women 
despite higher P.
Increasing but normal P and coronary artery calcification (CAC): evidence for 
potential causality
Patients with severe hyperphosphatemia develop a premature ageing phenotype 
(105) with AC as one of the key components of the clinical cluster, leading to 
increased risk for CVD events and death (20). Whether normal P is causally related 
to AC has not been clarified. If confirmed, it would become not only a pathologic 
mechanism underlying the relation between higher P within the normal range and 
CVD mortality; however, it would also mean that an increasing P even within 
normal range should be considered a CVD risk factor, as postulated 10 years ago 
(106).
Chapter 6 is composed of two sections. In the first, we describe a phenotypic 
association between P and CAC, an AC process that occurs mainly in the intima 
and is specific of atherosclerosis (20) and predictive of coronary heart disease 
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(107). Hyperphosphatemia has been related to CAC, but its association with 
normal P has yet to be fully elucidated (102). We hereby show this association in 
subjects even without hyperphosphatemia, CKD and prevalent CVD.
In the second section, we apply Mendelian Randomization (MR) (108), an approach 
to improve causal inference. Our results indeed supported a causal relation 
between P and CAC in the Rotterdam Study. Causality was also supported for 
subjects without hyperphosphatemia, CKD, and prevalent CVD. As sensitivity 
analyses (109), we found that one SNP lying close to the ALPL locus (110, 111) 
exerts a major influence on our results – supporting an important role for alkaline 
phosphatase (ALP) and P release from pyrophosphate (PPi) on CAC (112).
Two main pathways of P-induced calcification have been described in the coronary 
bed: 1) a passive deposition of calcium and P, regulated by ALP/PPi/P axis; and 
2) an active process of osteoblastic differentiation of vascular pericytes and 
calcifying cells that are able to synthesize matrix vesicles (MV), which start the 
mineralization process. Current evidence has shown the presence of ALP/PPi/P 
in MV surfaces of atherosclerotic plaques (40), closely linking both mechanisms 
of calcification in CAC and providing a biological explanation for our results.
Remarkably, MR sex-stratified analyses showed a more consistent association in 
men. Previous literature (85-87, 89) and a study from this thesis [Chapter 5] have 
systematically reported stronger (or unique) results of P in men for all-cause and 
CVD mortality and atherosclerosis. These results could be seen as counterintuitive 
because postmenopausal women have higher P and lack a protective effect of high 
17β-estradiol levels on AC as shown in premenopausal women.
With these results, we can answer the fifth question in the following terms:
Q5a. Are P serum levels causally related to coronary calcification? If so, are 
the results driven by hyperphosphatemia, CKD or prevalent CVD? Q5b. Can 
we find evidence at the MR level of a sex-difference, strongly suggested by 
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epidemiological papers on the association between P & coronary calcification, 
CVD morbidity and CVD mortality?
Our results from MR analysis support a causal role of serum P levels in coronary 
artery calcification in the general population, meaning that our findings were 
not driven by hyperphosphatemia, CKD or prevalent CVD. The sex-stratified 
MR analysis strongly suggests a more consistent causal association in men than 
in women, which is in line with the systematic sex-difference in the association 
between P and CVD outcomes described in the literature.
	 	Sex-difference in the association between P and CVD outcomes
We can only speculate whether the association between ionized calcium and 
P plays a role in the sex differences for P and CVD outcomes as we [Table 1, 
Chapter 6] and others (113-116) have found an inverse relation between them in 
women but not in men; moreover, an inverse reciprocal  relation seems necessary 
to keep a constant calcium*phosphate product (Ca*P product) in serum (117). 
Animal studies carried out in rodent models have shown an inverse relation 
between Ca and P across a wide range of values [Figure 1] (117). Human studies 
have also shown an inverse relation between ionized Ca and P and, importantly, 
the available data support a sex dimorphism in this association, as several authors 
(113-116) have found that ionized calcium decreases with increasing P in women, 
but not in men (116).
It must be added that recent research has reaffirmed the importance of the Ca*P 
product, as it tightly correlates with calciprotein particle formation - a key step 
in AC pathogenesis (103, 118).  Several authors, such as Parfitt et al. & Felsenfeld 
et al., have shown that hyperphosphatemic states induce skeletal resistance to 
PTH, with decreased calcium release from bone (117). The status of decreased 
calcium release in the presence of hyperphosphatemia has been proposed as an 
important mechanism to achieve the constancy of Ca*P product. Whether there is 
sex dimorphism in this mechanism warrants further research.
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Figure 1. Reciprocal relationship between serum calcium and phosphorus
in animal studies.
 
The figure shows the inverse relation between serum calcium and phosphorus after PTH infusion 
found in animal studies on rat models. (Reproduced with permission from authors and with 
authorization from the Journal of the American Society of Nephrology. Source (117)).
	 	 Phosphate as the factor underlying the calcification paradox: the 
importance of the bone compartment
More recent studies applying quantitative computed tomography (QCT) have 
compared the independent contributions of trabecular versus cortical bone 
compartments in relation to arterial calcification (AC) and have shown what seems 
to be an exclusive association of trabecular bone compartment (volume, trabeculae 
number and separation), especially in older men (14, 119-121). Indeed, several 
authors have described elderly men as the only subgroup displaying a consistent 
inverse relation between trabecular bone and AC after adjustments (119, 120) and 
suggesting a role for trabecular bone deterioration in arterial calcification. 
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No association between QCT-assessed cortical bone compartments and arterial 
calcification has been identified in either sex (119, 120).
Findings from Chapters 4 and Chapter 6 from this thesis support the concept 
of a role of trabecular bone in arterial calcification pathogenesis. First, the 
demonstration of a significant inverse association between LS-BMD and P in men 
only - without such an association with FN-BMD (72) suggests a predominant 
role of trabecular osteocytes (over cortical osteocytes) as a source of FGF23 and 
subsequent regulators of P levels in men [Chapter 4].
Second, the demonstration of a potential causal role of P in coronary calcification 
in men and women (more consistent in men) through Mendelian Randomization 
and in the absence of CKD and hyperphosphatemia [Chapter 6].
There is supportive evidence from basic and clinical research that strengthens 
this postulate, especially a preferential location of FGF23-secreting osteocytes 
in trabecular bone, consistently described in studies including FGF23 expression 
data and performed in animal models (122, 123), in both diseased subjects (79, 
124-126) and in healthy controls (125).
This preliminary evidence leads to a postulation of P as the main link between 
(trabecular) bone and AC. Importantly, experts in the research field, such 
as Demer & Tintut (127), have suggested three pathological mechanisms as 
pathways to explain the association between arterial calcification and osteoporosis 
–previously known as the “calcification paradox” and termed by the authors as the 
“bone-vascular axis”: 1) arterial calcification promoting bone loss; 2) bone loss 
promoting arterial calcification; and 3) a common underlying mechanism, such 
as low estradiol (previously commented on but not further elaborated here as it 
discards a primary role for both bone and blood vessels).
The second pathological mechanism has more validity than the other two as bone 
resorption can release several factors active in the vascular system. The authors 
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postulate that P could act as one such mediating agent. Of course, other bone-
derived substances could also exert a role, but current evidence supports P released 
from bone as a factor able to exert arterial calcification, based on experimental 
(48), epidemiological [(102) and Chapter 6] and clinical (100) data. As additional
evidence for P as a good candidate to underlie the bone-vascular axis, other 
potential bone-derived candidates exert rather anti-calcifying properties in the 
vascular system (e.g., FGF23, osteopontin) (128-130).
In summary, the main results from Part I of this thesis provide evidence for an 
association between low BMD and P in COPD mortality. In addition, P is related 
to fracture risk and CVD mortality and causally linked to coronary calcification, 
even at normal levels. Most results were characterized by a marked sex difference, 
with more prominent associations seen in men and attenuated or null results in 
women. We aim to explore further this finding in the next section of this thesis.
Part II. Sex differences in calcium and phosphate levels
 
Clinical research from decades ago has systematically reported a sex dimorphism 
in the epidemiology of CVD (131). In addition, differences in serum levels of 
minerals across men and women, especially for calcium (Ca) and P, have been 
previously reported (132, 133). For example, Haglin et al. (132) found a decreased 
P level in men of 8% in comparison to women (50 years of age in average).
More recently, the literature has described a relation of these minerals with hard 
outcomes – including mortality – characterized by a marked sex difference driven 
by stronger or unique findings in men. Cohorts and post-hoc analyses of the RCTs 
such as NHANES, Framingham, the Tromsø Study and CARE have reported 
associations between Ca & P with CVD events in men only. This sex-difference 
has been found to be more consistent for P than for Ca (87, 106, 134).
In a similar way, several studies in this thesis reported important sex-differences 
in the relations between BMD & P with several outcomes and traits. Concerning 
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outcomes, the following can be mentioned: BMD & P in all-cause mortality 
[Chapters 2 and 5], P in CVD mortality [Chapter 5], BMD & P in COPD mortality 
[Chapter 5], P in fracture risk [Chapter 4] and P in coronary artery calcification 
also in the Mendelian Randomization analysis [Chapter 6]. Concerning traits, the 
association between P and LS-BMD in the Rotterdam Study showed a consistent 
sex difference [Chapter 4].
Total calcium & phosphate levels in the Rotterdam cohorts: potential role for 
25OHD and gonadal steroids in the sex differences
In Chapter 7, we investigated differences in Ca and P levels between sexes in the 
Rotterdam Study. The results from 9.253 participants showed that Ca levels were 
1% higher and P levels were 6% higher in women when compared to men (Ca: 
9.76 mg/dL vs 9.64 mg/dL; P: 3.16 mg/dL vs 3.63 mg/dL) and, as a consequence, 
the Ca*P product is also higher in women than men. These results correspond well 
with previous observations (132).
Several studies have shown that Ca and P levels and albumin differences between 
sexes oscillate according to age and menopausal status (135). Therefore, we 
investigated whether sex differences in Ca and P were already present at younger 
ages in the patients assessed routinely at Erasmus MC spanning a wider range of 
ages than the Rotterdam Study (older than 45 years only).
In Chapter 8, we analyzed laboratory data from the Hospital Information System 
of Erasmus MC, Rotterdam, on Ca, P and albumin levels from patients of 1-17 
years, 18-44 years and > 45 years. Three such age-stratified “cohorts” were 
selected, differing by year of sampling (2005, 2010, and 2014) and including a 
total of 15.215 patients. We observed that serum levels were consistently higher 
for both Ca (2%) and P (7%) in women than men in the age category above 45 
years, while  no differences could be observed at younger ages. The higher Ca and 
P levels in women than in men of this age group in the large Erasmus MC patient 
series were also observed in the Rotterdam Study in a similar magnitude for Ca 
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levels, while P levels were 15% higher in women than in men.
We went on to test for a potential role of serum levels of 25-hydroxyvitamin D 
(25OHD) and gonadal steroids in this dimorphism. These differences were not 
explained by 25 OHD nor by 1,25(OH)2D3, alkaline phosphatase, and albumin 
levels. Nor did we see consistent effects of adjustments for gonadal steroids in Ca 
levels when compared across subgroups diverging in fasting status prior to blood 
drawing.
Finally, we noticed that the adjustment for testosterone levels attenuated the 
sex difference by 38%. In contrast to expectations (136, 137), the adjustment 
for 17β-estradiol levels has no influence in the sex difference. Previously, the 
MrOS US study found a role for testosterone as a partial explanation of the sex 
differences in P levels (136). This influence of testosterone could reflect its relation 
to aromatization into 17β-estradiol in adipose tissue (138) and the phosphaturic 
actions of estradiol through direct downregulation of renal NaPi-IIa transporters 
(139), and through enhanced FGF23 synthesis (137).
We therefore answer the sixth question as follows:
Q6a. Do the differences in calcium and P span several age categories? Are they 
explained by gonadal steroids? Q6b. Can we find evidence in our data of another 
potential mechanism underlying the sex differences in calcium and P levels?
Our data provide evidence for a sex difference in Ca and P levels above 45 years. 
Our results confirm the 1-2% higher levels of Ca and the 7-15% higher levels of 
P in women compared to men, and showed that this difference is only apparent 
above 45 years of age and not at younger ages. 17β-estradiol serum levels do not 
seem to influence this difference, while testosterone partially explains the higher 
P levels in women. Our results do not highlight additional mechanisms to explain 
the sex difference in serum calcium and P levels.
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Part III. Genetic studies in relation to bone and phosphate
	 	Exploring unusual genetic causes for osteoporosis and fractures: 
a Mendelian approach
The integration of the inheritance pattern proposed by Fr. Gregor Mendel from 
his experiments with peas (140) with the observation of continuous variation 
induced the postulation of the infinitesimal model, published in 1918 (141) and 
later referred to as “the polygenic model”. Most complex traits were initially 
proposed to follow such model as underlying genetic architecture. This meant 
that a substantial fraction of their variance is explained by the joint effect of a 
large number of single nucleotide polymorphisms (SNPs) exerting each one a 
minuscule effect. More recently, it has become evident that most traits are causally 
determined by a few thousand loci (142) – yet with large heterogeneity, according 
to trait category (143).
BMD is no exception: the largest genome-wide association study (GWAS) to date 
identified ~600 independent SNPs that account for 20% of its population variance 
(144). However, clinical data have shown that not all BMD variation is attributable 
to SNPs, as rare mutations in several genes can exert a large influence on BMD, 
usually detrimental and seen in families with pedigrees of segregating disease. 
Examples of these “major genes” are COL1A1 [type 1 collagen synthesis], WNT16 
& LRP5 [WNT signaling pathway] and TNFRSF11, TNFRSF11A & TNSF11B 
[RANK/RANKL/OPG pathway] (145).
We hereby present a cluster of exceptional cases of severe osteoporosis identified 
from general practice; their clinical evolution highlights the fact that, although not 
frequent, Mendelian disorders of BMD can exert a large impact on bone health.
PLS3: the first identified cause for X-linked osteoporosis
Chapter 9 (146) is composed of the presentation of 5 families with early-
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onset osteoporosis and high fracture incidence in men but milder or no clinical 
presentation in women – highly suggestive of an X-linked pattern of inheritance. 
After testing for common mutations of osteogenesis imperfecta proved negative 
(COL1A1 and COL1A2), a large collaborative effort among several bone groups 
identified the gene, mapped it to the X-chromosome, and demonstrated causality.
Though the setting of X-linked osteoporosis has been cited previously, to the best 
of our knowledge, this is the first study that confirms this inheritance pattern in 
osteoporosis.
The clinical picture can be summarized as follows. Most men from the 5 (outbred) 
families were affected by fractures since early childhood, and the pattern of 
severe bone fragility continued throughout life to the point of gathering multiple 
fractures (even up to 20) by early adulthood. No clear clinical signs of osteogenesis 
imperfecta were noticed, with the exception of joint laxity and short stature in 
isolated cases. Low BMD was present since early age, with Z-scores substantially 
below -2.0 SD; bisphosphonates proved to be a useful therapy in most of them in 
terms of BMD.
In women, the clinical picture was heterogeneous, ranging from no bone-related 
pathology to several fractures, but at later presentation and in fewer numbers 
than men. BMD values ranged in most cases from normal to the osteopenic 
range; however, osteoporosis was uncommon. Similar to men, no clear signs of 
osteogenesis imperfecta were noticed with the exception of occasional joint laxity
	 	Summary of the PLS3 genetic findings
X-linked whole exome sequencing revealed a frameshift mutation in exon 3 of 
PLS3 [which encodes for plastin] in three male patients from family 1. PLS3 maps 
to Xq23. Sanger sequencing of PLS3 exons confirmed this finding, identified the 
same mutation in three additional affected men, and identified 4 novel pathogenic 
variants in 95 men from families 2 to 5, including non-sense, frameshift, and 
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splice-site mutations.
In addition, a previously described PLS3 variant (rs140121121; MAF 1.3%) was 
identified in five affected men. This variant was de novo genotyped in the RS 
cohorts to study the influence of more common genetic variation in the PLS3 
gene on bone phenotypes in the normal population, in contrast to the few families 
with very severe bone phenotype due to the rare mutations. It was shown that 
heterozygous women who were carriers of the risk allele (A) displayed a higher 
odds ratio for fracture than non-carriers [OR 1.95 (1.39-2.74)]. A lower LS-BMD 
was also observed in such heterozygous women. Perhaps constrained in power 
due to a small sample size, no consistent bone effects were shown in hemizygous 
men.
Linkage analysis was carried out to test for cosegregation of the discovered 
mutations in PLS3 and the phenotypes at a genome-wide scale. Only families 1 
and 2 contributed to the calculation of the lod score, which was estimated to be 
3.40. Such linkage findings are consistent with a high probability (p<4.9x10-5) that 
the identified variants are causative factors for the bone phenotype of low BMD 
and increased fracture risk (147, 148).
	 	Confirmatory findings at the functional level
Through pls3 knockdown in zebrafish, it could be demonstrated that plastin plays 
a key role in skeletal development, as affected larvae showed severe craniofacial 
dysplasia and malformations in body axis and tail. All skeletal defects could be 
rescued by dose-dependent injections of human PLS3 mRNA, proving causality 
of this gene in the bone phenotype.
More recent work, including bone histomorphometry on patients with PLS3 
mutations, has revealed a low bone turnover pattern and prominent focal areas 
of osteoid accumulation, suggesting a role of PLS3 in local bone mineralization 
(126). In addition, a substantial decrease in FGF23 expression has been noticed, 
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and, as FGF23 expression was found only in trabecular areas in patients with PLS3 
mutations, cannot be explained by cortical osteocyte apoptosis, which has been 
shown to be increased in patients harboring PLS3 mutations (126). The decrease 
in FGF23 expression can not be explained by increases in DMP1 either, which is 
a regulator of the mineralization process that has been shown to decrease FGF23 
production by bone cells through FGF receptor signaling (149).
LRP5 mutations and osteoporosis diagnosed at pregnancy
In Chapter 10 (150), we describe the case of a young woman with very low 
BMD who was suspected to have pregnancy and lactation associated osteoporosis 
(PLO) before genetic analysis was performed.
The clinical picture was characterized by severe back pain during her late 
pregnancy and she was subsequently found to have very low BMD on a DXA 
scan [Z score L2L4: -5.6 SD; FN: -3.9 SD] and three vertebral fractures. She had 
unspecified congenital unilateral blindness and a mild form of bilateral exudative 
vitreoretinopathy. No secondary causes of low BMD could be identified. Her 
mother had low BMD and her brother had early-onset fractures. Her father was 
deceased.
	 	Pregnancy and lactation osteoporosis
Pregnancy and lactation are associated with a decrease in (mainly trabecular) 
bone content estimated in 5-7% (151); both osteoclast-mediated resorption and 
osteocytic osteolysis have been described as pathogenic mechanisms (152). BMD 
loss during lactation can reach 1-3% per month, but longitudinal studies have 
shown (almost) full recovery in BMD. Consistently, parity and lactation are not 
risk factors for incidental fractures at the population-based level (153). Although 
long bones do not recover fully, there is a compensatory increase in their volume 
and in their cross-sectional diameters (154). As a consequence, the strength of 
long bones is not permanently decreased after each reproductive cycle (154). 
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In rare cases, there is a more severe decrease in BMD with microarchitectural 
changes, which cause an increased incidence of fractures, preferably at the spine.
Fractures are uncommon in normal pregnancy (151). However, when they do 
occur, a complete clinical examination should be undertaken, as a condition of 
low BMD prior to pregnancy is highly probable. Indeed, this case shows that a 
preexisting low BMD condition due to a genetic disease might be an important risk 
factor for the skeleton to decrease the tolerance to the physiologic bone content 
loss induced by pregnancy and, especially, by lactation.
	 	Summary of genetic findings
Firstly, COL1A1 and COL1A2 analyses were not compatible with a diagnosis 
of osteogenesis imperfecta. Secondly, considering the joint involvement of 
bone and ophthalmic tissues, DNA analysis of low density lipoprotein receptor-
related protein 5 (LRP5) was carried out and showed compound heterozygosity 
for c.1519G>A (p.Gly507Ser) and c.3758G>T (p.Cys1253Phe) mutations, each 
predicted to affect conserved aminoacid residues. Her mother and brother were 
subsequently shown to be carriers of the LRP5 c.3758G>T mutation.
In 1996, Gong and coauthors identified LRP5 as the causative gene of osteoporosis-
pseudoglioma syndrome (OPPG; OMIM 259770), an autosomal recessive 
disorder characterized by severely low BMD and congenital blindness (155). This 
dual affection is due to the key roles of LRP5 on both WNT and Norrin signaling; 
the latter is an atypical WNT ligand crucial in retina vascularization (156, 157). 
Obligate carriers can have low BMD, showing that bone effects of LRP5 can be
dominant.
In addition to OPPG, LRP5 mutations can induce familial exudative 
vitreoretinopathy (FEVR), a heterogeneous disorder with milder bone involvement 
than OPPG. Both mutations have been found to segregate in families with OPGG 
or with FEVR (158,159). To the best of our knowledge, functional analyses 
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have not been carried out; nevertheless, novel machine learning techniques have 
predicted the pathogenicity of p.Cys1253Phe (160), a mutation predictive to 
rupture disulfide bonds. Qin et al postulated that there is a continuous clinical 
spectrum spanning the diagnoses of OPPG and FEVR (161). Indeed, this seems to 
be the case for our patient and we found the spectrum of OPPG/FEVR underlying 
the diagnosis of PLO.
We can answer the seventh question as follows:
Q7a. What are the genetic variants underlying the phenotype of these patients? 
Are they lying in BMD annotated genes? If not, what additional evidence can be 
obtained to support causality? Q7b. What lessons useful for the common clinical 
practice can be learned from these cases?
Next to clear polygenicity of BMD genetic architecture, several Mendelian 
disorders can exert a strong detrimental influence in bone strength. A pathogenic 
variants in PLS3 at the X chromosome has been found for the first time underlying 
an X-linked pattern of inheritance of severe osteoporosis with fractures; for the 
pregnant woman who presented with osteoporosis, heterozygous compound LRP5 
variants were found to underlie a diagnosis of PLO.
Several lessons to highlight from these two genetic causes of osteoporosis are: 
a) men are often understudied and underdiagnosed for BMD-related pathology, 
but we hereby showed that a variant in an X-linked gene that had never been 
associated with osteoporosis before causes a severe bone phenotype in men; b) a 
solely low BMD diagnosed in pregnancy or lactation without fractures is not in 
itself mandatory of bone-sparing treatment, as in most cases a (almost) complete 
BMD recovery is achieved following the transient loss; and c) fracture occurrence 
is uncommon during pregnancy or lactation. Its occurrence, together with a not-
recovering low BMD, should necessitate a complete clinical workup to exclude 
secondary factors and the consideration of an underlying genetic bone disease. 
Moreover, the risks of rapid bone loss during breastfeeding in patients with 
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osteoporosis and/or fractures should be discussed with the patient. In cases of a 
preexisting low BMD before pregnancy, breastfeeding is discouraged or advised 
to be limited to short duration.
Genome-wide Association Study of human serum phosphate levels: a large 
Biobanks approach 
Lately, the availability of large-scale biobank resources has made it possible for 
an exponential increase in sample sizes to analyze phenotypes and genotypes that 
have been measured in such biobanks. This has also led to GWAS of ever increasing 
sample size, and, therefore, to increase the discovery of more causative genetic 
variants and to explain a larger fraction of the genetic variance of the available 
phenotypes. In particular, the UK Biobank (162) contains many phenotypes that 
are relevant to bone research. This section focuses on the genetic architecture 
of serum phosphate levels (P), whose measurements were available in close to 
400.000 subjects.
In Chapter 11, we analyzed GWAS data in relation to serum P levels from 
392.655 participants from the UK Biobank (162). We excluded those with a 
glomerular filtration rate below 39 mL/min, as below this threshold the prevalence 
of hyperphosphatemia is markedly increased (81). The implementation of a mixed 
model regression allowed us to keep related subjects (close to 33% of the total of 
the UK Biobank) and is robust against population stratification. In addition, we 
allowed for the inclusion of the non-infinitesimal model, since most traits seem to 
be explained by a few thousand causative loci and not by the totality of SNPs, as 
implemented in standard mixed models (142). We applied a significance threshold 
of 5x10-9, as previously suggested for large datasets with many phenotypes and 
genetic variants (163).
After applying approximate conditional analyses through GCTA (164) to identify 
independent variants, we were able to find 264 genetic variants for serum P levels, 
explaining 7.62% of its population variance. The genetic variants included 261 
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independent autosomal SNPs, three SNPs in the X-chromosome in men and one 
SNP in the X-chromosome in women (the latter corresponds to one of the locus in 
men). The top hit (rs9469580; 6:33715837) lies in the short arm of chromosome 6, 
in the region flanking the Major Histocompatibility Complex (MHC) (165). This 
common SNP has a minor allele frequency (MAF) of 0.08, a β of 0.195 and a p 
value of 1.6 x10-468. There were 34 primary independent signals in chromosome 6, 
nine of them were flanking the large MHC region (24-36 Mb, hg19). This region 
has been identified as genome-wide significant in previous GWAS (110, 111) but 
has not been identified as the top hit until now.
When restricting the analyses to a subset composed of White-British ancestry 
subjects (n=354.798), determined by UK Biobank as self-reported White British 
ancestry and after applying a Bayesian outlying algorithm based on the first six 
PCs (166), we obtained similar results.
Estimates for P explained variance are ~ 7.62%, according to the formula described 
by Visscher and colleagues (167), and when applying the infinitesimal model 
(the standard approach in classic mixed models) the estimate for P explained 
variance was ~ 5%. There was an important increase in this parameter since the 
first GWAS, that described 1.5% of explained variance in P based on analysis of 
16.264 subjects (110).
Our GWAS could replicate previous findings in the locus near ALPL and FGF23, 
genes known to exert important effects in P. But the vast majority of the novel 
hits were lying not close to annotated genes previously known to be involved in 
controlling P serum levels. Furthermore, our results from a Bayesian statistical 
fine-mapping approach in the three main associated loci confirmed the  role of 
ALPL and FGF23 in P levels but strongly suggested that other genes underlie 
P homeostasis. Remarkably, fine-mapping results within 6p21.31 (the region 
flanking the MHC that showed the strongest association of our GWAS) strongly 
suggested that both IP6K3 and ITPR3 play key roles in determining serum P levels. 
This therefore opens up the description of new biology underlying P homeostasis.
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Our results provide a slight better fit for the non-infinitesimal model, suggesting that 
P genetic architecture in humans is probably defined by a few thousand loci across 
the genome, instead of the classic assumption underlying standard mixed models 
that all variants are causal, each one with a minuscule effect on the trait or disease 
(142, 168, 169). Although there is an important fraction of missing heritability 
to be explained, the identified variants can be used in Mendelian Randomization 
studies to test for causality in the associations between P and disease. Further 
research is warranted to explore the mechanisms determining serum P levels for 
most of the 264 hits we found, especially the inclusion of genomic annotations 
in the fine-mapping approach and the performance of trans-ethnic meta-analysis, 
highly useful to leverage LD patterns in the MHC region (170,171).
Therefore, we answer the last set of questions in the following lines:
Q8a. What are the common genetic determinants of P levels in humans? Q8b. 
Are we able to identify low frequency or rare genetic variants with large effects? 
Q8c. Is there evidence of a noninfinitesimal architecture for P? Q8d. Can we find 
evidence of a sex-dimorphism in the genetic structure for serum P levels?
Through this large-scale GWAS, we identified 264 genetic variants explaining 
7.5% of the genetic variance of serum P levels. We were able to replicate the 
ten previously known hits, and quadrupled the variance explained. We found 
enrichment for low frequency variants, but not for rare variants. As expected, our 
results were suggestive of a better fit for the non-infinitesimal model for P genetic 
architecture. Most identified variants have no evidence of sex-dimorphism.
Future Directions
The studies described in this thesis have shown a role for bone and serum P on 
important outcomes, such as coronary artery calcification and mortality, including 
COPD mortality. Two important strengths of our results are a) they stem from 
population-based cohorts and b) the findings that a decreased BMD and increased 
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P are associated with adverse consequences on health even at a common fluctuation 
range. In summary, our findings were:
	 	a low BMD lying within the category of osteopenia was already found 
to be associated with COPD mortality in men;
	 	an increasing but normal P was related to increased fracture risk, lower 
lumbar spine BMD, CVD mortality and COPD mortality: all of these findings 
were constrained to men. In women, serum P was also positively associated with 
all-fracture risk but with weaker estimate than in men and this relation was not 
significant when restricting analyses to normal P levels.
	 	an increasing P within the normal range was phenotypically related to 
coronary artery calcification in both sexes. However, our data supports causality 
for this association in men but not in women, according to MR analysis.
Simply put, there seems no need of extreme variations on bone and P to exert 
impact on public health – certainly not in men. Based on our findings, we hereby 
summarize what potential remedial measures could be applied from both a 
preventive and a therapeutic perspective.
	 	Low BMD, P and COPD mortality
Considering that 80% of P is stored in bone, that bone-derived FGF23 is critical 
for P homeostasis in health and disease (71) and that osteocytes compose 95% of 
bone cells (172), the findings of:
a)  an association between low BMD and COPD mortality and
b) an association between an increasing (yet normal) P with COPD mortality 
can be theoretically connected. A decrease in BMD [proxy of bone mass in fully 
mineralized bone (173)] implies a decrease in osteocyte number and density and, 
therefore, a decrease in FGF23 synthesis (79, 80) with the subsequent reduction 
in P renal excretion (174-177).
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Two potential measures to mitigate consequences for COPD can be suggested, as 
follows:
	 	1) Measures to prevent a decrease in FGF23 synthesis
First, COPD  patients should be screened for a low BMD condition. Our results 
were suggestive of a dose-effect for BMD decrease and the hazard of dying of 
COPD was found to be particularly high in subjects with baseline osteoporosis. 
Low BMD in general is an undertreated and neglected condition (178); this 
statement is unfortunately also valid in COPD despite its highly prevalent 
osteoporosis associated condition (~40%) (179-181), especially when the 
prevalence of vertebral fractures is taking into account.
The proper assessment of vertebral fractures should be emphasized due to the 
restrictive pattern in ventilatory mechanics and increased mortality that they 
impose in COPD (29,31). In particular, the high prevalence of atraumatic vertebral 
fractures in stable COPD patients (~36%) (180) – especially in men with COPD 
(182), the high risk of incident vertebral fractures during COPD progression 
(183, 184) and the fact that the increase in osteoporosis prevalence during COPD 
progression is due mainly to vertebral fractures and not to BMD decrease (183), 
warrants further research to test for a potential role of trabecular bone quality 
deterioration (manifested clinically as vertebral fractures) in COPD progression.
Some previous meta-analyses and individual studies have found or suggested that 
antiosteoporosis medication may be associated with decreased all-cause mortality 
(185-188). Although Cummings et al (189) did not find a statistical significant 
advantage for anti-osteoporosis treatment on survival overall, the authors 
described a suggestive potential benefit of nitrogen-containing bisphosphonates. 
Consistently, a recent mediation analysis study has shown a benefit in survival 
for nitrogen-containing bisphosphonates and, in addition, this benefit was mostly 
explained by a reduction in bone loss and only partially explained by fracture 
prevention (190).
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A recent study provided evidence of benefit of inhaled bisphosphonates in mice 
models with elastase-induced COPD: the inhaled nitrogen-bisphosphonates 
alendronate and risedronate decreased emphysema through a macrophage-
mediating mechanism (191,192). In addition, alendronate also showed a benefit 
in smoking-induced emphysema. If these findings can be translated to human 
populations awaits further research. Considering some epidemiological evidence 
that nitrogen-containing bisphosphonates may decrease mortality and this new 
line of evidence from animal studies, it will be of interest to investigate whether 
this type of antiosteoporosis medication may offer a survival advantage in COPD 
patients.
	 	2) Measures to decrease P burden
Although not a topic of this thesis, high phosphorus intake correlates to serum P 
levels: more precisely with time-average P levels (193). The European Food and 
Safety Agency (194) called for an evaluation of potential adverse effects of P 
added in food additives. High P intake may cause an acute decrease in KLOTHO 
expression with potential adverse cardiovascular and renal effects (91,103). 
The evaluation of the effects of high P diets is a challenge, as highly-absorbable 
phosphorus from food additives is not commonly stated in food labels.
There is suggestive evidence to link high phosphorus intake with adverse outcomes: 
a) NHANES data showed that phosphorus intake increases all-cause mortality not 
explained by CVD (195); b) a large-scale diet study proved high cured meat intake 
(expected to have high phosphorus) to increase COPD risk in men (196); c) high 
cured meat intake is also associated with worsening of spirometrically-determined 
lung function and in COPD hospital readmissions (197). Whether these are effects 
of high phosphorus content in meat remains to be determined.
High phosphorus intake can in theory impair kidney function (even in healthy 
subjects) through tubular damage and nephron number decrease (103), establishing 
therefore a potential vicious cycle for P retention. Patients with COPD and in-
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progress CKD may be at particular risk and a low P diet and, eventually, P binders, 
should be implemented when indicated [KDIGO (101)].
Another line of future investigation can be to study whether it is useful to add 
BMD to the survival discrimination indexes in COPD. BMD is not part of the 
widely used BODE (body mass index, airflow obstruction, dyspnoea, and exercise 
capacity) and ADO (age, dyspnoea, and airflow obstruction) indexes in COPD 
(198), but several comorbidities were included in the most recently described 
COTE index (COPD specific comorbidity test) (199). The condition of osteoporosis 
was not included but there was a rather low prevalence of osteoporosis [10% 
versus the accepted 35% stem from meta-analysis (179)] and the difference of low 
BMD across survivors and non-survivors was borderline (p=0.07). Because the 
assessment of comorbidities was based on direct questioning, an underestimation 
of low BMD and vertebral fractures cannot be discarded. It calls for further 
investigation to test for a potential role of the inclusion of BMD on survival 
discrimination indexes of COPD patients.
	 	P and coronary artery calcification (CAC)
Our findings from Mendelian Randomization analysis of an increasing yet normal 
serum P as a causal factor in CAC pathogenesis in the general population of 
healthy subjects may have importance especially because an increasing - but still 
normal - P has been associated with the hazard of dying of CV diseases (106), 
especially in men (85).
Severe hyperphosphatemia is a well-known causative factor for arterial 
calcification, as extensively shown in advanced CKD (101) and in Mendelian 
disorders with loss of function mutations in FGF23 and KLOTHO (61,177).
However, in the general context of normophosphatemia, P intake might also be a 
causative factor for arterial calcification as it has been shown that a P (or calcium) 
enriched meal intake is immediately followed by an acute increase in portal P and 
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subsequent nucleation – i.e., an association with calcium to create calciprotein 
particles (CPPs), recently described to be related to arterial calcification 
pathogenesis (103). If our findings from the MR study can be replicated and if more 
prospective studies with varying amounts of P intake would confirm detrimental 
effects of high P intake on health, this could lead to general measures to decrease 
P intake, especially in subjects at higher risk for arterial calcification, such as men, 
smokers and patients with diabetes mellitus.
	 	Genetic variants associated with P
Although we were able to increase the variance explained in serum P levels through 
the identification of 172 new loci and we implemented fine-mapping in the main 
associated loci, a large amount of research lies ahead, especially in the application 
of fine-mapping for the totality of loci and posterior gene prioritization.
Of particular high interest will be the implementation of specialized fine-mapping 
techniques for the MHC region, characterized by recent population-specific high 
selection pressure, high variability, long-range haplotypes and strong LD (200). 
Especially because of the strong LD, the precise identification of the causative 
variants will be a difficult task. The implementation of trans-ethnic meta-analysis 
(to leverage the differences in LD in this region, especially between populations 
from European and Asian ancestries) and subsequent trans-ethnic fine-mapping 
(170) can offer a high probability of identifying the causative variants responsible 
for the strongest signal not only from our GWAS, but also from GWAS performed 
in East Asian ancestry populations (165).
The advance we made, with the largest GWAS ever on phosphate levels so far, in 
explaining more of the variance in P levels also opens up the possibility to apply 
polygenic risk scores in stratifying subjects in those with, e.g., high, medium, and 
low phosphate levels. Together with other risk stratification tools, such genetic 
predisposition information might be useful in disease management but obviously 
needs further exploration.
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Through this thesis, it is our hope to contribute to the acknowledgment of the 
importance of bone health status and serum P levels (201). In particular, we 
hope that our GWAS will be a first step for the improvement and deepening of 
knowledge in P homeostasis by insights in biology and by MR studies on causality 
of epidemiological associations, and for the identification of future therapies, of 
potential benefit for a large fraction of the general population.
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Summary
Recent technological advances have provided a valuable set of tools in Imagenology 
and Pathology, among other disciplines, that have induced an unprecedent burst in 
our knowledge. Bone tissue has been no exception to these advances; in fact, the 
last decades have witnessed an ever-growing knowledge in bone physiology and 
bone pathology fields. 
As a consequence, several concepts have gradually evolved, such as the old 
conceptualization of a) bone as solely a weight bearer and b) fractures as the 
only skeletal adverse effect when bone tissue is compromised. More recently, 
the notion of the intriguing evolution of bone from calcium-only aragonite to 
calcium-and-phosphate hydroxyapatite, has highlighted the tight association 
between bone tissue and calcium (Ca) but, in particular, between bone tissue and 
serum phosphate levels (P) – although this relationship is still not widely known, 
or acknowledged. 
Precisely, the first part of this thesis emphasizes on the adverse effects associated 
with both low bone mineral density (low BMD, not necessarily reaching the 
osteoporosis threshold) and increasing P levels. Most importantly, we found 
evidence of a detrimental impact on health beyond fractures. Our data, derived 
mainly from the Rotterdam Study cohorts but also from MrOS USA, made it 
possible to conclude that several other outcomes are importantly impaired either 
when bone density decreases or when P levels increase. Some of these associations 
have been described previously, but some are hereby described in humans for the 
first time. 
Chapter I provides the introductory section of this thesis book. We mention the 
concept that bone does not solely provides support and locomotion but, instead, 
we emphasize on the emerging incorporation of bone tissue within several 
physiologic axes that play an important role in keeping homeostasis. In particular, 
the discovery of bone cells as the main source of FGF23, currently considered the 
key regulator of P levels, has established the “bone-kidney axis”, highly relevant 
in both health and in diseased conditions. 
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We provide a brief summary of the main findings of the previous research 
performed between low BMD and all-cause mortality, which has been the most 
relevant outcome for bone beyond fracture incidence. Despite the fact that several 
studies found an association between low BMD and mortality, these findings 
were initially attenuated through the concept that the association was mediated by 
shared risk factors for both conditions of low BMD and increased risk of death. 
Nevertheless, the evidence of low BMD increasing mortality independently of 
confounders became consistent enough to be successfully demonstrated in meta-
analyses. 
Yet, the specific type of disease underlying this relationship was not clear. Many 
research efforts were oriented towards the demonstration of an association 
between low BMD and increased cardiovascular mortality. The reason for this 
was the finding of a (apparently) paradoxical association between low BMD and 
arterial calcification (AC), initially termed the “calcification paradox”. Despite 
the well-known increased risk in CVD mortality that AC confers, no consistent 
relationship has been found between low BMD and CVD mortality, probably 
reflecting heterogeneity across sexes and different skeletal sites assessed. 
Besides exploring whether a low BMD at the femoral neck (FN-BMD) was related 
to increased mortality in the Rotterdam Study cohorts independently of fractures, 
we considered of high relevance the identification of the type of disease in which 
the condition of a low BMD impairs survival. Data from the Rotterdam Study 
cohorts allowed the demonstration that a low FN-BMD was related to an increase 
in all-cause mortality, although our findings were restricted to men. The work 
done to further explore these associations is the topic of the following Chapter. 
Chapter 2 presents a prospective research done in 7.834 participants from the 
Rotterdam Study I and II cohorts (RS-I, RS-II), including 3392 male participants, 
in whom each decrease in standard deviation (SD) of FN-BMD (i.e., approx. 0.14 
g/cm2) was related to a 9% increase in all-cause mortality risk [(HR: 1.09 (1.04-
1.15)]. 
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We moved forward to identify the specific disease (s) underlying this relationship 
and intriguingly, we found that our results were mostly driven by mortality due to 
chronic lung diseases, as follows: a) men with osteoporosis at baseline had a hazard 
of dying from chronic lung disease during the follow-up of 1560% compared 
to men with normal FN-BMD at baseline; and b) women with osteoporosis at 
baseline had a hazard of dying from chronic lung disease of 490% compared with 
women with normal FN-BMD at baseline. 
Of note, chronic obstructive pulmonary disease (COPD) was the specific disease 
driving this association. It must be added that we performed adjustments for 
all the potential confounders available in our data sets, including body mass 
index, smoking, vitamin D status and prevalent and incident vertebral fractures. 
Importantly, COPD as the main driver of the association between low BMD and 
mortality has also been described in NHANES III, increasing the consistency of 
our findings. 
Remarkably, we found no association between low FN-BMD and cardiovascular 
disease (CVD) mortality. This finding adds to the inconsistent studies in the 
literature in this topic. However, there is a clear evidence from meta-analyses that 
shows that low BMD is associated with arterial calcification (AC), an important 
risk factor for CVD mortality. Because most published reports have emphasized 
the relation of BMD with AC measured in the aorta, we aimed to explore whether 
a similar relation exists between BMD and AC measured in the coronary arteries 
(CAC). The following Chapter describes our findings. 
In Chapter 3, we analyze the first cohort of the Rotterdam Study (RS-I) and 
test three associations, as follows: a) the cross-sectional relation of FN-BMD 
with CAC; b) the prospective relation of FN-BMD loss with CAC; and c) the 
prospective relation of baseline CAC with fracture risk. We found no association 
between cross-sectional FN-BMD and CAC. Similarly, there was no evidence of 
CAC influencing fracture risk. But we found that FN-BMD loss was related to 
CAC in women (not in men), as follows: each 1% increase in FN-BMD loss was 
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related to increased CAC scores [β: 0.22 (0.06-0.38)]. 
However, our results were constrained to women with the lowest 17β-estradiol 
levels and the highest alkaline phosphatase levels, suggesting that a condition of 
hypo-estrogenism, in association with increased bone turnover, were mediating 
our results. In line with this, previous research has shown that the bone-derived 
protein Receptor Activator of Nuclear Factor κβ (RANK) is expressed in human 
endothelial cells and that a condition of marked hypo-estrogenism induces its 
activation not only in bone (with subsequent bone mass loss) but also in the 
vasculature; in the latter it increases the expression of osteogenic genes, such as 
ALPL (gene encoding for alkaline phosphatase).
We conclude from the first two Chapters the following: a) FN-BMD is associated 
with mortality in men, and this association is mainly explained by COPD mortality; 
b) there is no evidence of a primary role of FN-BMD (mainly cortical bone) on 
coronary artery calcification. 
We moved in the following Chapters to investigate whether phosphate levels (P) 
were associated with several health outcomes in our study population, composed 
mainly of participants without chronic kidney disease (CKD). The first outcome 
that we tested was bone-related, namely BMD itself and fracture risk. Our findings 
are detailed in the following Chapter. 
Chapter 4 summarizes our findings from both the Rotterdam Study cohorts and 
MrOS USA. Intriguingly, P was negatively related to lumbar spine BMD (LS-
BMD) in men but not in women while FN-BMD was not related to P levels in 
either sex. We found that each 1 mg/dL higher P increased fracture risk in 52% in 
men and in 32% in women. However, only men showed a) a relationship between 
an increasing yet normal P and fracture risk; and b) a consistent relation between 
P and fracture risk across the entire range of kidney function, including CKD. 
We found a suggestion for a sex dimorphism in the skeletal site affected by 
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increased P, as men displayed increased fracture risk in trabecular-enriched bones, 
such as wrist and vertebra, while women displayed increased fracture risk only in 
the humeral bone. 
For the general setting, we propose the concept of “osteocyte deficiency” as a 
potential explanation of our findings, a term coined by JESUS Delgado-Calle to 
denote the association between fracture risk and decreased FGF23 expression 
in trabecular osteocytes. For the CKD setting, it has been shown that marked 
increase in FGF23 levels triggered by the progression of CKD induces impaired 
mineralization and 1,25 dihydroxyvitamin D synthesis. 
The second outcome that we tested in association with P was mortality. The results 
are summarized in the following Chapter. 
Chapter 5 describes a prospective study between serum P levels assessed at 
baseline and mortality risk in two cohorts from the Rotterdam Study followed for 
more than 10 years. P was found to be related to an increase in all-cause mortality 
risk in men (46% per 1 mg/dL increase in P levels) but not in women. The 
assessment of cause-specificity replicated previous evidence of P as a risk factor 
for increased CVD mortality in men [66% per 1 mg/dL increased P (HR: 1.66 
(1.29-2.14))]. Intriguingly, we also found that P was related to COPD mortality in 
men [344% per 1 mg/dL increased P (HR: 4.44 (2.08-9.49))]. These results were 
not attenuated when we constrained the analysis to normal P. 
Therefore, we identified a consistent relationship between P and COPD mortality in 
humans for the first time, which proved to be of larger magnitude than P and CVD 
mortality. Remarkably, an association between P and lung emphysema in animal 
models has been described since the discovery of the klotho gene, an important 
anti-ageing gene. Normal expression of this gene is required for keeping alveolar 
integrity, and knockout rodents [fgf23-/- and klotho-/-] develop severe emphysema 
that can be rescued with restoration of normophosphatemia.
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The association between P and CVD mortality has been described previously. From 
a mechanistic perspective, it is known that high P can induce arterial calcification 
(AC) in the media layer of the vasculature. However, whether normal P can induce 
AC has been largely unexplored. We aim to explore it in the first cohort of the 
Rotterdam Study, and the results are summarized in the following Chapter. 
The first section of Chapter 6 describes a consistent phenotypic relationship 
between P and AC measured in the coronary arteries (CAC). In the second section, 
we aim to improve causal inference and applied Mendelian Randomization 
(MR), and our results were consistent with a causal relationship of P in coronary 
artery calcification, even after excluding participants with prevalent CV disease, 
CKD, and hyperphosphatemia. The sex-stratified MR analysis showed a more 
consistent association in men. This result is in line with a substantial amount of 
evidence from literature that has found that P is related to adverse outcomes in 
men only. Nevertheless, this result could be also seen as counterintuitive, because 
postmenopausal women have higher P levels than men and lack the protective 
effect of high 17β-estradiol on arterial calcification. 
For the sex difference, we can only speculate whether the association of P and 
ionized calcium is playing a role in our findings. It is well acknowledged that 
both phosphate and calcium (Ca*P product) are needed for AC pathogenesis and 
normally, an inverse relationship should be expected between them. However, 
we (and other authors) have found an inverse relationship between Ca and P in 
women only. 
As most of our results displayed a marked sex difference, we aim to explore further 
whether there was evidence in our data of a difference between serum calcium and 
phosphate levels and if so, we aim to identify a potential causative mechanism. 
These results are summarized in the following two Chapters. 
Chapter 7 describes that women from the Rotterdam Study displayed higher 
calcium and phosphate levels than men. This difference was not fully explained 
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by differences in levels of gonadal steroids, albumin, 1,25(OH)2D3 or alkaline 
phosphatase. In Chapter 8 we describe that the sex difference for calcium and 
phosphate levels was evident only above 45 years of age. 
We moved on to the genetic section of this thesis book in order to explore genetic 
determinants of low BMD and P levels. For low BMD, we aim to identify genes 
with large effect, causative of  Mendelian disorders. For P levels, we aim to identify 
multiple sites in the human genome through the implementation of genome-wide 
association study (GWAS). 
Chapter 9 describes the clinical picture of a cluster of five families affected by a 
mutation in PLS3, a gene that encodes for plastin and previously unknown to exert 
a role in bone. Moreover, we identified an X-linked pattern of inheritance, largely 
unusual for osteoporosis. As expected, men were more severely affected than 
women, and some of them displayed multiple fractures (~20) by early adulthood. 
The clinical picture in women was heterogeneous, but we were able to identify that 
a common PLS3 single nucleotide polymorphism was associated with increased 
fracture risk in women within the Rotterdam Study cohorts.
Chapter 10 describes the clinical picture of a young woman with amblyopia in 
one eye since childhood who complained of severe back pain during pregnancy 
and delivery. Multiple vertebral fractures were identified in the clinical work-
up after delivery. We identified a mutation in LRP5 as the cause of her severe 
osteoporosis, located within the spectrum of osteoporosis-pseudoglioma/familial 
exudative vitreoretinopathy. 
Chapter 11 describes the results from the analysis of genetic determinants of 
serum P levels within the United Kingdom Biobank, a large cohort composed of 
~500.000 participants. Our analyses, performed in 392.655 subjects, were able 
to identify 264 independent signals within the genome associated with P at a 
stringent statistical level. These signals could be clustered in 182 loci of which 
172 are new. We could explain 7.62% of the variance of serum P levels. We found 
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suggestive evidence of sex-difference in three genetic variants. By far, the most 
powerful signal mapped to the Major Histocompatibility Complex, at 6p21.31. 
As next step, we aim for replication in a large Biobank of different ancestry, 
perform trans-ethnic meta-analyses and Bayesian fine-mapping.
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Samenvatting en conclusies
Recente technologische ontwikkelingen hebben geleid tot een waardevolle set 
hulpmiddelen voor onder andere medische beeldvorming en pathologie, wat tot 
een ongekende toename van onze kennis heeft geleid. Botweefsel vormt hierop 
geen uitzondering. Sterker nog, we zijn de afgelopen decennia getuige geweest 
van continu groeiende kennis op het gebied van botfysiologie en botpathologie. 
Als gevolg hiervan zijn verschillende concepten geleidelijk geëvolueerd, zoals 
de veronderstelling dat a) bot enkel een rol speelt bij de ondersteuning van het 
lichaam en b) fracturen het enige schadelijke gevolg zijn van  aantasting van 
het botweefsel. Door nieuwe inzichten in de fascinerende evolutie van bot van 
enkel uit calcium bestaand aragoniet naar het uit calcium en fosfaat bestaande 
hydroxyapatiet, is de nadruk gelegd op het nauwe verband tussen botweefsel en 
calcium (Ca), en bovendien op de relatie tussen botweefsel en serum fosfaat (P). 
Deze relatie is echter nog steeds niet algemeen bekend en erkend. 
Juist in het eerste deel van dit proefschrift wordt de nadruk gelegd op de 
schadelijke effecten van zowel lage botmineraaldichtheid (lage BMD, waarbij 
niet noodzakelijkerwijs sprake hoeft te zijn van osteoporose) als verhoogde serum 
P-waarden. We hebben aanwijzingen gevonden dat het schadelijk effect op de 
gezondheid zich niet beperkt tot fracturen alleen. Met onze data, voornamelijk 
afkomstig uit cohorten van de Rotterdam Studie maar tevens van MrOS USA, 
kunnen we concluderen dat verschillende andere uitkomsten worden beïnvloedt 
wanneer er sprake is van een afname in de botdichtheid of een stijging in de serum 
P-waarden Sommige van deze associaties zijn eerder beschreven, maar in dit 
proefschrift worden een aantal associaties voor het eerst bij mensen beschreven. 
Hoofdstuk 1 verzorgt het inleidende gedeelte van dit proefschrift. We benoemen 
het concept dat bot niet slechts ter ondersteuning en voortbeweging dient, maar 
benadrukken het groeiende besef dat het botweefsel een belangrijke rol speelt 
bij verschillende fysiologische processen die van belang zijn bij het in evenwicht 
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houden van homeostase. Zo is door de ontdekking dat botcellen de belangrijkste 
bron zijn van FGF23 – momenteel beschouwd als de belangrijkste regulator van 
de P-waarden – de ‘bot-nieras’ vastgesteld, welke uiterst relevant is onder zowel 
gezonde als zieke omstandigheden. 
We geven een korte samenvatting van de belangrijkste bevindingen van eerder 
onderzoek dat is uitgevoerd omtrent een lage BMD en mortaliteit, de meest 
relevante uitkomst voor bot op fractuurincidentie na. In verschillende studies werd 
een verband gevonden tussen een lage BMD en mortaliteit maar deze bevindingen 
werden aanvankelijk verklaard door gedeelde risicofactoren voor zowel een lage 
BMD, alsook een verhoogd risico op overlijden. Niettemin was het bewijs dat bij 
een lage BMD de mortaliteit toeneemt, onafhankelijk van verstorende variabelen, 
consistent genoeg om succesvol aangetoond te worden in meta-analyses. 
Toch bleek de specifieke soort ziekte die aan deze relatie ten grondslag lag 
onduidelijk. Er is veel onderzoek verricht om een verband aan te tonen tussen een 
lage BMD en verhoogde cardiovasculaire mortaliteit. De reden hiervoor was de 
ontdekking van een (ogenschijnlijk) paradoxaal verband tussen een lage BMD en 
slagaderverkalking (atherosclerose, AC), aanvankelijk de ‘verkalkingsparadox’ 
genoemd. Ondanks het bekende verhoogde risico op HVZ-mortaliteit als gevolg 
van AC, is er geen consistent verband gevonden tussen een lage BMD en HVZ-
mortaliteit, waarschijnlijk het resultaat van heterogeniteit tussen geslachten en de 
verschillende plaatsen van het skelet die geëvalueerd zijn. 
Naast onderzoek naar een relatie tussen een lage BMD bij de femurhals (FN-
BMD) en een verhoogde mortaliteit, onafhankelijk van fracturen in de Rotterdam 
Studie vonden wij het belangrijk om te onderzoeken welke soort ziekte de kans 
op overleving vermindert bij een lage BMD. Het werk dat is gedaan voor het 
verkennen van deze associaties, is het onderwerp van het volgende hoofdstuk. 
Data verkregen uit de Rotterdam Studie maakte het mogelijk om aan te tonen 
dat een lage FN-BMD gerelateerd was aan een toename van mortaliteit door alle 
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oorzaken, al moet hieraan worden toegevoegd dat onze bevindingen zich beperkten 
tot mannen. In Hoofdstuk 2 wordt een prospectief onderzoek gepresenteerd, 
uitgevoerd onder 7.834 deelnemers uit cohort I en II van de Rotterdam Studie 
(RS-I, RS-II), waaronder 3.392 mannelijke participanten, bij wie iedere afname 
van de standaarddeviatie (SD) van FN-BMD (ongeveer 0,14g/cm2) gerelateerd 
bleek te zijn aan een toename van 9% van het mortaliteitsrisico door alle oorzaken 
[(HR: 1,09 (1,04-1,15)]. 
We vervolgden het onderzoek met de identificatie van de specifieke ziekte(s) 
die aan deze relatie ten grondslag liggen en constateerden dat onze resultaten 
voornamelijk verklaard worden door mortaliteit als gevolg van chronische 
longziekten, dat wil zeggen: a) mannen met osteoporose in de uitgangssituatie 
hadden 1560% meer kans om te overlijden aan chronische longziekte tijdens de 
follow-up dan mannen met een normale FN-BMD in de uitgangssituatie; en b) 
vrouwen met osteoporose in de uitgangssituatie hadden 490% meer kans om te 
overlijden aan chronische longziekte dan vrouwen met een normale FN-BMD in 
de uitgangssituatie. 
Opvallend is dat de chronische obstructieve longziekte (COPD) de belangrijkste 
verklaring is van het verband tussen BMD en mortaliteit. Hieraan moet worden 
toegevoegd dat we aanpassingen hebben doorgevoerd voor alle mogelijke storende 
variabelen die in onze datasets beschikbaar zijn, inclusief body-mass index, 
roken, de vitamine D-status en aanwezige en incidentele wervelfracturen. Ook de 
NHANES II beschrijft COPD als de belangrijkste oorzaak van het verband tussen 
een lage BMD en mortaliteit, wat de consistentie van onze bevindingen versterkt. 
Opmerkelijk genoeg hebben we geen verband gevonden tussen een lage FN-BMD 
en mortaliteit door hart- en vaatziekten (HVZ). Deze bevinding draagt bij aan de 
inconsistente studies in de literatuur omtrent dit onderwerp. Er is echter duidelijk 
bewijs uit meta-analyses dat een lage BMD gerelateerd is aan slagaderverkalking 
(atherosclerose, AC), een belangrijke risicofactor voor HVZ-mortaliteit. Omdat 
in de meeste gepubliceerde rapporten de nadruk wordt gelegd op de relatie tussen 
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BMD en AC, gemeten in de aorta, wilden we onderzoeken of er een vergelijkbare 
relatie bestaat tussen BMD en AC, gemeten in de kransslagaders (CAC). Het 
volgende hoofdstuk beschrijft onze bevindingen. 
In Hoofdstuk 3 analyseren we het eerste cohort van de Rotterdam Studie (RS-
I) en testen we drie verbanden: a) de cross-sectionele relatie tussen FN-BMD 
en CAC; b) de prospectieve relatie tussen FN-BMD-afname en CAC; en c) de 
prospectieve relatie tussen CAC in de uitgangssituatie en het fractuurrisico. We 
vonden geen verband tussen cross-sectionele FN-BMD en CAC. Er was evenmin 
bewijs dat CAC het fractuurrisico beïnvloedde. We ontdekten wel dat FN-BMD-
afname gerelateerd was aan CAC bij vrouwen maar niet bij mannen: iedere 1% 
toename in FN-BMD-afname was gerelateerd aan een toename van de CAC-
scores [β: 0,22 (0,06-0,38)]. 
Onze resultaten bleven echter beperkt tot vrouwen met de laagste 
17β-estradiolwaarden en de hoogste alkalische fosfatasewaarden, wat suggereert 
dat een laag oestrogeen gehalte, in combinatie met een verhoogd botmetabolisme, 
onze resultaten medieerde. Overeenkomstig dit resultaat heeft eerder onderzoek 
aangetoond dat het van bot afgeleide eiwit Receptor Activator van Nucleaire 
Factor-kappa B (RANK) tot expressie komt in de menselijke endotheelcellen en 
dat een laag oestrogeen gehalte zijn activatie niet alleen in bot induceert (met 
botmassaverlies tot gevolg) maar ook in het vaatstelsel. In het laatste geval verhoogt 
het de osteogene genexpressie, waaronder het enzym alkalische fosfatase. 
Uit de eerste twee hoofdstukken concluderen we het volgende: a) FN-BMD is 
geassocieerd met mortaliteit onder mannen, en dit verband wordt voornamelijk 
door COPD-mortaliteit verklaard; b) er is geen bewijs dat FN-BMD (voornamelijk 
corticaal bot) een primaire rol speelt bij verkalking van de kransslagaders.  
In de volgende hoofdstukken gaan we verder met het onderzoeken van het verband 
tussen serumfosfaatwaarden (P) en verschillende gezondheid-gerelateerde 
uitkomsten binnen onze onderzoekspopulatie, die voornamelijk bestaat uit 
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participanten zonder chronisch nierfalen (CKD). De eerste uitkomst die we testten 
was botgerelateerd, namelijk BMD zelf en het fractuurrisico. Onze bevindingen 
worden in het volgende hoofdstuk in detail beschreven. 
Hoofdstuk 4 biedt een samenvatting van onze bevindingen in zowel de Rotterdam 
Studie- als MrOS USA. Het viel op dat P negatief gerelateerd was aan de BMD 
van de lumbale wervelkolom (LS-BMD) bij mannen maar niet bij vrouwen, terwijl 
FN-BMD duidelijk niet gerelateerd was aan P-waarden in beide geslachten. We 
vonden dat elke 1 mg/dL toename van P het risico op fracturen verhoogt met 52% 
bij mannen en met 32% bij vrouwen. Echter, alleen mannen vertoonden a) een 
verband tussen een toenemende maar normale P-waarde en het fractuurrisico; en 
b) een consistente relatie tussen P en het fractuurrisico over het gehele bereik van 
het functioneren van de nieren, inclusief mensen met CKD. 
We vonden een suggestief geslachtsverschil in de door verhoogde P-waarden 
beïnvloede skeletplaats, aangezien mannen een verhoogd fractuurrisico vertoonden 
in trabeculair verrijkte botten, zoals de pols en de wervels, terwijl vrouwen enkel 
een verhoogd fractuurrisico vertoonden in het bot van de bovenarm. 
Voor het algehele kader stellen we het concept van ‘osteocytdeficiëntie’ voor 
als een mogelijke verklaring voor onze bevindingen, een term geïntroduceerd 
door Jesus Delgado-Calle om het verband tussen fractuurrisico en verminderde 
FGF23-expressie in trabeculaire osteocyten aan te duiden. In het kader van CKD 
is aangetoond dat een duidelijke toename van FGF23-waarden, veroorzaakt door 
de progressie van CKD, een verstoorde mineralisatie en 1,25-dihydroxyvitamine 
D-synthese induceert. 
De tweede uitkomst die we hebben getest in verband met P is de mortaliteit. De 
resultaten hiervan zijn samengevat in het volgende hoofdstuk.
In Hoofdstuk 5 wordt een prospectieve studie beschreven tussen serum P-waarden 
in de uitgangssituatie en het mortaliteitsrisico binnen twee cohorten van de 
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Rotterdam Studie die meer dan 10 jaar werden gevolgd. P bleek gerelateerd te 
zijn aan een toename van het mortaliteitsrisico door alle oorzaken onder mannen 
(46% per 1 mg/dL toename van de P-waarden) maar niet bij vrouwen. Een analyse 
van verschillende oorzaken van mortaliteit bevestigde de eerdere bevinding dat 
P een risicofactor is voor verhoogde HVZ-mortaliteit onder mannen [66% per 1 
mg/dL verhoogde P (HR: 1,66 (1,29-2,14)]. Interessant is dat P tevens gerelateerd 
was aan COPD-mortaliteit bij mannen [344% per 1 mg/dL verhoogde P [HR: 4,44 
(2,08-9,49)]. Deze resultaten werden niet afgezwakt toen we de analyse beperkten 
tot mensen met een normale P spiegel. 
Hiermee hebben we voor het eerst een consistente relatie aangetoond tussen P en 
COPD-mortaliteit bij mensen, een relatie die sterker bleek te zijn dan die tussen 
P en HVZ-mortaliteit. Opmerkelijk is dat een verband tussen P en longemfyseem 
in diermodellen is beschreven sinds de ontdekking van het klotho-gen, een 
belangrijk anti-verouderingsgen. Normale expressie van dit gen is vereist voor 
het behouden van de alveolaire integriteit, en knock-out knaagdieren [ fgf23-/- 
en klotho-/-] ontwikkelen ernstig emfyseem wat gecorrigeerd kan worden door 
normofosfatemie te herstellen. 
Het verband tussen P en HVZ-mortaliteit is eerder beschreven. Vanuit 
mechanistisch oogpunt is het bekend dat hoge P-waarden aderverkalking (AC) in 
de middelste laag van de bloedvaten kunnen induceren. Of een normale P-waarde 
tot AC kan leiden, is echter niet bekend. Wij streven ernaar dit te onderzoeken 
middels het eerste cohort van de Rotterdam Studie. De resultaten worden 
samengevat in het volgende hoofdstuk. 
In het eerste deel van Hoofdstuk 6 wordt een consistente fenotypische relatie 
beschreven tussen P en AC, gemeten in de kransslagaders (CAC). In het tweede 
deel streven we ernaar om aan te tonen dat er sprake is van een causale relatie en 
passen we Mendeliaanse randomisatie (MR) toe. Onze resultaten bleken consistent 
met een causaal verband tussen P en de verkalking van de kransslagader, zelfs 
na het excluderen van participanten met reeds aanwezige hart- en vaatziekten, 
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CKD en hyperfosfatemie. De naar geslacht gestratificeerde MR-analyse toonde 
een consistenter verband bij mannen. Dit resultaat is in overeenstemming met 
een aanzienlijke hoeveelheid bewijs uit de literatuur die heeft aangetoond dat 
P alleen bij mannen gerelateerd is aan negatieve uitkomsten. Niettemin kan dit 
resultaat ook als contra-intuïtief worden beschouwd, omdat postmenopauzale 
vrouwen hogere P-waarden hebben dan mannen en het beschermende effect van 
hoge 17β-estradiol op arteriële verkalking bij hen ontbreekt. 
Voor het geslachtsverschil kunnen we slechts speculeren of het verband tussen P 
en geïoniseerd calcium een rol speelt in onze bevindingen. Het wordt algemeen 
erkend dat zowel fosfaat als calcium (Ca x P-product) nodig zijn voor de 
ontwikkeling van AC en normaal gesproken zou er een omgekeerd verband tussen 
beide mogen worden verwacht. Wij (en andere auteurs) hebben echter alleen bij 
vrouwen een omgekeerde relatie tussen Ca en P gevonden. 
Omdat we bij de meeste van onze resultaten een geslachtsverschil observeerden, 
willen we verder onderzoeken of we aanwijzingen in onze gegevens kunnen vinden 
die duiden op geslachtsverschillen tussen serum calcium- en fosfaatwaarden en 
indien dit het geval is willen we een potentieel causaal mechanisme proberen te 
identificeren. Deze resultaten zijn samengevat in de volgende twee hoofdstukken. 
Hoofdstuk 7 beschrijft dat vrouwen uit de Rotterdam Studie hogere calcium- en 
fosfaatwaarden vertoonden dan mannen. Dit verschil werd niet volledig verklaard 
door verschillen in waarden van geslachtshormonen, albumine, 1,25(OH)2D3 of 
alkalische fosfatase. In Hoofdstuk 8 beschrijven we dat het geslachtsverschil 
voor calcium- en fosfaatwaarden alleen evident is boven de 45 jaar. 
Vervolgens richten we ons op de genetische sectie van dit proefschrift om 
genetische determinanten van lage BMD- en P-waarden te onderzoeken. Voor 
een lage BMD willen we genen identificeren met een groot effect die de oorzaak 
vormen van Mendeliaanse aandoeningen. Voor de hoogte van P-waarden 
willen we meerdere locaties in het menselijk genoom identificeren middels een 
285
Chapte r  9
genoomwijde associatiestudie (GWAS). 
Hoofdstuk 9 beschrijft het klinische beeld van een cluster van vijf families met een 
mutatie in PLS3, een gen dat codeert voor plastine en waarvan voorheen onbekend 
was dat het een belangrijke rol speelt met betrekking tot BMD. Bovendien hebben 
we een X-gebonden overervingspatroon geïdentificeerd, wat zeer ongebruikelijk 
is voor osteoporose. Zoals verwacht werden mannen veel zwaarder getroffen 
dan vrouwen, en sommigen van hen vertoonden al meerdere fracturen (~20) op 
adolescente leeftijd. Het klinische beeld bij vrouwen was heterogeen, maar we 
konden vaststellen dat een veel voorkomend PLS3-enkel-nucleotide polymorfisme 
geassocieerd is met een verhoogd fractuurrisico bij vrouwen binnen de Rotterdam 
Studie. 
Hoofdstuk 10 beschrijft het klinische beeld van een jonge vrouw met slecht 
zicht in een oog sinds de jeugd die zich presenteerde met ernstige rugpijn tijdens 
zwangerschap en bevalling. Na de bevalling bleek bij de medische valuatie sprake 
van meerdere wervelfracturen. We slaagden erin om een mutatie in LRP5 te 
identificeren, binnen de context van een diagnose van het spectrum osteoporose-
pseudoglioom - familiaire exudatieve vitreoretinopathie, als de oorzaak van haar 
ernstige osteoporose. 
Hoofdstuk 11 beschrijft de resultaten van de analyse van genetische determinanten 
van serum P-waarden binnen de Biobank van het Verenigd Koninkrijk, een 
groot cohort bestaande uit ~500.000 deelnemers. We zijn er in geslaagd 264 
onafhankelijke signalen in het genoom van 392.655 personen te identificeren 
die geassocieerd zijn met P-waarden, onder strikte statistische condities. Deze 
signalen kunnen worden geclusterd in 182 loci waarvan er 172 niet eerder 
beschreven zijn. Hiermee kan 7,62% van de variatie van serum P-waarden 
verklaard worden. We vonden suggestief bewijs voor een geslachtsverschil in drie 
genetische varianten. Verreweg het sterkte signaal werd gevonden ter plaatse van 
het Major Histocompatibiliteits Complex, op 6p21.31. 
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In een volgende stap streven we naar replicatie van onze bevindingen in een grote 
Biobank met mensen van een andere afkomst waarbij we trans-etnische meta-
analyses en Bayesiaanse fine-mapping willen ondernemen.
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